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Abstract 
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Title: ONCOPROTEOMIC APPLICATIONS FOR DETECTION OF BREAST 
CANCER  
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The heterogeneity of breast cancer (disease stage and phenotype) makes it 
challenging to differentiate between each subtype; luminal A, luminal B, HER2, 
basal-like and claudin-low, on the basis of a single gene or protein. Therefore, 
a collection of markers is required that can serve as a signature for diagnosing 
different types of breast cancer. New developments in proteomics have 
provided the opportunity to look at phenotype-specific breast cancer cell lines 
and stage-specific liquid biopsies (nipple aspirate fluid [NAF], plasma samples) 
to identify disease and phenotype specific signature.  
An 8-plex iTRAQ quantification strategy was employed to compare proteomic 
profiles of a range of breast cancer and ‘normal-like’ cell lines with primary 
breast epithelial cells. From this, 2467 proteins were identified on Orbitrap 
Fusion and Ultraflex II, of which 1430 were common. Matched pairs of NAF 
samples from four patients with different stages of breast cancer, were analysed 
by SCX-LC-MS and a total of 1990 unique gene products were identified. More 
than double the number of proteins previously published data, were detected in 
NAF, including 300 not detected in plasma. The NAF from the diseased patients 
have 138 potential phenotype biomarkers that were significantly changed 
compared to the healthy volunteer (7 for luminal A, 9 for luminal B, 11 for HER2, 
14 for basal-like and 52 for claudin-low type). The average coefficient of 
variation for triplicate analyses by multiple reaction monitoring mass 
spectrometry (MRM-MS), was 9% in cell lines, 17 % in tissue biopsies, 22% in 
serum samples and 24% in NAF samples.  
Overall, the results provide a strong paradigm to develop a clinical assay based 
on proteomic changes in NAF samples for the early detection of breast cancer 
supplementary to established mammography programmes. 
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CHAPTER 1. INTRODUCTION 
1.1 Breast Cancer   
Breast cancer is the leading cause of death in the world among women 
aged 40-59 years, with an estimated 1.67 million new cancer cases diagnosed 
in 2012 (25% of all cancers). It is the most common cancer; with 883,000 cases 
each year in developing and 794,000 cases in more advanced regions of the 
world. (Ferlay J et al., 2013). In UK, around 55,200 new cases of breast cancer 
were diagnosed in 2014, which was an average of 150 cases diagnosed every 
day. The breast cancer mortality rate in UK is 31 deaths every day according to 
Cancer Research UK (CancerResearchUK, 2016b). The breast cancer 
incidence is high, almost 60%, in women aged 55 and over, while women under 
the age of 40 have a considerably lower chance of developing the breast cancer 
(Figure 1-1) (CancerResearchUK, 2016b).  
 
Figure 1-1: Average number of new cases per year and age-specific incidence 
per 100,000 population of female breast cancers in UK (CancerResearchUK, 
2016b). 
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                     Limited breast health awareness and access to screening has a 
significant impact on the ability of health services to diagnose and treat the 
disease at a sufficiently early stage, and in many cases, by the time the patient 
presents at clinic, the cancers have already become aggressive. This problem 
is not unique to less developed countries as deaths also reached an all-time 
high during 2014 in the UK for women under 50 years old (CancerResearchUK, 
2016b). The risks associated with breast cancer are well established and 
include genetic predisposition, reproductive factors (menarche, parity, lactation, 
menopause), environment (chemical exposures, drugs, infectious agents), 
demographic factors (age, race, sex, socio-economic status, geographic 
location), systemic factors (epigenetics) and lifestyle (smoking, alcohol use, diet, 
obesity, exercise) (Eccles et al., 2013),  
The major risk factor is age and the majority of breast cancer cases 
occur in women after menopause. However, the correlation of risk with 
reproductive, environmental and lifestyle parameters, strongly indicate the 
origins of many breast cancers are concealed by a prolonged period of 
dormancy that only manifest in later life (Banys et al., 2012). Lifestyle 
parameters are unique among these factors, in that they fall within the scope of 
the individual to proactively reduce these risks by taking preventative measures, 
whereas reproductive, environmental and demographic factors are beyond the 
control of most individuals. 
Breast cancer may be an inherited or an acquired genetic disease that 
is influenced by reproductive, environmental and behaviour factors. Hereditary 
breast cancers, account for 5-10% of cases, and in most cases, are related to 
mutations in BRCA-1 and BRCA-2 genes. Women with these genetic mutations 
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have 10- to 30-fold higher risk of developing breast cancer in life as compared 
to the general population (King et al., 2003). Genetic predisposition can be 
identified initially through investigation of family history of the disease and 
confirmed by screening for predictive mutations associated with specific high-
penetrance genes, including BRCA1, BRCA2, TP53 and PTEN (Aloraifi et al., 
2015).  
Sporadic breast cancer developed due to consequences of somatic 
mutations over the life time account for 90–95% of cases. These mutations may 
be the result of polymorphisms in genes, encoded in the synthesis of proteins 
involved in cell signalling pathways, estrogen metabolism and DNA repair 
(Zhang et al., 2006).  
The critical and poorly understood events in breast tumour development 
that have major effects on clinical management and outcome are (a) the 
changes from DCIS to invasive carcinoma and (b) the metastatic blowout of 
primary tumours to distant organs (Hu and Polyak, 2008). Heterogeneity of 
breast cancer is caused by different genetic and epigenetic mutations, which 
results in alterations of cell functions such as apoptosis, cell proliferation and 
angiogenesis (Reis-Filho and Lakhani, 2003). The major genetic mutations 
observed are high expression of proto-oncogenes, alterations of DNA repair or 
tumour suppressor genes, chromosomal instability and reactivation of 
telomerase, causing uncontrolled cell proliferation and tumour formation 
(Rodenhiser and Mann, 2006).  
Because of extensive epidemiological and etiological studies, it is 
becoming easier to identify those women who are at highest risk of breast 
cancer. Unfortunately, none of these measures can predict when breast cancer 
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will occur. Regular screening for the appearance of breast cancer, as 
recommended for women reaching menopause, is critical in high risk women 
during their reproductive years. There are various screening modalities, each 
with advantages and disadvantages (Table 1-4), making them sub-optimal for 
more frequent monitoring that is required for this group. Consequently, the major 
means of preventative intervention for these women can be extreme, involving 
elective surgery to remove both breasts. Therefore, new and more sensitive 
approaches are required to detect the earliest stages of the disease, which will 
enable less drastic means of intervention. 
1.2 Stages, Types and Grades of breast cancer 
1.2.1 Histopathological types 
Breast cancer is a complex and heterogeneous disease and 
understanding this diversity is important for diagnostic and prognostic 
applications. A wide range of histopathological types (Table 1-1) include: ductal 
carcinoma, tubular carcinoma, lobular carcinoma, mucinous carcinoma and 
some rare types like papillary and metaplastic breast cancer 
(Cancerresearchuk, 2016a). 
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Table 1-1: Histopathological types and characteristics of breast cancer (DeSantis et al., 2014).
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Breast cancer heterogeneity is due to the alteration of numerous 
oncogenic pathways, germ line mutations like breast cancer 1 early onset 
(BRCA-1) and breast cancer 2 early onset (BRCA-2) (Petrucelli et al., 1993), as 
well as many non-genetic factors such as hypoxia and lactic acidosis which are 
involved in tumour micro-environmental stresses (Gatza et al., 2011). 
Furthermore, there is etiological heterogeneity of hormone-receptor defined 
subtypes of breast cancer (Redondo et al., 2012).  
1.2.2 Breast cancer staging and grades 
There are different staging systems for breast cancer but the most 
common one is the TNM (Tumour size, Lymph Nodes and Metastasis) system. 
Different stages of breast cancer are summarised in Table 1-2, using the TNM 
system (Cancerresearchuk, 2016a, Sobin and Fleming, 1997, Singletary et al., 
2002). If cancer has not spread beyond the breast or the lymph nodes, it is 
considered as an early breast cancer, but if it has spread to another part of body 
such as the liver or bones (metastasis), then it is called advanced breast cancer. 
Grading of breast cancer is performed by using tissue biopsies and 
observing the shape of cancer cells under the microscope (Singletary et al., 
2002, Cancer, 2002). Breast cancers can be (Cancerresearchuk, 2016a, 
Cancer, 2002, Brierley, 2017):  
a. Grade 1; tumour cells are dividing at a slow rate and shape of nuclei are 
small and uniform. 
b. Grade 2; tumour cells are dividing at moderate rate and nuclei are 
medium-to-large size but of uniform size and shape within the tissue. 
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c. Grade 3; tumour cells are dividing at a fast rate and nuclei are large and 
vary in size and shape. 
 
Table 1-2: TNM (Tumour size, Lymph Nodes and Metastasis) system for 
different stages of breast cancer. 
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1.2.3 Genetic phenotypes 
The genomic status can be a key aspect to understanding the biological 
characteristics of a tumour, where the DNA content is investigated to 
differentiate between subtypes. There are two types of epithelial cells in the 
human mammary glands; basal and luminal (Perou et al., 2000). Breast tumours 
are composed of a variety of associated cells alongside the cancerous cells and 
gene expression profiling of histology complex tissue has identified the cell-type-
specific expression of certain clustered groups of genes. On the basis of 
microarray gene expression profiling, breast cancer can be classified into 
different molecular phenotypes. Genetic phenotyping initially identified 4 
phenotypes; Luminal A, Luminal B, HER2 positive, and Basal type(Perou et al., 
2000), later the basal type was more extensively classified as  Basal-like and 
Claudin-low (Holliday and Speirs, 2011) (Table 1-3).  
 
Table 1-3: Molecular classification of breast carcinoma (Holliday and Speirs, 
2011). 
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The luminal category is characterised by endocrine receptor expression 
(estrogen - ER and progesterone receptors - PR), which was subdivided into 
luminal A and luminal B based on the expression of HER2. The second group 
was called the basal-type because cancerous cells’ gene profiling is similar to 
the cells located outside the breast duct (basal cells). This category (basal) lacks 
the expression of hormonal receptors as well as HER2 so it is known as triple-
negative breast cancer (TNBC), which has the poorest prognosis (Holliday and 
Speirs, 2011). 
1.2.3.1 Luminal-type breast cancer 
1.2.3.1.1 Luminal A and Luminal B 
Luminal epithelia cells can be differentiated from basel epithelia cells by 
immunohistochemistry detection of keratin 8/18 (Perou et al., 2000). 
Furthermore, altered activity of antigen Ki-67 (MKI67) index has been shown to 
differentiate luminal breast cancers, with lower expression in luminal A compare 
to luminal B (Goldhirsch et al., 2011) Hence, the cell proliferation activity is lower 
in luminal A than other phenotypes of breast tumours (Cheang et al., 2009). 
Both luminal A and luminal B are ER-positive-luminal subtypes, but luminal A 
also exhibited high expression of GATA binding protein 3, X-box binding protein-
1 and estrogen regulated LIV-1 transcription factors by hierarchical clustering 
(Sørlie et al., 2001). The expression of HER2 differentiates luminal B from 
luminal A, however MKI67, cyclin B1 (CCNB1) and Myb-related protein B 
(MYBL2) are also proliferation signature genes for luminal B. The high 
expression of these genes in luminal B tumours clarifies the main difference 
between the two subtypes (Cheang et al., 2009). More-over increased 
expression of HER2 associated genes (HER2 and GRB7) were also observed 
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in luminal B subtype. The high cost of gene expression profiling makes it difficult 
to differentiate between the two luminal subtypes in the clinic but the MKI67 
labelling index, which is based on immunostaining, can serve as a valuable 
labelling biomarker for the luminal B subtype (Cheang et al., 2009). The luminal 
B subtype is a worse type of breast cancer with poor outlook. Only 30% of 
luminal B tumours are HER2 positive, so a single marker is not sufficient to 
differentiate between luminal subtypes (Cheang et al., 2009). 
1.2.3.1.2 HER2 enriched breast cancer 
The ErbB family has four receptor tyrosine kinases members; HER1 
(EGFR, ErbB1), HER2 (Neu, ErbB2), HER3 (ErbB3), and HER4 (ErbB4). The 
ErbB family is involve in triggering the cell proliferation and cell growth by 
binding to extracellular domain of tyrosine kinase receptors (O'Neill et al., 2012). 
The HER2 gene product (protein) has predictive and prognostic significance in 
invasive breast cancer (Seal et al., 2012). Approximately 15%-25% of breast 
tumours expressed high levels of HER2, yet are associated with poor prognosis 
(Seal et al., 2012). The PI3K pathway is most common up-regulated pathway in 
breast cancer. Among mechanisms of PI3K enhancement, PI3K3CA mutations 
are only observed in HER2+ breast cancers and are potentially a good 
prognostic biomarker (Mukohara, 2015). Targeted therapy of HER2 positive 
breast cancer by Trastuzumab; a monoclonal antibody and Lapatinib; a tyrosine 
kinase inhibitor, has increased survival significantly. The high expression of 
HER2 receptor in HER2 positive breast cancers activate cell proliferation (Paul 
and Mukhopadhyay, 2004), so early detection of the HER2 positive cancer is 
essential to prevent unnecessary cell growth.  
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1.2.3.2  Basal-type breast cancer 
1.2.3.2.1  Basal-like (Basal A) 
Triple negative (ER, PR and HER2 negative) breast cancers are the 
focus of much current research among the five different phenotypes because of 
poor clinical outcome.  Basal-like tumours account for up to 15% of all breast 
cancers and mostly affect younger patients (Alluri and Newman, 2014). 
Histologically, the majority of basal-like breast cancers are Invasive ductal 
breast cancers of no special type (IDC-NST) type, with high histological grade, 
high mitotic indices and conspicuous lymphocytic infiltration (Livasy et al., 2006, 
Fulford et al., 2006). However, not all basal-like cancers are of the IDC-NST 
type; metaplastic carcinoma (Weigelt et al., 2009), adenoid cystic (Weigelt et 
al., 2008), secretory(Laé et al., 2009), and myoepithelial carcinomas (Azoulay 
et al., 2005) of the breast also show a basal-like phenotype. There is still no 
internationally accepted characterisation for basal-like breast cancers and how 
best to describe these tumours is a matter of controversy and ongoing debate 
(Telli, 2016). However, the proposed immunohistochemistry approach can be 
used to differentiate basal-like breast cancer by characterising the higher 
expression of cytokeratin 5/6 or lower expression of cytokeratin 8/18 or lack of 
expression of ER, PR, and HER2 (Nielsen et al., 2004). TP53 gene mutations 
are observed in up to 85% of breast cancers (Olivier et al., 2006), and alterations 
of the retinoblastoma protein (pRB) and cyclin-dependent kinase inhibitor 2A 
(CDKN2A), the G1/S cell-cycle checkpoint are remarkably dominant in basal-
like breast cancers (Moore, 2016, Leidy et al., 2014). A recent study conducted 
by Moore et al 2016, showed that basal-like breast cancers lack pRB 
expression, and overexpress CDKN2A and p53 based on immunoreactivity 
(pRB−/CDKN2A+/p53+), whereas this immune-profile was rarely observed in 
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tumours of other molecular subtypes (Moore, 2016).  Epidermal growth factor 
receptor (EGFR or HER1) and cytokeratin 5/6 are immunohistochemical 
biomarkers, used to identify the basal-like phenotype (Nielsen et al., 2004), but 
these markers are not specific because basal/myoepithelial cells of normal 
breast, almost uniformly express high-molecular-weight/basal cytokeratins 
(CK5/6, CK14, and CK17) (Mayer et al., 2014). Therefore, there is a need for a 
precise biomarker for diagnoses and prognoses of basal-like breast cancer.  
1.2.3.2.2 Claudin-low (Basal B) 
Gene expression studies of breast cancer provide better molecular 
understanding of the breast cancer and one of the latest molecular subtypes 
defined is claudin-low (Herschkowitz et al., 2007). Claudin-low tumours only 
represent 10% triple-negative breast cancers and are associated with young 
age of onset, larger tumour size and therefore higher tumour stage/grade, 
extensive lymphocytic infiltrate and a poorly defined tumour margin (Dias et al., 
2017, Prat et al., 2010). Patients diagnosed with claudin-low breast cancer had 
a worse overall survival rate compare to patients with luminal breast cancer but 
interestingly, claudin-low cancers had low local recurrence ratein the area of the 
breast after treatment (Perou, 2011). Claudin-low subtype is also characterised 
with low expression of ER alpha, PR, HER2 and proliferation marker Ki67, but 
in addition by down-regulation of claudin-3, claudin-4, claudin-7 and E-cadherin; 
a glycoprotein, involved in calcium dependent cell-cell adhesion (Prat et al., 
2010). A large-scale study, conducted recently by Dias et al 2017, on formalin 
fixed paraffin embedded 1600 human breast cancer tissues, showed typically 
negative expression of ER, PR, HER2, claudin 3, claudin 4, claudin 7 and E-
cadherin in  90% claudin-low breast cancer (Dias et al., 2017).  
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1.3 Methods for detecting Breast cancer  
1.3.1 Self-examination 
Self-examination provides an effective way to encourage early 
detection of potentially harmful lumps that does not involve any specialist 
equipment or professional health care assistance (Güth et al., 2008). Self-
examination can also encourage women to be involved in the maintenance of 
their own health,  detecting up to 50% tumours and improving discovery of other 
breast-related diseases (Güth et al., 2008). Despite the advantages of early 
cancer diagnosis, engagement in breast self-examination by women is still low, 
particularly in educationally-deprived and developing countries (Hacihasanogˇlu 
and Gözüm, 2008, Lechner et al., 2004). 
1.3.2 Molecular imaging for breast cancer  
1.3.2.1 Mammography  
Mammography is by far the most common approach for screening 
breast cancer. In Europe, women aged 50 to 70 are invited for breast screening 
every two to three years, while in US annual mammograms are recommended 
from 50 to 74 years equating to nearly 39 million images in 2014. Women who 
have an increased risk of developing breast cancer, but are too young to join 
national screening programs, are offered annual screening using 
mammography and magnetic resonance imaging (MRI) based on a risk-benefit 
decision. Sensitivity of mammography can vary from almost 100% to 40% 
dependent on tissue composition (Drukteinis et al., 2013, DeSantis et al., 2011), 
and positive association for prediction of disease is only 50%. False-positive 
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rates in breast cancer screening are a significant limitation, as high call-back 
rates and unnecessary biopsies result in increased cost, radiation dose, and 
patient anxiety during re-screening (Stout et al., 2014, Loberg et al., 2015). Over 
a period of 20 years, based on 7 trials of more than 600,000 women, screening 
was shown to reduce breast cancer mortality by 15%, however over-diagnosis 
was estimated at 29% (Gotzsche and Jorgensen, 2013, Nelson et al., 2009). In 
particular, mammography is around 10% less sensitive in women under 50 than 
in postmenopausal women (Mushlin et al., 1998). Women in their 40s screened 
within the UK Age Trial had a 5% risk of a false-positive result at their first screen 
(Johns et al., 2010) and a random clinical trial of 161,000 women showed that 
women aged 39 onwards did not significantly reduce their risk of dying from 
breast cancer within 5-15 years (Moss et al., 2006).  
The continuing development of mammography, including digitisation 
with improved resolution (full field digital mammography), has increased its 
position as the gold standard for screening but still requires the presence of a 
substantial mass in the breast for a diagnosis (Obenauer et al., 2002, Pisano et 
al., 2005). Many breast tumours may have already metastasised before 
detection by mammography. Equally, a mammogram cannot distinguish 
between DCIS that will remain benign (therefore not requiring treatment) and 
those that will progress to a malignant invasive tumour (Espina and Liotta, 
2011). Furthermore, radiation exposure has been shown to contribute to an 
increased incidence in breast cancer, particularly in high risk populations 
(Drukteinis et al., 2013). Consequentially, some women receive a cancer 
diagnosis even though their cancer would not have led to death or sickness, 
resulting in unnecessary surgery to remove the lump or whole breast. At worst, 
over-diagnosis can lead to unnecessary treatment, and some healthy women 
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dying needlessly from heart disease induced by radiotherapy, with the overall 
conclusion that screening did not reduce total mortality. 
One of the challenges for imaging methods is breast tissue density, 
which is higher in younger women, making their mammograms harder to 
interpret, whereas postmenopausal women with extensive fatty breast tissue or 
ductal atrophy are more likely to have an accurate diagnosis (Martin and Boyd, 
2008). Breast density is strongly associated with tissue composition (collagen, 
epithelial cell and non-epithelial cell content, glandular area), genetic influences 
and hormonal regulation (prolactin, IGF-1). Furthermore, mammographic 
density is positively associated with alcohol consumption, smoking in post-
menopausal women and with breast cancer (Martin and Boyd, 2008, Vachon et 
al., 2007). It is possible to quantitatively measure breast density using 
established and specialised imaging modalities in combination with bespoke 
algorithms (Yaffe, 2008), however this strategy has not been widely accepted. 
1.3.2.2 OTHER IMAGING TECHNIQUES 
Digital breast tomosynthesis (DBT) is a relatively new screening 
approach, which uses an X-ray beam in an arc around the breast to provide a 
3D reconstruction of the tissue. In a comparison of DBT with digital 
mammography for 2,666 breast lesions, the former had improved performance 
(sensitivity and specificity of 90% and 79%) compared to the latter (89% and 
72%, respectively)(Lei et al., 2014), but was also subject to the same limitations 
incurred by breast density. There were fewer recalls with DBT compared to 
digital mammography, particularly in younger women, and although approved 
by the food and drug administration (FDA) for breast screening, it is not widely 
available (Haas et al., 2013). Ultrasonography, using high-resolution linear 
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transducers, is readily accessible, similar in cost to mammography and 
moderately improves cancer detection, but has lower specificity, lower positive 
predictive value and was similarly obfuscated by tissue density (Giuliano and 
Giuliano, 2013).  
Contrast-enhanced MRI, by comparison is not limited by breast density, 
nor does it use ionising radiation. In a review of 11 studies comparing MRI with 
digital mammography, the former achieved 94% sensitivity, but identified few 
cases of cancer in addition to those discovered by digital mammography alone 
(Warner et al., 2008). Furthermore, MRI exhibits relatively low specificity, is not 
as accessible and is expensive to run. Positron emission tomography with 
computer tomography (PET-CT) uses gamma-radiated emitting fluorine-18 
fluorodeoxyglucose (FDG), a glucose analogue, injected into arm veins to 
accumulate in areas of high metabolic activity, such as tumours, and is then 
detected using a PET-CT x-ray scanner (Avril et al., 2000). Sensitivity of PET-
CT ranged from 71% and 90%, which was improved further when combined 
with mammography, but results were affected by breast size (Schirrmeister et 
al., 2001). However, PET-CT is more often used to assist surgery to remove 
diseased tissue rather than as a front-line routine screen for initial detection of 
breast cancer.  
Wave elastography uses ultrasound or MRI techniques to measure 
tissue stiffness, which is positively associated with a tumour mass compared to 
normal tissue.  The application of shear wave elastography, which uses the 
force of acoustic radiation produced by an ultrasound beam, demonstrated 
improved sensitivity and specificity (Krouskop et al., 1998). Electrical impedance 
scanning is another modality under development for breast cancer detection 
especially in young women with dense breasts, which is based on lower 
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electrical impedance in malignant tumours compared to the surrounding normal 
tissue (Hope and Iles, 2004). Recent technological advances have facilitated 
dynamic thermal analysis of the breast by recording of circadian rhythm 
variations and analysing the recorded data using highly sophisticated statistical 
algorithms, but the approach currently suffers from high false positive rates 
(Salhab et al., 2006). Although showing great promise, none of these innovative 
imaging approaches are in a position to replace mammography as the 
mainstream approach to routinely detect breast cancer and most importantly 
cannot differentiate between benign and malignant growths. Furthermore, the 
instrumentation for these types of screening is expensive and not readily 
available in all hospitals. The current molecular imaging techniques have been 
used for detection of breast cancer in clinical practise is summarised in Table 
1-4 (Specht and Mankoff, 2012). 
Despite this progress, there are still significant challenges, (i) detection 
of the earliest stages of cancer (differentiating between DCIS that will remain 
benign or become malignant) to enable early intervention for triple negative 
breast cancer patients (for whom there is no targeted therapy, poor prognosis, 
lower survival rate and higher chance of re-occurrence), (ii) avoiding 
unnecessary preventative surgery (particularly for BRCA-1/BRCA-2 mutation 
carriers) and (iii) identifying those patients who will not respond or become 
resistant to chemotherapy and hormone therapy. 
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Modality Indication Sensitivity Specificity Advantages Disadvantages Reference 
Self-examination 
Tumour 
detection 
53.9% 54–59% 
A free and easy way to look for 
cancer and reduce mortality, 
Some breast lumps can be missed, 
cause unnecessary distress 
(Güth et al., 
2008) 
Mammography 
Tumour 
detection 
73-86% 88-93% 
Inexpensive, highly portable and 
does not necessarily require a 
contrast agent 
Discomfort, limited depth penetration, 
challenging spatial localization, and 
radiation exposure, False positive and 
false negative results 
(Smith et al., 
2012) 
Ultrasound, 
especially with 
contrast 
enhancement 
Detection 
Tumour 
characterization 
61.4% 82% 
Highly portable, inexpensive 
Molecular microbubble agents 
possible 
Operator dependence Contrast agents 
confined to vascular system. 
(Houssami and 
Turner, 2014) 
Magnetic 
resonance 
imaging (MRI) 
Tumour 
characterization 
77-99% 81-99% 
Quantification of tumour perfusion 
and tumour capillary permeability 
Confined space, Contrast design 
limited by need for magnetic atom. 
(Bleicher and 
Morrow, 2007) 
Magnetic 
resonance Proton 
spectroscopy 
Tumour 
characterization 
91% 93% 
Can measure wide range of 
molecules No contrast necessary 
Limited spatial resolution Challenging 
to obtain high-quality spectra in routine 
imaging 
(Berg et al., 
2006) 
Positron emission 
mammography 
Detection 
Tumour 
characterization 
71-99% 66-69% 
More sensitive for smaller tumours 
Higher spatial resolution 
Increased radiation dose Visualization 
of posterior lesions Variable uptake of 
18F-fluorodeoxyglucose (FDG) in small 
and less metabolically active tumours 
(Sachelarie et 
al., 2005) 
Positron emission 
tomography 
Detection 
Response 
evaluation 
characterization 
64-96% 73-99% 
Wide range of molecular imaging 
probes Tracer imaging without 
perturbing biologic system 
Limited spatial resolution (improved 
with use of non-contrast computed 
tomography) Some radiation exposure 
(Specht and 
Mankoff, 2012) 
Core biopsy 
Detection, 
Tumour 
characterization 
91.5% 87.7% 
Differentiating benign and 
malignant, 
Discomfort and painful because a 
surgical procedure required, Risk of 
complications like infection and 
bleeding. 
(Bianchi et al., 
2015, 
Yamaguchi et 
al., 2015) 
Table 1-4: Methods for detecting breast cancer. 
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1.4 Biomarkers 
A biomarker is defined as “A characteristic that is accurately measured 
and evaluated as an indication of normal biologic developments, pathogenic 
processes, or pharmacologic effect to a therapeutic intervention” (Aronson, 
2005).  The utility of a biomarker lies in its ability to provide an early indication 
of the disease, to monitor disease progression, to provide ease of detection, and 
to provide a factor measurable across populations. There are three functional 
types of biomarkers; (1) diagnostic, (2) prognostic and (3) predictive. Diagnostic 
markers are used confirm the presence or absence of disease, prognostic 
markers help to define a suitable clinical treatment for the disease and predictive 
markers forecast the likely outcome of treatment or disease progression in the 
absence of treatment (Azad et al., 2006).  
1.4.1 Biomarkers of breast cancer 
There have been extensive studies to identify breast cancer biomarkers, 
but with varying degrees of success. Genomics has already stratified the 
disease to identify high risk individuals and histopathological approaches are 
used to determine ER, PR and HER2 expression, helping to direct clinical 
intervention.  A key challenge in breast cancer clinics is the resolution of tumour 
heterogeneity, particularly at the molecular level. The investigations, over the 
past few years, have identified key genes (e.g. BRCA-1 and BRCA-2) and 
specific proteins (e.g. ER, PR and HER-2) as markers for selection of therapy, 
through genomic techniques (Galvão et al., 2011). Differentiation of ER, PR and 
HER2 expression status, have played a valuable part in the prognosis and 
identification of the different subtypes of breast cancer. For example, women 
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diagnosed with estrogen receptor positive (ER+) and progesterone positive 
(PR+) tumours have a better prognosis and high response to hormonal 
treatment, using tamoxifien and ramoxifen, than those who are oestrogen 
receptor negative (ER-) and progesterone receptor negative (PR-). An example 
of a biomarker in breast cancer is estrogen receptor that is expressed by some 
sub-groups of breast tumours. Various anti-estrogens molecules; tamoxifen or 
aromatase inhibitor (like Anastrozole) have been developed to target this 
receptor for breast cancer treatment (Ariazi et al., 2006).  
 Indeed, microarray-based technologies for routine prognostic 
screening of  multigene signatures (for example, 70-gene MammaPrint for 
tumour aggressiveness/chemotherapy requirement /metastatic prognosis, 
Celera 14-gene metastasis score, Oncotype-DX 21-gene signature for 
measuring risk of re-occurrence, and 76-gene Veridex signature for tamoxifen 
therapy benefit (Zhang et al., 2009)) have been invaluable in supporting 
treatment of ER/PR positive breast cancers. However, the identification of a 
specific biomarker for the detection of breast cancer at the earliest stage that 
can be analysed in biopsies, has so far evaded the diagnostic industry. Proteins 
and metabolites have been discovered which were increased in malignant 
tissues compared to normal, but were subsequently found to be diluted beyond 
the level of detection in plasma or urine, or were found not to be specific to 
breast cancer  (Brooks, 2009). In addition, depletion methods may be required 
to remove the most abundant proteins such as albumins and immunoglobulins 
from plasma, prior to analysis, which can result in losses and further reduced 
sensitivity. Suffice to say, a comprehensive review of breast cancer biomarkers 
in 2007 by the update committee of the American Society of Clinical Oncology 
failed to recommend any of the most promising candidates, including blood 
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levels of CA 15-3 and CA 27.29 (both forms of mucin-1) for diagnosis, detection 
of recurrence, decisions on therapy or metastasis, or circulating truncated 
extracellular HER2 for detection of breast cancer (Harris et al., 2007). Clearly, 
accessing tissue biopsies to look at tumour-associated biomarkers, where they 
are most concentrated, on a regular basis is not practical, though most of the 
accepted biomarkers ER, PR, HER2, uPA and PAI-1 are currently analysed in 
tissues by immunohistochemistry or ELISA (Harris et al., 2007). Hence, the 
challenge remains, how to provide a low cost, safe, simple, sensitive and 
specific method for detecting breast cancer, early enough, to improve the 
direction of current treatment regimen and avoid extreme preventative 
intervention such as elective bilateral mastectomy. In this context, molecular 
diagnostic approaches for the early detection of breast cancer remain largely 
untapped. 
By far the best biofluids for developing a screening diagnostic are those 
readily accessible and closely aligned with the disease area, such as saliva for 
oral cancers or urine for bladder or renal cancer. In this respect, various 
methods have been developed to access ductal liquids that are associated with 
cells that are the origin of most breast cancers (see Table 1-5, and section 1.6 
for further details on biopsy materials). 
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1.5 Proteomics 
The term ‘Omics’ describes all the biological constituents of a system and 
common examples are genomics, epigenomics, transcriptomics, proteomics, 
metabolomics and lipidomics. The main aim of these is to characterise the profile of 
their given area in a comprehensive and unbiased way. These ‘omics’ approaches 
are based on whole biological system which defines the whole process from which 
DNA is transcribed to mRNA then translated to proteins, which in turn affect almost 
every omic system (Crick, 1970, Hegde et al., 2003). In the case of cancer, omics 
helps to differentiate patterns in biomolecules that are characteristic of neoplasia. 
Understanding these characteristics is important to identify the main differences 
between normal and cancerous cells, which can be used to target cancers or 
oncogenic mechanisms. 
. Next-Generation Sequencing (NGS) allows sequencing of DNA and RNA 
much more quickly and cheaply, with high-throughput sequencing (van Dijk et al., 
2014). The most common NGS technologies include; Illumina (Solexa) sequencing, 
Roche 454 sequencing, Ion torrent: Proton / PGM sequencing and SOLiD 
sequencing (Metzker, 2010). A single nucleotide alteration can induce altered 
translation, and can cause major changes to the function of a protein, which may 
have an important role in tumour suppression. For example, tumour protein p53 
(TP53), has more than 2500 known mutations of which 52 have been identified in 
cancers (Leroy et al., 2013). TP53 mutations has been shown to be an important 
player in human cancers; activate angiogenesis and DNA repair proteins when DNA 
has sustained damage, cell proliferation, and inhibition of apoptosis (Leroy et al., 
2014). Genomics also helps profile the effect of these mutations on promoter or 
enhancer regions and other noncoding DNA, by explaining the genetic cancer risk 
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factors, cancer screening and prevention, and targeted therapy, fulfilling the 
potential of personalized medicine(Weitzel et al., 2011). 
The expression of total RNA molecules in a tissue or cell is characterised 
by Transcriptomics and is a useful approach to differentiate the mutated gene 
expression in a tumour (Hegde et al., 2003). The physio-chemical nature of mRNA 
makes the specific profiling of transcripts a rapid and reproducible method. 
Microarray technology, such as Affymetrix GeneChip microarray allows large scale 
investigation of thousands of transcripts simultaneously (Eddy et al., 2010). The 
shotgun sequencing ‘RNA-seq’ is a deep sequencing approach and presents the 
opportunity to obtained high-resolution total transcriptome characterisation (Maher 
et al., 2009). Protein translation process is controlled by numerous RNA binding 
factors, processing bodies, RNA secondary structures and ribosomal mechanisms 
(Kozak, 2007). So protein expression profiling does not directly correlate with 
transcript expression, presenting a need for the direct measurement of relative 
protein expression (De Godoy et al., 2008). Hence, to fully understand the 
phenotype of a cell, investigation of protein expression is very important. 
Proteomics is the analysis of a complete set of proteins synthesized by a 
cell under a given set of physiological or developmental conditions (Anderson et al., 
2000). The final product of a gene has even more complex functionality compared 
to the gene itself, so investigation of proteins is essential. Moreover, only through 
proteomics, can post-translational modifications be determined which have a 
diverse range of effects on the function of proteins. The emergence of proteomics 
is based on; developments in mass spectrometry, internet-based DNA and protein 
sequences databases and computer algorithms for database searching using mass 
spectrometric data (Lamond et al., 2012). A range of different disciplines such as 
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molecular biology, biochemistry and bioinformatics are required to achieve this 
ambitious target. The value of proteomics has broader applications: in medical 
research, drug discovery, forensics science, food quality control and microbial 
interactions Figure 1-2 (Lamond et al., 2012). 
 
Figure 1-2: The significance of Proteomics on human life. 
At the protein level, due to post-translational modifications (e.g. acetylation, 
glycosylation, phosphorylation), alternation in RNA splicing or proteolytic processing 
the 20,193 genes of the human genome inflates to expression of 500,000–
1,000,000 variations (Galvão et al., 2011). Hence, proteins indicate the precise 
genetic mechanisms and their effect on the microenvironment of the cell making 
them more accessible therapeutic targets (Galvão et al., 2011).  
Proteomics enables two main strategies for biomarker identification; (a) 
discovery approach and (b) targeted approach. Most biomarkers are proteins, 
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therefore  investigation of protein expression that reflect changes healthy and 
diseased cellular behaviour using proteomics provides the opportunity to identify 
new biomarkers (Matt et al., 2008). The discovery approach is quantitative and 
qualitative proteome profiling of appropriate tissues, cell lines and bio-fluids to 
observe as many changes as possible between normal and disease protein profiles 
(Matt et al., 2008). The targeted approach is based on traditional hypothesis of a 
biological rational for investigation of a specific protein or pathway. Strategies for 
discovering a novel protein biomarker of breast cancer are shown in Figure 1-3 
(adapted from (Aronson, 2005, Azad et al., 2006, Matt et al., 2008)).  
 
Figure 1-3: Strategies for discovering novel breast cancer protein biomarkers. 
1.6 Proteomics and Mass Spectrometry  
The profiling of the proteome is more challenging as compared to the 
genome, with potentially more than 5 times as many proteins than coding genes 
(Gstaiger and Aebersold, 2009). Proteins have enormous diversity due to different 
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combinations of the 20 amino acids from which they are built, amplified by many 
potential post-translation modifications. Where DNA and RNA investigation can be 
facilitated through their logarithmic amplification using methods such as the 
polymerase chain reaction (PCR), proteins don’t have such properties and their 
detection is determined by the sensitivity of available proteomics methods and 
techniques (Altelaar et al., 2013).  Most proteomics approaches are based on mass 
spectrometry, which allows precise mass measurements by MS and fragmentation 
by MS/MS of a peptide confident identity of a protein (Karas and Hillenkamp, 1988, 
Hunt et al., 1986). There are two main strategies for MS based proteomics; top-
down, to characterise intact proteins and bottom-up, which first converts proteins 
into peptides by amino acid-specific protease digestion or chemical cleavage.  The 
use of bottom-up proteomics for more complex samples, is called as ‘shotgun 
proteomics’, which is the conversion of 1000’s of protein to 10,000’s of peptides 
(Wolters et al., 2001). One of the most important challenges in proteomics is the 
separation of these complex peptide digests for characterisation, and is essential 
prior to sensitive and accurate analysis by MS (see section 1.6.3 for MS analysis).  
The proteomics approach process consists of a number of steps; 
preparation of biological samples, separation of peptides mixture, ionization of 
peptides, acquisition of full spectrum, selection of specific precursor ions, 
fragmentation and identification of peptides or proteins through databases search 
(Figure 1-4) (Domon and Aebersold, 2010). 
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Figure 1-4: Workflow illustrating typical proteomic experiment (Domon and 
Aebersold, 2010). 
1.6.1 Sample preparation 
In bottom-up Proteomics, the sample preparation is very important and 
includes three steps; cell/tissue disruption, protein solubilisation in a buffer, and 
removal of interfering substances. A well-controlled procedure is required to extract 
high quality and adequate amounts of proteins from sample for proteomics analysis, 
to maximize reproducibility of data. Protein extraction can be performed on cultured 
cell lines and tissues by three methods; mechanical, chemical, enzymatic, 
individually, and/or in combination. Chemical based extraction methods involve the 
use of organic solvents or detergent and are very popular because of low cost and 
high protein yield. Detergents (for example, SDS, CHAPS, Triton X-100) disrupt the 
cell membrane by breaking the lipid-protein interactions and result in solubilisation 
of proteins in the extraction buffer. The main challenge of detergent-based 
extraction methods, are suppression of peptide derived signals in MS analysis by 
residual detergent (Wisniewski et al., 2009). Therefore, extraction buffer must have 
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optimised amount of detergent and/ or be followed by detergent removal step before 
MS analysis. 
Mechanical extraction methods have an advantage over chemical methods, 
because they can keep the activity of the protein of interest but yield less protein 
amount compare to chemical based method (Moore et al., 2016). There are different 
type of mechanical methods such as; freeze-thaw (Kumar et al., 2004), cryo-
pulverization (Moore et al., 2016), sonication (Rial-Otero et al., 2007), and electrical 
homogenizers or blenders (Bodzon-Kulakowska et al., 2007), but the choice of 
method depends on different factors; type of biological material, cellular location, 
stability and post extraction analysis. 
The most common protein extraction method for whole proteome analysis, 
is a combination of detergent and sonication (Bodzon-Kulakowska et al., 2007, 
Wisniewski et al., 2009). In this assay, samples are first solubilised in extraction 
buffer (detergent and protease inhibiter; to prevent protein degradation), followed by 
probe sonication to disrupt the cells or tissues by high-frequency sound waves. 
These sound waves can increase the temperature of sample, so this process is 
conducted in multiple short bursts and an ice bath to maintain the samples at low 
temperature (Wisniewski et al., 2009). 
1.6.2 Preparation of peptides mixture 
After protein extraction, proteins are broken into peptides by chemical or 
enzymatic digestion in an approach called Mudpit (Multidimensional protein 
identification technology) or Shotgun proteomics. Extracted proteins are desalted 
using cut off filters or precipitation with organic solvents, to remove contaminants 
such as; salts, nucleic acids, detergent, and lipids (Feist and Hummon, 2015). 
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Protein samples are treated with a reducing reagent (e.g. β-mercaptoethanol or 
dithiothreitol (DTT), to cleave disulphide bonds within and between protein subunits, 
result in opening of 3D structure of proteins. This step is further supported by 
alkylating reagents (e.g. iodoacetamide, or vinyl pyridines), to prevent reforming 
disulphide bonds (Bai et al., 2005, Righetti, 2006). After reduction and alkylation, 
proteins are broken into peptides (protein digestion) with chemicals or enzymes. 
The most common method of proteins digestion is based on trypsin, a protease with 
well-defined cleavage specificity. Trypsin cleaves at the C terminal side of the basic 
amino acid residues lysine (K) and arginine (R) unless the next residue is a proline 
(P) (Olsen et al., 2004). The MS and MS/MS analysis is conducted on the digested 
peptides and the information acquired then transferred to a search engine to identify 
and/or quantify the original proteins. Hence, careful sample processing at the protein 
and peptides level is the key for high quality MS data. 
1.6.3 Fractionation of peptides mixture 
Different fractionation or separation methods are used in proteomics, to 
improve proteome coverage and signal-to-noise and to reduce interference between 
peptides in MS analysis. These fractionation methods also provide some additional 
information about analytes, such as molecular weight, hydrophobicity or isoelectric 
point. The most common fractionation methods are; strong cation exchange (SCX) 
chromatography, peptide isoelectric focusing (pIEF) and high-pressure liquid 
chromatography. 
1.6.3.1 Peptides IPG-IEF fractionation 
Peptide isoelectric focusing (IEF) in immobilized pH gradients (IPG) 
fractionations can be performed in two ways: in-gel or off-gel, but in both 
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approaches, a peptide mixture is applied on to an IPG strip by rehydration and 
focused within the gel matrix by IEF, which separates peptides based on the 
isoelectric point (pI), a physicochemical feature of charged analytes. The 
fractionated peptides are extracted from wells of an IPG strip (off-gel) or excised 
sections of the strip (in-gel) (Pernemalm and Lehtiö, 2012, Cargile et al., 2005, Hörth 
et al., 2006). The most rapid effective off-gel separation system for state-of-the-art 
proteomics, is the Agilent Technologies 3100 OFFGEL Fractionator (Pernemalm 
and Lehtiö, 2012). 
1.6.3.2 Liquid chromatography 
Liquid chromatography (LC) provides a source of separation for proteins or 
peptides on the bases of their physicochemical properties. The separation is carried 
out using columns packed with chromatography beads with specific binding 
properties, within which different molecules have different levels of interaction, 
described as a retention. The two major components of LC; a stationary phase, the 
material with which the analytes can interact and the mobile phase, the continuously 
flowing solvent transporting the analytes (Di Palma et al., 2012). There are a number 
of types of chromatography; ion exchange chromatography, normal phase 
chromatography, reverse phase chromatography, flash chromatography, size 
exclusion chromatography and  affinity chromatography (Snyder et al., 2011). 
Reverse-phase (RP) LC is used in proteomics, which enables the 
separation of peptides based on hydrophobicity. The stationary phase is a 
hydrophobic resin, consists of long hydrophobic alkane molecules, typically 8 or 18 
carbon atoms in length, termed C8 and C18, respectively (Di Palma et al., 2012). 
Digest peptides are injected onto the stationary phase, which cause partition of 
peptides into the stationary phase, resulting in retention. RP LC also provides 
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desalting capability because buffers are not partitioned on the stationary phase.  The 
hydrophobicity of the mobile phase is then gradually increased as a ‘gradient’, which 
results in release of peptides into the mobile phase. The retention time of each 
peptide is therefore proportional to its hydrophobicity (Di Palma et al., 2012). 
1.6.3.3 Ion-exchange chromatography 
Ion-exchange chromatography (IEC), is based on electrostatic attraction 
between the analytes and the functional groups of the stationary phase, which 
results in the fractionation or separation of peptides according to differences in their 
charge (Phyllis, 1997). IEC has two types; (a) anion-exchange chromatography 
(SAX), positive functional groups have affinity for negatively charged peptides at 
basic pH and (b) cation-exchange chromatography (SCX), negative functional 
groups attract positively charged peptides at acidic pH. In IEC techniques, the 
elution of peptides is performed by changing the pH or ionic strength of mobile 
phases to disrupt the peptide interaction with the stationary phase. Strong cation 
exchange (SCX) chromatography with a salt gradient or incremental salt steps such 
as potassium chloride (KCl), is frequently used in peptides mass spectrometry, with 
combination of  reversed-phase (RP) chromatography as a second dimension 
(Manadas et al., 2010, Essader et al., 2005). 
1.6.4 Types of Mass spectrometry 
Mass Spectrometry based characterisation of peptides is performed by 
several techniques, depending on the type of instrument, and means of ionisation. 
By definition, a mass spectrometer consists of three parts; (i) an ion source, (ii) a 
mass analyser that measures the mass-to-charge ratio (m/z) of the ionized analytes, 
and (iii) a detector that reads the number of ions with each m/z value. Matrix-
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assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI), are 
the two common techniques to volatise and ionise proteins or peptides for mass 
spectrometric analysis (Fenn et al., 1990, Karas and Hillenkamp, 1988). In the 
MALDI approach, samples are ionised via laser pulse, on a dry mixture of sample 
and crystalline matrix, while ESI ionises the analytes out of solution and is therefore 
coupled to liquid based separation tools such as liquid chromatographic 
instruments. ESI-MS systems (LC-MS) is normally used to analyse more complex 
samples, whereas MALDI-MS systems are preferred for the analysis of simple 
peptide mixtures (Walther and Mann, 2010). After ionisation, charged molecules are 
focused with lenses then separated with the mass analyser. There are different 
types of mass analyser, such as; Ion trap, Orbitrap, Quadrupole, time of flight (TOF), 
and the mass-to-charge ratio (m/z) determined with a detector (Walther and Mann, 
2010). 
1.6.4.1 MALDI-MS 
Matrix Assisted Laser Desorption Ionization (MALDI) instrument is usually 
coupled with TOF analysers but instruments with quadrupole ion-trap and two types 
of TOF mass analysers are also available, to allow the fragmentation of MALDI-
generated precursor ions (Krutchinsky et al., 2001). In MALDI-TOF/TOF 
instruments, two TOF sections are separated by a collision cell (Medzihradszky et 
al., 2000), whereas in the hybrid quadrupole instrument, the collision cell is placed 
between a quadrupole mass filter and a TOF mass analyser (Loboda et al., 2000). 
TOF or quadrupole analysers are used to select ions of a particular m/z, then 
fragment these molecules in a collision cell and generated fragments separated in 
TOF analyser.  The MALDI-TOF/TOF mass spectrometer (Ultraflex TOF/ TOF, 
Bruker) consists of a  MALDI ion source (King et al., 1995, Juhasz et al., 1996, Holle 
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et al., 1997), a high-resolution timed ion selector (TIS), a “lift” device for raising the 
potential energy of the ions (analytes), a further subsequent post-acceleration 
(source 2) to focus the ions, a post-lift metastable suppressor (PLMS), an energy 
focusing reflector, and fast ion detectors for the linear and reflector mode (Figure 
1-5, adopted from Suckau et al 2003) (Suckau et al., 2003). 
 
 
Figure 1-5: Schematic view of a MALDI-TOF/TOF mass spectrometer (Suckau et 
al., 2003). 
 34 
 
1.6.4.1.1 MALDI-TOF/TOF ion source 
The MALDI ion source accepts target plates of the same shape and size 
as microtiter plates. MALDI target plates (AnchorChip), equipped with 384 
hydrophilic anchors on a hydrophobic surface, which enhance the sensitivity for 
peptide samples at least 10-fold in MS analysis (Schürenberg and Franzen, 
2001, Schuerenberg et al., 2000). All AnchorChip plates have a bar code, which 
is read by the mass spectrometer, to specify for sample-specific analytical tasks. 
The AnchorChip targets are automatically introduced into the source chamber, 
where a vacuum system is maintained through a vacuum lock. The MALDI 
source has an image recognition system, to find the exact locations of the 
analyte spots. This feature allows automated MS and MS/MS analysis in the 
instrument without manual interference. However, MALDI-TOF/TOF is not 
directly coupled to liquid chromatography, so peptides must be deposited on a 
sample plate and mixed with the MALDI matrix, a process that has thus far 
proven difficult to automate MALDI-MS analysis. 
1.6.4.1.2 Laser 
The most common type of laser used in MALDI-TOF/TOF, operates at 
200 Hertz. When the laser is fired on matrix crystals, causing ionisation of matrix 
(addition of a proton), then this proton is transferred to proteins or peptides, thus 
charging the analytes. A typical MS spectrum with good dynamic range and high 
signal-to-noise ratio can be achieved with 50–200 laser shots. In MS/MS mode 
typically 300-600 shots are required to get better spectra when analysing 
biological samples (Suckau et al., 2003). 
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1.6.4.1.3 MS mode for analytes acquisition 
In the MS mode, the instrument operates as a MALDI-TOF 
spectrometer in linear, reflector, positive and negative modes. In linear MS 
mode, a gated MCP (micro channel plate) detector is applied to prevent detector 
saturation from low-mass ions and neutrals and increases the sensitivity MS, 
especially for high-mass proteins. In reflector mode, a fast dual MCP detector is 
used with micro channels (5µm bore diameter and a bias angle of 12°), to get 
symmetrical peak shapes for determining the exact mass of isotopic peaks in 
the spectrum by software algorithms such as SNAP (Sjoberg, 2014). The 
instrument is prepared for a full mass-range high resolution mode, from 500Da 
to 4000Da and lower mass range is limited by the detection system which 
enhances a constant signal width to the ion signal (Suckau et al., 2003, Han et 
al., 2008). 
1.6.4.1.4 MS/MS mode for analyte identification 
After full MS scan, acquisition conditions must be modified to generate 
high quality MS/MS scan; fragmentation of parent peptides. This is achieved by 
increasing laser power to provide a larger number of precursor and fragments 
ions per shot. Once these fragments ions are generated, the velocity is 
maintained with the corresponding precursor, so this ‘ion family’ (precursor and 
its fragments), will reach the timed ion selector (TIS) together. The TIS will only 
allow selected ion family to enter “LIFT” device and deflect all other ion families. 
The LIFT technology consists of three steps; (a) increasing the potential on the 
two adjacent grids forming the cell, (b) a focusing cell to modulate the speed of 
the ions, and (c) accelerating the ions at full speed by post-acceleration cell and 
time-focused onto the detector. The gridless two-stage reflector also plays its 
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role by focusing the divergent ion beam onto the detector. The high sensitivity 
and high signal-to-noise ratio can be achieved on MALDI-TOF/TOF by utilising 
“post lift metastable suppressor” (PLMS) and gridless reflector. Both features 
prevent undesired fragment ion formation after post-acceleration and the PLMS 
works as an ion deflector same like TIS before LIFT device (Jurinke et al., 2004, 
Suckau et al., 2003, Han et al., 2008). 
1.6.4.2 ESI-MS 
Over the last decade, electrospray ionisation mass spectrometry (ESI-
MS) has become an important analytical technique in scientific laboratories. It 
provides a sensitive, robust and reliable method to investigate at femtomole 
quantities in micro-litre sample volumes that are impossible to analysis by other 
conventional techniques.  Mass spectrometers coupled with high performance 
liquid chromatograph (HPLC), provides very powerful approach for analysing 
both small and large molecules of various polarities in a complex biological 
sample (Han et al., 2008). Automated sample introduction system; HPLC-ESI-
MS, make this a technique for rapid analysis and high sample throughput. 
1.6.4.2.1 Electrospray Ionisation Process 
Electrospray ionisation (ESI) is carried out through electrical energy to 
assist the transfer of ions (analytes) from solution into the gaseous phase before 
they are subjected to MS analysis. The transfer of analytes from solution into 
the gas phase by ESI involves three steps: (a) dispersal of a fine spray of charge 
droplets, (b) solvent evaporation and (c) ion discharge from the highly-charged 
droplets (Desiderio, 2013, Fenn et al., 1990, Bruins et al., 1987). ESI source 
coupled with mass spectrometer, is maintained at a high voltage; 1.8 - 5.0 kV, 
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while a continuous stream of sample solution is passed through a stainless steel 
or quartz silica or glass emitter. A mist of highly charged droplets; positive or 
negative, are generated according to polarity of the capillary voltage.  ESI 
process can be further improved by an elevated ESI-source temperature and 
using a nebulising gas; such as nitrogen, if a solution is being injected at a higher 
flow rate(Ho et al., 2003). These factors; electric field, elevated temperature and 
nitrogen gas, result in ejection of ions from charged droplet into the gaseous 
phase. Only charged ions are sampled by skimmer cone and analysed by mass 
spectrometer (Ho et al., 2003). 
1.6.4.2.2 Orbitrap Fusion 
The Orbitrap Fusion is a tribrid architecture mass spectrometer (Figure 
1-6) with three mass analysers; quadrupole, linear ion trap, and Orbitrap, with 
multiple fragmentation techniques (CID, HCD, ETD) at any stage of MSn, 
maximise the amount of high-quality data acquisition(Senko et al., 2013). Ultra-
high-field Orbitrap mass analyser with resolving power up to 500,000 FWHM at 
m/z 200 and dual pressure linear ion trap mass analyser, are especially useful 
when dealing with complex and low-abundance samples in proteomics, 
glycomics, metabolomics, lipidomics and similar applications. Synchronous MS3 
precursor selection (SPS) significantly increases number of peptides and 
quantification accuracy of iTRAQ or TMT experiments (Senko et al., 2013). 
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Figure 1-6: Schematic view of Orbitrap Fusion Tribrid mass spectrometer. 
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1.6.4.2.2.1 Quadrupole mass analyser 
A quadrupole mass analyser is an assembly of 4 parallel metal rods and 
is kept at equal distance. When ions pass through these metal rods, they travel 
forward in the z direction with oscillatory motion in the x-y plane because an 
equal but opposite DC voltage and radio frequency (RF) AC voltage is applied 
to the diagonally placed pair of rods. The amplitude of oscillation contains a 
unique relationship with the m/z ratio and can be controlled in pre-fixed ratio, by 
changing the DC and RF voltages simultaneously. These DC and RF voltages 
values, allow only desirable m/z ratios (target ions) to travel along the z-axis 
without hitting the quadrupoles, while removing undesirable ions which are 
neutralised and fail to reach the detector (Ho et al., 2003, Marmet, 1971).  
1.6.4.2.2.2 Ion trap mass analyser 
Ion trap mass analyser consists of three hyperbolic electrodes: (a) the 
ring electrode, (b) the entrance end cap electrode, and (c) the exit end cap 
electrode, to form a cavity in which ions are trapped (stored). Ions travel through 
a small hole in the centre of both end cap electrodes and the ring electrode is 
located in the middle between the end cap electrodes. The ions are trapped and 
ejected from the mass analyser by applying various voltages. A 3-dimensional 
quadrupolar potential field within the trapping cavity is produced by ring 
electrode RF potential. This AC potential of constant frequency and variable 
amplitude stores ions in a stable oscillating trajectory within the trap cell. These 
trapped ions are ejected to detector system in order of increasing m/z ratio, by 
altering the potentials on electrodes. During MS/MS acquisitions, the precursor 
ion is selected inside the trap cell where an inert gas; helium is introduced for 
collision-induced dissociation (CID). After fragmentation of precursor ion, the 
product ions are ejected for detection or kept inside the trap cell for further CID 
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reactions (MSn); to differentiate molecules with similar structures (Yoshinari et 
al., 2000, Makarov et al., 2006). 
The main limitation of ion trap instrument is cycle time for a single 
MS/MS scan; how fast the ions are transferred out of the analyser to the 
detectors. But novel dual-pressure linear ion trap mass analyser in Orbitrap 
Fusion instrument, provides increased ion transmission because of a two-
chamber ion trap mass analyser regulated at different pressures (Senko et al., 
2013). Dual-pressure linear ion trap mass analyser, provides higher resolution, 
more efficient isolation and dissociation of ions, and much faster scanning rates 
than the basis linear ion trap instrument (Pekar Second et al., 2009).  
1.6.4.2.2.3 Orbitrap Mass analyser 
The orbitrap analyser is a member of Fourier transform ion cyclotron 
mass spectrometry (FTMS), based on Fourier transform ion cyclotron 
resonance (FTICR) principle (Comisarow and Marshall, 1974).  In FTMS 
instruments, ions are trapped in a strong magnetic ﬁeld combined with weak 
electric trapping plates, where they are excited by an oscillating electric field 
orthogonal to the magnetic field and detected, digitized, and converted in mass 
spectrum using Fourier transform into the frequency domain. The Orbitrap mass 
analyser has three electrodes; two outer electrodes and a central ring electrode. 
The outer electrodes have the shape of cups, facing each other and electrically 
isolated by a hair thin gap but secured by the central electrode (Makarov et al., 
2006, Michalski et al., 2012). A linear electric field is maintained between the 
outer and the central electrodes by voltage current, to create purely harmonic 
oscillations. At the same time, the centrifugal force of the ﬁeld strongly attracts 
ions to the central electrode but with Orbitrap configuration, the ions remain on 
a nearly circular spiral inside the trap cell, much like planets in a solar system. 
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In the Orbitrap Fusion, ions are stored in the C-trap after the quadrupole, then 
a high-voltage pulse is applied across the trap, each m/z being ejected as small 
packets between the outer and central electrodes through a specially machined 
slot in one of the outer electrodes. The special conical shape of electrodes, push 
the ion toward the widest part of the trap cell, initiating harmonic axial oscillations 
then outer electrodes are used as image current detectors for these axial 
oscillations. The digitised image current in the time domain is Fourier-
transformed into the frequency domain to give a mass spectrum (Michalski et 
al., 2012, Zubarev and Makarov, 2013). 
1.6.4.2.3 Triple quadrupole mass spectrometer 
A triple quadrupole mass spectrometer consists of three quadrupoles (3 
x 4 parallel metal rods), arranged in a linear fashion. A typical work flow on this 
instrument has following steps; (a) selection of analyte ion in first quadrupole 
(Q1), (b) fragmentations of the precursor ion in second RF-only quadrupole 
collision cell (Q2) by collision gas (usually argon) and (c) third quadrupole mass 
analyser (Q3) is used to monitor generated fragments to determine the 
quantitative information of the analyte ions (Hunt et al., 1986).
 42 
 
  
 
Figure 1-7: Schematic view of a triple quadrupole mass spectrometer system 
(Ho et al., 2003).  
The process of fragmentation of precursor ion is known as collision-
induced dissociation (CID). This tandem system is commonly denoted as “QQQ” 
mass spectrometer. When Q1 is applied for specific m/z ratio, it filters out all 
other precursor ions with different m/z ratios. This step is like a “purification” 
inside the mass spectrometer, eliminating time-consuming and complicated 
sample purification or enrichment procedures prior to MS analysis. The QQQ- 
MS system is commonly used for product ion scanning to study molecular 
structure of molecules drug metabolites (Hunt et al., 1986). Nowadays, triple 
quadrupole mass spectrometers are commonly used in clinical laboratories for 
multiple reaction monitoring (MRM) assay, to quantify disease related markers 
in complex biological sample (Ho et al., 2003). 
1.6.5 Peptide fragmentation 
Each precursor (peptide) is isolated by applying a mass filter and is then 
subjected to fragmentation. This process is called MS to MS/MS or MS2, which 
generates daughter ions that are representative of fragmentation across the 
peptide backbone (Washburn et al., 2001). Fragmentation of peptides is 
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performed inside the mass spectrometer by using a gas (nitrogen or helium) or 
a reagent (Fluoranthene). The resulting fragments ions have a mass difference 
corresponding to the residue masses of respective amino acids. If charge is 
retained on the N- terminal of peptide residue, the fragment ions are called a, b 
or c transitions and x, y, z transitions if charge is maintained at C-terminal 
(Figure 1-8). This information is subsequently used to identify the peptide, in a 
process known as peptide mass fingerprinting.  
There are three common types of peptides fragmentations; Electron-
transfer dissociation (ETD), collision-induced dissociation (CID) and high-
energy collisional dissociation (HCD). ETD is performed in an ETD ion source 
(Fluoranthene 202 m/z), on the Orbitrap Fusion, which induces fragmentation 
of cations (e.g. peptides or proteins) by transferring electrons to them. Electrons 
are transferred via an ion-ion reaction between the peptide cation and the 
radical reagent anion (electron carrier) (Shin et al., 2003). HCD is performed by 
introducing nitrogen gas in the ion trap producing smaller peptides fragments 
(Olsen et al., 2007) while CID is performed with helium gas, produces large 
fragments of the peptide being analysed (Wells and McLuckey, 2005). ETD 
induces fission at the C-N-R bond of O=C-NH-R peptide bond while CID and 
HCD induce at the C-N bond of the O=C-N-H peptide bond (Figure 1-8) (Olsen 
et al., 2007, Wells and McLuckey, 2005). Using HCD or CID, mainly two 
fragments types are produced; the N-terminus fragment is termed a ‘b’ ion and 
the C-terminus fragment is termed a ‘y’ ion.  
Under different fragmentation methods like Negative electron-transfer 
dissociation (niETD) and Electron detachment dissociation (EDD), fission can 
occur between the carbon of an amino acid and the carbon of the peptide bond 
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generating ‘a’ and ‘x’ ions or negative-ion electron capture dissociation (niECD) 
can induce between the N-Cα bond of the peptide, generating ‘c’ and ‘z’ ions 
(Figure 1-8) (Senko et al., 2013). 
 
Figure 1-8: Peptide backbone fragmentation: peptide structure, selected 
fragmentation techniques, and fragment ion nomenclature (Zhurov et al., 
2013). 
1.6.6 Shotgun Proteomics 
There are two main types of bottom-up proteomics; Data dependent 
acquisition (DDA) and data independent acquisition (DIA) (Doerr, 2015). DDA 
is the more common process, in which a full spectrum of all ionised peptides is 
obtained (MS) then all precursors are fragmented (MS/MS) in order of intensity, 
starting with the most abundant. This process can also be called as ‘top N’ or 
‘top S’ where N is the number or speed of peptides characterised before another 
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full spectrum scan is performed and the process is repeated (Lopez, 2007). 
Another important feature for of DDA process is dynamic exclusion, which 
excludes those peptides which were fragmented in the previous MS scan, to 
focus on the less abundant and newly eluting peptides from the LC (Senko et 
al., 2013). DIA is newly emerging technique, where all MS and MS/MS data are 
acquired on mass analysers autonomously by scanning specific mass windows, 
then data is processed with DDA spectral libraries (Doerr, 2015). 
1.6.7 Database searching 
After MS analysis, the next step in the proteomics pipeline is to conduct 
a database search to identify the peptides and proteins. A number of parameters 
should be considered during database searching; for example, the nature of 
samples, organism, reduction, alkylation, and type of digestion (chemical or 
enzymatic) (Gundry et al., 2009).  
A typical protein database has a collection of protein amino acid-based 
sequences in FASTA format, used to generate the in-silico peptide database 
against which the raw MS data file will be searched. So, it is very important for 
protein database to have sufficient protein coverage, otherwise the search 
engine will not find suitable match. SwissProt (Boutet et al., 2016), TrEMBL 
(Boeckmann et al., 2003), IPI (Kersey et al., 2004), RefSeq (Pruitt et al., 2007) 
and PRIDE (Vizcaíno et al., 2013) are commonly used protein databases for 
searching proteomic MS data. The protein database can be restricted at the 
species level (e.g. Homo sapiens) or class level (e.g. mammals), to get high 
confidence protein data. The peptide database is generated by the same 
enzyme, the way peptides were prepared prior to MS analysis, because of 
cleavage specificity of the enzyme, trypsin cleaves mainly the lysine or arginine 
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in the peptide chain, except when either is followed by proline. There is the 
possibility of missing the cleavage site with enzymatic digestion, therefore a 
missed cleavage value between 0-2 is also considered during database search. 
The main challenge for bottom-up proteomics is post-translational 
modifications; directly related to sample processing. The modifications can be 
either fixed; for example, carboxyamidomethylation of cysteine, which occurs 
after treatment with iodoacetamide or variable; for example, oxidation of 
methionine. These modifications increase the MS data processing time and 
false positive matches, which require considerable manual validations. There 
are software packages to deal with these issues such as Percolator (Brosch et 
al., 2009) and Fixed value PSM validator (Elias and Gygi, 2007). 
Instrumentation-specific parameters are also considered during database 
search; for example, mass and charge of precursors, fragmentations method 
(CID, ETC and HCD), mass accuracy for parent and fragments, masses 
acquisition is monoisotopic or average (Gundry et al., 2009).  
MS data processing is performed through search algorithms (Mascot 
(Matrix-Science, 2016), SEQUEST (Diament and Noble, 2011),  OMSSA (Geer 
et al., 2004), MS Amanda (Dorfer et al., 2014), Comet (Eng et al., 2013) and 
Morpheus (Wenger and Coon, 2013)) and the choice is orientated around ease 
of use, cost, features, accessibility, vendor compatibility, performance with 
certain data types, or a combination of all the above. These search engines 
(search algorithm) work by using a scoring algorithm and widely depends on 
type of data searched. 
Mascot is a powerful search engine which uses MS data to identify 
proteins from protein sequence databases. There are a number of similar tools 
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available, but Mascot is unique in that it supports all type of MS instruments, 
fragmentations, and methods of searching; such as peptide mass fingerprint, 
sequence query and MS/MS ion search from both Fasta files and spectral 
libraries. The logarithm of Mascot is based on probability scoring; a simple rule 
to be used to define whether a result is significant or not. Mass values of 
peptides and or MS/MS fragment ions match to theoretical masses in database, 
are always treated on a probabilistic basis (Matrix-Science, 2016). The 
probability of the observed match is the total score and reported in -
10*LOG10(P), where P is the absolute probability and significance threshold 
(p<0.05) expected to occur at random with a frequency of less than 5%. If a 
match has probability of 10-20, then Mascot score will be 200. The search 
parameters like mass tolerance and post-translational modifications, affect the 
significance threshold (Matrix-Science, 2016).  
1.6.8 Target-Decoy peptide searching 
Because both the MS spectra and theoretical spectra number many 
thousands, the probabilities of false discovery matches occurring by chance are 
very high. To fix this false discovery, a second ‘decoy’ search is performed which 
reverses the sequences of the target proteome and outlines the probabilistic 
score of those spectra matching by chance. The probabilistic scores of both 
searches; target and decoy, present an overlap which is frequently set at 1% 
overlap, termed a false discovery rate (FDR) of 1%. This can also be called as 
a ‘q-value’, and for a <1% FDR equates to q<0.01. The process of target decoy 
searching is performed in some search engines; Andromeda, SEQUEST and 
MASCOT (Aebersold and Mann, 2016, Zhang et al., 2014b) based on different 
algorithms but the basic target decoy process is the same; assigning each PSM 
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with a false discovery rate. Then FDR of PSMs is define by different ways but 
‘Percolator’ is a semi-supervised machine learning for peptides identification, 
which is based on many features such as Mascot score, precursor mass error, 
fragment mass error, number of variable modifications, of the target and decoy 
PSMs providing a far more accurate and efficient method of separating the true 
matches in the data (Käll et al., 2007). 
Several thousand MS/MS, acquired by shotgun proteomics experiment, 
must be searched to identify peptides and the original protein. This process is 
very simple for unique peptides because they map to single proteins. However, 
this process is more complicated for protein isoforms where many of the 
searched peptides match to two distinct protein sequences. The proteome of 
higher eukaryotic organisms has more redundancy, therefore a process of 
protein’s grouping on the base of unique peptides is applied to get high 
probability of both the identified peptides and the aligned proteome (Nesvizhskii 
et al., 2003). 
1.6.9 Quantitative Proteomics 
The qualitative analysis of a protein present in complex biological 
sample is useful but quantitative information is more important for the 
perspective from the perspective of understanding a biological problem or 
discovery of biomarkers. The quantitative proteome approach allows the 
characterisation of disease samples quantitatively, relative to control or healthy 
proteomes. These quantitative experiments help to compare different biological 
hypotheses within two or more samples. There are two main types of 
quantitative experiments; label-based and label-free approaches. Label-free 
approaches based on data derived from separate LC-MS experiments, whereas 
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label-based approaches are based on combining quantitation into a single LC 
MS workflow (Bantscheff et al., 2012). 
1.6.9.1 Label-free quantitation 
Label-free quantitation is performed by using peak area or intensity of 
precursors, or peptides spectral counting. The relative intensity of comparable 
precursors is calculated on the base of mass and retention time of analyte 
(Bondarenko et al., 2002).  Spectral counting approach works on the principle 
that there is a correlation between the number of peptides spectrum matching 
to a protein and the protein’s abundance (Old et al., 2005).  Label-free 
quantitation is least accurate means of proteins quantitation, requiring multiple 
replicate analyses to determine intra- and inter-experimental variation, therefore 
required more sample and instrument time (Bantscheff et al., 2012). 
1.6.9.2 Label-based quantitation 
There are two major types of label-based proteomics; incorporate stable 
isotopes into the protein during its synthesis in a cell and covalently modify 
peptides with isotope-coded tags as part of the proteomics workflow (Aebersold 
and Mann, 2016, Bantscheff et al., 2012). Peptides labelled with stable isotopes 
are quantified by using the intensity of precursors with MS1 while isobaric tag-
labelled peptides are quantified by the intensity of reports ion at MS2 or MS3 
level. The other main purpose of labelling approach is to eliminate the variability 
seen when chromatography is performed iteratively (Bantscheff et al., 2012).   
The advantage of Stable isotope labelling by amino acids in cell culture 
(SILAC), is that cell lines are grown under identical conditions. The only 
difference between two conditions, is supplementing one of the cell lines (most 
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commonly the control) with amino acids incorporating stable isotopes, typically 
arginine and lysine (Ong et al., 2002). The relative spectral intensities of stable 
isotope labelled and unlabelled peptides provide quantitate information between 
two cell lines (Ong et al., 2002). The application of metabolic labelling is limiting, 
especially in the context of primary human tissue (Aebersold and Mann, 2016). 
The basic principle of SILAC is that the cell line under investigation is cultured 
with isotopic labelled amino acids, which are consumed by cell lines and 
incorporated into its proteome. Once fully labelled, the protein extract from a 
SILAC cell line is combined with that of another cell line; grown in normal 
medium. This enables the same preparative procedures on the two combined 
samples, eliminating quantitation inaccuracies introduced during sample 
handling. Finally, the proteome of two cell lines is acquired on same LC-MS 
analysis and mass shift introduced by the isotopic labelled and natural amino 
acids, provides the quantitative information between two biological conditions. 
But the SILAC approach has few limitations; (a) not straight forward for tissue 
biopsies and only possible for simple organisms like cell lines (Pan and 
Aebersold, 2007), (b) only two conditions can be compared in a single 
experiment (Ong, 2012), (c) diet containing isotopic labelled peptides could 
effect on development, growth or behaviour of cells (Cutillas and Timms, 2010), 
(d) inaccuracies in quantification due to conversion of isotopic labelled arginine 
to proline in cells (Van Hoof et al., 2007). 
Isotope-coded tags contain an amine reactive group, which modify the 
primary amines at either lysine residues or the N-terminus of peptides. These 
tags are called isobaric labels because they maintain the identical mass by 
different combinations of a reporter group and a balancing group (Ross et al., 
2004). The identical peptides labelled with these tags maintain same 
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physiochemical properties and elute in same time from LC and consider as 
single precursor in MS analysis. This provides a single MS/MS spectrum of 
peptide for identification and relative quantitation. The two most common 
reagents are isobaric tags for relative and absolute quantitation (iTRAQ) and 
tandem mass tags (TMT) (Aebersold and Mann, 2016). iTRAQ offers the 
simultaneous relative quantitation of 4 and 8 samples, termed as 4-plex and 8-
plex respectively, with quantitation occurring at MS2 or MS3 level.  iTRAQ 4-plex 
reagent is based on the relative intensities of reporter ions at 114, 115, 116 and 
117 Da (Ross et al., 2004) while 8-plex has 4 further labels; 113, 118, 119 and 
121 Da, in the low mass region of the MS/MS spectrum (Choe et al., 2007) (for 
further details about iTRAQ, see Chapter 3). iTRAQ based MS quantification 
has a number of advantages; (a) simple workflow for peptide labelling and data 
interpretation for relative quantitation, (b) quantitation of up to 8 samples 
simultaneously in a single LC-MS experiment and (c) high confident 
identification and quantification data by tagging multiple peptides per protein 
(Ow et al., 2009). On other side, isobaric workflows has a few limitations as well; 
cost, labelling inefficiencies and  reporter ion ratio compression due to precursor 
ion co-isolation (Karp et al., 2010). The labelled peptides with similar mass-to-
charge ratios and chromatographic retention times, result distorted ratios of 
reporter ions due to the inability to differentiate co-isolated precursors. 
Therefore, ratio suppression effect is more common due to co-isolation and co-
fragmentation. New advances in MS-based approaches have been proposed to 
minimise or eliminate the effects of co-isolation. Some of these approaches are 
multi-notch MS3  fragmentation (see Chapter 3), traveling wave ion mobility 
separation, gas phase purification, improved chromatographic resolution and 
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optimisation of DDA settings (McAlister et al., 2014, Ow et al., 2011, Savitski et 
al., 2011, Ting et al., 2011). 
1.6.10 Targeted mass spectrometry (MRM/PRM) 
Both multiple reaction monitoring (MRM) and parallel reaction 
monitoring (PRM), are highly sensitive mass spectrometry based techniques to 
quantify selected analytes in complex samples. This assay is commonly 
performed on a mass spectrometer with quadrupole (triple quadrupole or 
Orbitrap) to select the target ion corresponding to the compound of interest, then 
a selected ion is fragmented to produce a range of daughter ions (Figure 
1-9)(Harlan and Zhang, 2014, Wasinger et al., 2013). These daughter ions are 
then collected at the MS detector for quantification purposes.  Only analytes of 
interest are isolated and all other ions that flow into the mass spectrometer 
ignored, giving high sensitivity, whilst maintaining exquisite accuracy. MRM 
assay was initially developed for quantification of small molecules but nowadays 
is also used for quantitation of proteins, peptides, metabolites and lipids from 
plasma, serum and other biological samples (Harlan and Zhang, 2014, Wolf-
Yadlin et al., 2007). MRM or PRM assays have several significant advantages; 
(a) short assay development time (4 to 10 weeks), (b) highly multiplexed (from 
10 to 100 peptides/proteins can be quantified in single experiment), (c) absolute 
quantification, (d) 100% specificity (because of unique peptides), (e) antibodies 
are not required for analysis, (f) same assay can be applied on any type of 
biological materials such as cell line, tissues and serum, and (g) minimal amount 
of sample is required (1-50g) (Liebler and Zimmerman, 2013). The one 
disadvantage of MRM assays is the high cost of stable isotope labelled standard 
peptides (Percy et al., 2014). 
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A PRM assay is normally performed on hybrid Quadrupole-Orbitrap 
instruments. The selection of precursor and fragmentation is similar to MRM but 
with the high-resolution, accurate-mass (HRAM) Orbitrap detection system, 
which allows the measurement of all fragment ions of a given precursor in 
parallel (Figure 1-9)(Ronsein et al., 2015). 
 
Figure 1-9: Schematic diagram of MRM/PRM. 
MRM/PRM assay ideally involves signature peptides, which are used as a 
reference for the identification and quantitation of the target proteins. Initially 
standard peptides of target proteins are used to optimise LC-MS conditions and 
to create the calibration curves for absolute quantification (for further details for 
proteins/ peptides selection, light and AQUA peptides, see Chapters 5). 
MRM/PRM assays provide reliable and robust quantitation of peptides or 
proteins with good accuracy and precision (Lesur and Domon, 2015). 
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1.7 Biological samples for identification of breast 
cancer biomarkers 
There are many strategies for identifying biomarkers and in the last 
decade, proteomics is one such approach that has been used extensively to 
identify changes in biological samples that correlate with breast cancer 
diagnosis. Proteome research of breast cancer has involved the analysis of a 
diverse range of samples, including tissues, cell lines and biological fluids such 
as saliva, serum, plasma, cerebrospinal fluid and nipple aspirate fluid, in order 
to understand the disease, identify diagnostic and prognostic biomarkers, and 
discover new targets for drug development. The biological samples used for 
biomarkers of breast cancer through proteomics are shown in Table 1-5. 
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Biological samples Advantages Dis-advantages 
Research 
Methods 
References 
Tissue biopsies Original disease source 
Complex nature of biological 
materials. 
TMA, LC/MS, IHC, 
WB, MRM RPPM 
(Hondermarck et al., 2008, Gujral 
et al., 2012, Shaheed et al., 
2013a, Gast et al., 2009) 
Cell culture 
Easy to use, relatively inexpensive, and 
reproducible, Ideal growth conditions, 
Lack of extracellular 
components 
WB, LC/MS, 
ELISA, IHC, MRM 
(Shaheed et al., 2013a, Geiger et 
al., 2012) 
Plasma 
Minimally invasive, the samples are technically 
and psychologically easy to process 
Abundance of Plasma 
proteins, sample preparation 
LC/MS, ELISA, 
WB, MRM 
(Hu et al., 2006b, Hanash et al., 
2008) 
Tear fluid Accessible 
Limitation of volume. 
dependent on fluid flow rates 
LC/MS, 
(Tiffany, 2003, Hu et al., 2006b, 
Böhm et al., 2012) 
Saliva 
Easy sample collection and processing, low 
cost, 
Dependent on fluid flow rates LC/MS (Zhang et al., 2013) 
Xenografts 
Easy to use, relatively inexpensive, and 
reproducible 
Not representative of the 
respective human tumour, 
cross-species 
IHC, MRI, TMA, 
LC/MS, WB 
(Pavlides et al., 2010, Drake et 
al., 2011) 
Breast Cyst Fluid (BCF) Original disease source Discomfort IHC, ELISA, 
(Mannello et al., 2006, Celis et 
al., 2006) 
Nipple Aspirate Fluid 
(NAF) 
Quick, Painless, and collected non-invasively. 
Limitation of volume and 
expression. 
LC/MS, 
(Pavlou et al., 2010, Villa Flor 
Brunoro et al., 2014) 
Nipple Discharge (ND) Frequently discharge from breasts. Limitation of expression. LC/MS, (Sauter et al., 2005) 
Pathologic Nipple 
Discharge (PND) 
Pathological spontaneous nipple discharge 
with a suspicious Lesion. 
Limitation of expression. LC/MS, (Sauter et al., 2005) 
Ductal Lavage (DL) More cells as compare to normal aspiration 
Discomfort and difficult to re-
cannulate the same ducts. 
QM-PCR, IHC, 
(Fackler et al., 2006, Khan et al., 
2009) 
Random Periareolar 
Fine Needle Aspiration 
(RPFNA) 
A snap-shot of whole breast, can be 
performed in majority of women, high number 
of cells. 
High cost, discomfort, low 
patient turn over, 
reproducibility of the method 
IHC, Reverse 
Phase Proteomic 
Microarray (RPPM) 
(Ibarra-Drendall et al., 2012) 
Milk and Colostrum Easy sample collection Sample preparation LC/MS 
(Hu et al., 2006b, O’Donnell et 
al., 2004) 
Table 1-5: Biological samples used for biomarker proteome of breast cancer.
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1.7.1 Cell culture 
Breast cancer cell lines provide models to investigate the molecular 
mechanism underpinning the disease as well as identification of biomarkers. 
The quantitative and qualitative proteome of cell lines and conditioned medium 
(CM) is well established and provides a rich source of potential biomarkers. The 
advantages of cell lines are; (1) cost effective, (2) easily propagated, (3) 
versatility, and (4) non-invasive (Hanash et al., 2008). The cell culture-based 
approach also provides a platform to validate the potential efficacy of a novel 
biomarker. The presence of potential biomarkers in CM, either due to secretion 
or cell death, provides promise to extrapolate biomarker detection in body fluids. 
Cell lines are grown in serum-free medium in order to enrich the secretome, an 
approach which cannot be used for tissues (Paul et al., 2013). Different breast 
cell lines represent different stages and type of tumour helping to provide 
relevant information of disease. But immortalised cell lines lose the control to 
divide after a certain amount of time and also contain mutations or genetic 
alterations introduced by transfection. Primary cell can be better option but 
frequently require special growth conditions, risk of contamination and generate 
only a few passages (Paul et al., 2013). Designing experiments on different 
phenotypes of breast cancer cells can be helpful for better understanding of cell 
signalling, migration, proliferation and survival. Cell lines can also be used for 
creating 3D tumour models (spheroids) and xenografts in preclinical models to 
test drug candidates, prior to clinical trials (Wilding and Bodmer, 2014). 
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1.7.2 Tissue biopsies  
Breast tissue biopsies take a number of forms, including core biopsies 
collected under local anaesthetic and larger samples collected during 
surgery/mastectomy. Breast tissue biopsies are heterogeneous cellular 
structures, with different proportions of epithelial, fibroblast, endothelial and 
myo-epithelial cells, accompanied by stroma, nerve fibres, macrophages, 
adipocytes, circulating cells, vasculature and lymphatics, representative of 
healthy and tumour environments (Hondermarck et al., 2008). Proteome 
profiling of tumour tissues can reveal the changes caused by disease 
progression that lead to breast cancer. Tissues offer the advantage of relating 
to the origin of the disease and the concentration of potential biomarkers may 
be high compared to surrounding to microenvironment. There are more than 
5,000 papers on tissue proteomics for identification of breast cancer specific 
biomarkers (NCBI, 2017) but the differentially expressed proteins identified 
varies considerably due different objectives, patient cohorts and experimental 
approaches, (Hanash et al., 2008). Tissue proteomic analysis from a diagnostic 
perspective, however is confounded by the presence of blood, is highly invasive 
and causes discomfort for the patient.  Sample acquisition, also requires co-
ordination with a clinician, a pathologist, snap-freezing to prevent tissue 
degradation and it can be very difficult to get matched healthy breast tissue [40] 
1.7.3 Plasma/Serum: 
There is a high probability for detection of a biomarker in biological 
fluids, but the link between expression of potential biomarkers at the tissue level 
and detectable levels in serum for disease specific profiles is not fully clear. The 
easy sample collection, the dynamic nature and constituents of serum, makes 
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it a logical choice for understanding the physiological or pathological states of a 
disease by biomarker applications (Hanash et al., 2008). Thousands of 
publications have reported a single protein or panels of targets as cancer 
biomarker(s) and have produced some encouraging data. For example, the 
level of prostate-specific antigen (PSA) in the blood to detect prostate and 
breast cancer or carcinoma embryonic antigen for therapy response in colon 
cancer have resulted from plasma proteomics (Hanash et al., 2008, Nikolenko 
et al., 2015, Chang et al., 2014, Steward et al., 1974). However, MS-based 
plasma/serum proteomics is extremely challenging for example; (i) the 
concentrations of individual proteins span 10–12 orders of magnitude and (ii) 
presence of few proteins in very high concentration such as albumin, represent 
more than 99% of the total bulk mass of protein content, and removal of these 
by, for example, by immunodepletion, requires additional steps with possible 
losses of less abundant proteins (Feist and Hummon, 2015).  
1.7.4 Milk and Colostrum 
There have been a number of proteomics studies on milk purely from a 
functional perspective, unrelated to cancer, with a recent study identifying up to 
1600 proteins (Roncada et al., 2013, Beck et al., 2015). Colostrum, produced 2 
or 3 days prior to lactation, prepares the infant‘s digestive system for milk as a 
food source and immunisation against infection, has also been characterised. 
In a study of 100 samples using 2D liquid chromatography mass spectrometry 
(LC MS), 151 proteins were identified after immunodepletion to remove the most 
abundant proteins, including 83 found in colostrum but not milk (Palmer et al., 
2006). Although available in useful volumes for analysis, the period of 
production during the reproductive phase of life is relatively narrow and in most 
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cases will not overlap with breast cancer development. Consequently, there has 
been very little research on proteomic profiling of breast cancer in milk or 
colostrum because of the relatively small proportion of women in which the 
disease and postnatal breast-feeding, coincide. Nevertheless, Schneider et al 
were able to profile samples from a small cohort and identified proteins that were 
uniquely present in milk from women diagnosed with breast cancer (Schneider 
et al., 2014).  
1.7.5 Breast Cyst Fluid 
Several epidemiological and prospective studies indicate there may be 
a relationship between cystic breast disease and cancer (Celis et al., 2006). 
There are two types of breast cyst (Type I or apocrine cysts and Type II) 
differentiated on the basis of morphological and cellular characteristics. 
Apocrine cysts differ from Type II cysts in having a higher K+/Na+ ratios while 
Type I cysts are more strongly related with breast cancer (Mannello et al., 2006). 
According to Mannello et al, more than 100 studies have identified 81 proteins 
in breast cyst fluid, with the major components identified as albumin, prolactin 
inducible protein, zn-α2-glycoprotein, and apolipoprotein D (Mannello et al., 
2006). A 2D gel electrophoresis/mass spectrometry study on apocrine 
macrocyst fluid collected identified that 15-hydroxy-prostaglandin 
dehydrogenase and 3-hydroxymethylglutaryl-CoA synthase were associated 
with cysts and tumour tissue but not in matched normal tissue (Celis et al., 
2006). 
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1.7.6 Ductal Lavage (DL) 
DL is a non-surgical breast epithelial sampling procedure that was 
developed to identify high risk breast cancer women and to detect malignant 
lesions in breast epithelial cells. In the DL procedure, a microcatheter is 
cannulated to the ducts, infused by a saline solution, and then aspirated by a 
suction device to collect cells from the lining of ducts. More cells are acquired 
through ductal lavage than from nipple aspiration (Dooley et al., 2001), and 
biopsy fluids can be obtained in women that do not yield fluid by passive nipple 
aspiration or discharge or from breast massage. However, ductal lavage can 
cause considerable discomfort and requires a specialist device which has 
prevented widespread clinical use (Mitchell et al., 2005). Ductal lavage 
containing sufficient cells was collected from 31 women (out of 36 volunteers) 
diagnosed with breast cancer and analysed for atypical cytology as a possible 
diagnostic indictor, however only 13% produced a significant positive indication 
(Khan et al., 2004).  A separate study of 30 samples found only 23.3% of women 
with atypical lavage cytopathology but these women had normal mammogram 
screening of breast, indicating the potential for improved sensitivity (Hartman et 
al., 2004). The isolation of cells from ductal lavage opens up the opportunity for 
applying molecular biology approaches. Quantitative multiplex methylation-
specific polymerase chain reaction (QM-PCR) was used to quantitate 
cumulative gene promoter hypermethylation in multiple genes, which are 
markers for breast cancer, and found to double the sensitivity of detection of 
cancer cells compared with cytology (Fackler et al., 2006). An attempt to identify 
biomarkers of tamoxifen treatment (estrogen receptor α, Ki-67 and 
cyclooxygenase-2) in ductal lavage, however, found no significant cytological or 
molecular biomarkers in patients (Khan et al., 2009). Recently, an improved 
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method of ductal aspiration, collecting multiple aliquots, considerably increased 
the cell recovery with 45/50 subjects yielding more than 1000 cells and 50% of 
those producing more than 20000 cells with 80-100% epithelial cell purity. This 
provided genomic DNA, RNA and miRNA samples for analysis however, to date 
only qualitative observations of the molecular profiles have been reported 
(Danforth et al., 2015). 
1.7.7 Random Peri-areolar Fine Needle Aspiration (RPFNA) 
RPFNA, developed by Dr. Carol Fabian in 1980, provides a snap-shot 
of the breast by sampling cells from the entire breast of asymptomatic women. 
The major advantage of RPFNA is that it can be performed in the majority of 
women and the cell yields vary from 72-85%, considerably higher than ductal 
lavage. (Zalles et al., 1995). After anesthetizing the breast with 1 % lidocaine, 
five needle aspirations are made on the lateral breast site and four from the 
middle skin of each. The aspirated fluid consists of epithelial, immune, stromal 
and adipose cells (Fabian et al., 2000).   
A clinical trial of 480 women indicated that RPFNA increased cytological 
atypia associated with breast cancer in high-risk women (based on family 
history, a prior diagnosis and precancerous biopsy) (Khan et al., 2009). Of the 
cohort, 20 women developed breast cancer after 45 months (7 DCIS and 13 
invasive), indicating the promise for very early diagnosis.  RPFNA was used for 
a chemoprevention study of alpha-difluoromethylornithine (DFMO) in 119 high 
risk women, but found no change in cytology or other RPFNA-based molecular 
markers such as expression of proliferating cell nuclear antigen, p53 or 
epidermal growth factor receptor (Fabian et al., 2002). A proteomic microarray 
study found that up to 60 phosphoproteins can be verified in triplicate from 5,000 
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to 10,000 micro-dissected RPFNA epithelial cells, suggesting the potential to 
track signalling pathways in order to understand the molecular changes 
occurring in mammary carcinogenesis (Ibarra-Drendall et al., 2012). The 
heterogeneous nature of the cell populations being tested for specific molecular 
markers and considerable discomfort to obtain the samples, are key limitations 
of the RPFNA approach. Furthermore, the difficulty in reproducing the method 
may preclude a role in screening of high risk women that involves repeated 
harvesting of material. 
Proteomic strategies have been developed for the analysis of complex 
samples such as serum and plasma, however due to the wide dynamic range 
of protein concentrations (1012 order of magnitude), still only the more abundant 
components are detected. Factors that may contribute to these incongruities 
are; (1) heterogeneity within tumours or patients, (2) obtaining adequate 
controls, (3) non-specific disease-associated changes in blood proteins (e.g. 
inflammation associated proteins) (Hanash et al., 2008). 
1.7.8 Nipple Aspirate Fluid (NAF) 
The breasts of adult non-lactating women secrete a small volume of 
fluid, called "nipple aspirate fluid” (NAF) into the breast ducts (Petrakis, 1993).  
The fluid passes down the main ducts and ampullae through alveolar glands of 
the breast, from which it enters the lymphatic and blood circulation (Petrakis, 
1986). Under normal conditions, the breast fluid cannot escape from nipple 
because the nipple ducts are blocked by viscous and dried secretions or 
constriction bands of smooth muscle and keratinized epithelium (Petrakis, 
1986). To maintain stable physiology of the breast, an equilibrium exists 
between fluid secretion and re-absorption. Several factors are associated with 
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NAF expression; age, ethnicity, early menarche, history of lactation, high dietary 
fat consumption and dietary intake of lactose (Zhao et al., 2009a). The 
concentration of proteins can be higher in NAF compared to plasma, enriched 
for proteins originating from epithelial cell lining the duct (Djuric et al., 2005). 
The potential biomarkers detected in NAF are summarised in Table 1-6. There 
is also a direct relationship between ear wax and NAF because both are 
produced by ceruminous glands. Women with wet ear wax yield more NAF s 
compared to women with dry ear wax (Hawke, 2002). Premenopausal women 
with lactation experience, aged 30 to 50 years and had early onset of menarche 
produce more NAF compared to those who have not had children (Zhao et al., 
2009a).  
Biomarkers 
Expression 
in NAF 
Characteristics Reference 
Prostate specific 
antigen (PSA) 
Down 
Inversely proportional to 
disease stage, size of tumour, 
node status and distant 
metastases. 
(Sauter et al., 1996, 
Sauter et al., 2004a) 
Thomsen-
Friedenreich (TF) 
Up 
Predictive for the presence of 
breast cancer or atypia. 
(Kumar et al., 2005, 
Deutscher et al., 
2010a) 
Testosterone UP 
Only in postmenopausal 
women is predictive. 
(Sauter et al., 1999, 
Sauter et al., 2002, 
Eliassen et al., 2006) 
Superoxide 
Dismutases (SOD-1) 
Down 
Involved in cancer initiation and 
progression by ROS related 
damages 
(Sinha et al., 2009, 
Mannello et al., 
2010) 
Protein DJ-1 Up 
mRNA level increased but 
protein level decreased in 
tissue. 
(Oda et al., 2012) 
Cytokines/chemokine
s 
Up 
High level of pro-inflammatory 
C–C and CXC chemokines. 
(Mannello et al., 
2013) 
Plasminogen 
activator inhibitor-1 
(PAI-1) 
Up 
Promotes breast cancer 
invasion and metastasis 
(Qin et al., 2012) 
Transferrin protein 
(TFR) and ferritin 
(FTN) 
Up Proliferation of cancer cells 
(Mannello et al., 
2011) 
C-reactive protein 
(CRP) 
Up 
Serum biomarker for 
metastasis of different type of 
cancers 
(Lithgow et al., 2007) 
Aluminium (Al) Up 
Varied concentrations between 
different tissue and fat of the 
breast. 
(Mannello et al., 
2009, Mannello et 
al., 2011) 
Table 1-6: Potential biomarkers in nipple aspirate fluid. 
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A study of 25 to 49-year-old premenopausal nulliparous women found 
that proportionately, Asian-descendant women were less likely to express NAF 
compared to White American women [53]. NAF collection has been achieved 
with varying degrees of success dependent on the method and the practitioner 
and, in some cases, has deterred researchers from further investigation. 
Electronic and manual breast pumps (normally used for lactation), massage, 
warming and combinations of each have been used to acquire NAF samples 
(Sauter et al., 1997b). Most promising has been the use of oxytocin nasal spray 
which helps the release of already existing fluid in the ducts increasing collection 
in 95% of patients and volunteers (Zhang et al., 2003). On the base of unique 
characteristics of NAF, the proteomic analysis of NAF for potential breast cancer 
biomarkers may serve as useful approach to understand the physiology of 
breast cancer. 
NAF is composed of a variety of endogenous substances such as 
lactose, proteins, fatty acids, hormones (estrogens, androgens, progesterone), 
sterols, but may also contain exogenous substances such as nicotine and 
cotinine from cigarette-smoking (Petrakis, 1993). The colour of NAF varies from 
clear to brown, bloody, black, pale yellow, dark yellow, white or green (Sartorius, 
1973), and is associated with the concentration of cholesterol, estradiol, 
estrone, cholesterol epoxides and peroxidated lipids (Petrakis et al., 1988). The 
colour of NAF is more an epidemiological factor than indicator of the risk of 
breast cancer, however one study found that women have a higher risk breast 
cancer with bloody or brown nipple discharge compared to those which were 
white, cream, yellow or green (Dietz et al., 2002). Another study of 327 women 
found that the frequency of red or brown colour was increased with progression 
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of disease from pre-cancer to cancer and surgical biopsy had more influence on 
NAF colour compared to needle biopsy (Sauter et al., 2006). 
NAF production, nutritional aspects and estrogen level have been found 
to be related with breast cancer risk. A large scale study of 1496 participants 
(1347 white and 153 black women) found a positive association between higher 
dietary fat and NAF secretion in the group aged 30-44 years (Lee et al., 1992). 
As obesity is associated with a high fat diet and is a major risk factor for breast 
cancer investigation, the correlation of fat intake and NAF expression and 
composition may be helpful for breast cancer prevention and prognosis (Huang 
et al., 2008). A link between lactose and soy intake has also been reported, 
however contrary results from a randomized crossover trial discovered no 
influence of soy on NAF volume and circulating estrogen level (Maskarinec et 
al., 2011). On the other hand, a fruit-and-vegetable diet was inversely related 
with NAF production while decreasing the circulating hormone concentration 
(Djuric et al., 2006) and the concentration of micro-nutrients, such as 
carotenoids and soy isoflavones in NAF, was related to dietary intake 
(Maskarinec et al., 2008).   
Some components of NAF have been investigated as biomarkers of 
breast cancer (Table 1-6). Based on the differential levels of testosterone in 
serum from pre- and post-menopausal women, Sauter et al measured 
testosterone levels in NAF samples and found it would be a suitable biomarker 
to predict breast cancer risk (Sauter et al., 1999). A separate study, which 
measured the level of free and albumin-bound testosterone in NAF, found high 
levels of the former in premenopausal women with breast cancer (Sauter et al., 
2002).  
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Proteins are major constituents of NAF with concentrations higher than 
plasma, typically averaging 71–170 mg/ml. NAF, however and most importantly, 
is enriched for proteins originating from epithelial cells lining the duct (Djuric et 
al., 2005), some of which have been evaluated as potential biomarkers of breast 
cancer. Prostate specific antigen (PSA), also known as kallikrein hK3, first 
identified in seminal plasma and prostatic tissue, produced by the epithelial cells 
lining the acini and ducts of prostate gland, has also been identified in female 
breast tumours. A study of NAF found that women with no risk factors or family 
history of breast cancer had high levels of PSA, but women with precancerous 
or invasive cancer had reduced levels (Sauter et al., 1996). Furthermore, PSA 
levels were inversely proportional not only to disease stage, but also tumour 
size, node status and distant metastases (Sauter et al., 2004a).  
The concentration of superoxide dismutase [Cu-Zn] (SOD-1) in NAF 
was decreased in breast cancer patients compared to healthy individuals 
(Mannello et al., 2010). SOD-1 is involved in cancer initiation and progression 
caused by reactive oxygen species-related damage. Therefore, it was proposed 
that measuring the concentration of SOD-1, a key antioxidant enzyme in breast 
microenvironment, may be helpful to differentiate between the normal and 
tumour breast. The expression of the anti-oxidant oncogene DJ-1 mRNA is 
increased in ductal carcinoma tissues but the opposite effect was observed at 
the protein level, where expression is decreased and contrarily was elevated in 
blood of breast cancer patients. A study on NAF collected from 136 patients 
identified high levels of DJ-1 protein in NAF from breast cancer patients, but low 
levels in benign papilloma cases (Oda et al., 2012).  
NAF samples collected from non-cancer and cancer women for cytokine 
profiling found no difference in anti-inflammatory cytokines (IL-4, IL-9, IL-10 and 
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IL-13), pro-inflammatory cytokines (IL-2 and interferon-γ), immuno-modulatory 
interleukins (IL-5, IL-7) or chemokines (RANTES, IP-10, eotaxin). However, 
NAFs from cancer patients with high levels of aluminium in the breast 
microenvironment, had higher concentrations of pro-inflammatory cytokines (IL-
1β, IL-6, IL-12 p70, and TNF-α), and C–C (MCP-1 and MIP-1α) and CXC-type 
chemokines (IL-8) compared to those cancer patients with low aluminium levels. 
This indicated a significant correlation between pro-inflammatory cytokines (IL-
6), monocyte/macrophage chemo-attractant chemokines (MIP-1α and MCP-1), 
oxidative stress and aluminium content in cancerous NAFs (Mannello et al., 
2013). 
1.8 NAF Proteomics 
On the basis of the unique characteristics of NAF, proteomic analysis 
should serve as a useful approach to understand the physiology of breast 
cancer and for biomarker discovery. However, early proteomic profiling of NAF 
samples collected from cancerous and non-cancerous breast of patients using 
surface-enhanced laser desorption ionization mass spectrometry (SELDI-MS), 
revealed no significant differences in the SELDI-MS peak profiles (Paweletz et 
al., 2001). Use of more powerful separation techniques, however, started to 
reveal differences. Varnum et al identified 64 proteins in immune-depleted NAF 
samples, using an ion trap mass spectrometer, among which 15 had previously 
been reported to be altered in tumour tissue and serum from women with breast 
cancer, including osteopontin and cathepsin D (Varnum et al., 2003). Two-
dimensional PAGE separation of proteins, followed by in-gel digestion with 
trypsin and matrix-assisted laser desorption ionization time-of-flight mass 
spectrometer (MALDI-TOF) analysis, identified 41 components in NAF 
(Alexander et al., 2004). Among these, levels of prolactin-inducible protein, 
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apolipoprotein D, and 1-acid glycoprotein, were observed to be changed in 
cancer NAF samples. Further validation by ELISA, indicated that expression of 
these proteins correlated with pre-/post-menopausal status and cancer stage. 
Pawlik et al (Pawlik et al., 2006) used Isotope-coded affinity tag (ICAT) tandem 
mass spectrometry (MS) for qualitative and quantitative analysis of tumour 
specific proteins in NAF, identified 353 peptides from 39 proteins in NAF 
samples from 12 women with breast cancer and 15 healthy volunteers. alpha-
2-HS-glyoprotein, was found to be decreased, whereas lipophilin B, beta-globin, 
hemopexin and vitamin-D binding protein were increased in breast cancer NAF 
samples. A recent study on six NAF samples (3 healthy individuals and 3 
patients) analysed by using an Orbitrap® mass spectrometer, identified more 
than 854 unique proteins, including established putative breast cancer 
biomarkers candidates, cancer antigen 15.3, tissue plasminogen activator, uPA, 
and cathepsin-D (Pavlou et al., 2010). Recently, in a series of experiments to 
optimise protein separation from a NAF sample, Brunoro et al identified 557 
different proteins (Brunoro et al., 2015). The different protein profiles identified 
in NAF samples clearly highlights the potential for identifying biomarkers that 
could be related to breast cancer. 
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1.9 Aims and objectives 
The overall aim of this study was to implement the latest advances in 
quantitative proteomics to characterise, as comprehensively as possible, 
protein biomarkers of breast cancer by using cell lines, tissue biopsies, serum 
and nipple aspirate. While several published researches have explained 
proteomic characterisations of breast cancers, none have successfully reached 
the full potential of quantitative proteomics in biological samples for early 
detection of breast cancer.  
Breast cancer cell lines (BCCL) and tissue biopsies are well studied 
models for investigation of cancer related markers because they provide a good 
representation of human breast cancer. Breast cancer cell lines provide the 
opportunity to investigate the phenotypic signatures and full development 
course of breast cancer. BCCL models are available for different phenotypic 
variations of breast cancer like luminal A, luminal B, HER2, basal-like and 
claudin-low. These transfected cell lines are partially artificial but allow 
predictable tumour development under spontaneous conditions in the space of 
months rather than decades. To date, no published studies have used human 
mammary epithelial cells (HMEC), to quantitatively characterise breast cancer 
cell lines or their respective phenotypic proteomes using iTRAQ based MS 
proteomics. 
In the clinical environment, the verification and validation of these 
signature proteins in breast cancer cell lines or tissue biopsies, is not an ideal 
approach for early detection of disease. Therefore, biofluids such as serum and 
nipple aspirate fluid (NAF) provide better options because of accessibility of 
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biopsies material. If the signatures are identifiable in the serum and NAF they 
can potentially reveal insights into how a whole organism progressively 
responds to development tumours. The contrast between serum and NAF, 
poses interesting questions as to the similarities and differences in proteome of 
both models. 
New advancements in quantitative proteomics, both in sample 
preparation techniques and instrumentation, have the potential to provide 
quantitation for thousands of proteins simultaneously and non-biasedly. Such 
near comprehensive quantification of protein, rather than mRNA, expression 
has far greater clinical applicability to understanding the phenotype of breast 
cancer. Protein based biomarkers have great diagnostic values because of their 
functional roles in promoting the hallmarks of cancer. Isobaric tags (iTRAQ) 
quantification provides an analytical approach for relative quantification of up to 
8 biological samples in a single LC-MS experiment, however, it still remains 
limited by the dynamic range compression because of the effects of precursor 
co-isolation. New Orbitrap Fusion mass spectrometer, with three mass 
analysers, provide an ideal proteomics workflow to deal with dynamic range 
compression of Isobaric tags quantitation and most effectively utilise 
quantitative MS data. Multiple reaction monitoring (MRM) assay allows the 
absolute quantification of protein-based biomarkers in complex biological 
samples. MRM assays are highly accurate for quantitation of hundreds of target 
proteins in a single LC-MS experiment and require very small amount of sample. 
MRM-MS assays are highly sensitive (targeted) because they are based on the 
tryptic peptides as stoichiometric representatives of the target proteins. The 
concentration of target peptides is quantified against the calibration of curves of 
 71 
 
these tryptic peptides, to get absolute amounts of protein in biological sample. 
But selection of the right instrument and right tryptic peptides is very important 
for sensitivity and accuracy of multiple reaction monitoring mass spectrometry 
(MRM-MS).This investigation therefore comprises 3 key aims: 
1. To use an iTRAQ quantitative proteomics strategy to to determine 
and compare phenotype-specific signatures in a panel of breast cell lines. In so 
doing, I will also explore the dynamic range compression of iTRAQ based 
quantitation by comparing the two different MS platforms; Ultraflex II and 
Orbitrap Fusion.  
2. Through label-free proteomics analysis to identify stage-related 
protein changes in nipple aspirate fluid samples from different stages of disease. 
From this, I will determine whether the proteomic composition of NAF can be 
used for biomarker discovery and breast health screening.   
3. To develop a multiplex MRM-MS assay for target proteins from the 
phenotype- and stage-specific data for evaluation in breast tissue and liquid 
biopsies. This will provide a platform for an expanded validation study of 
selected biomarkers that can be utilised for highly specific, early detection of 
breast cancer.   
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Chemical and regents 
Wherever possible, the highest quality reagents were used for this 
project; sodium dodecyl sulphate (SDS), Tris (hydroxymethyl) aminomethane 
hydrochloride (Tris-HCl), Glycine, Sodium bicarbonate (NaHCO3), Magnesium 
chloride (MgCl2), Sodium chloride (NaCl), Sodium deoxycholate (DOC), 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), Tetra 
methyl ethylenediamine (TEMED), urea, thiourea, glycerol, Bromophenol blue, 
ammonium persulfate, Triethylammonium bicarbonate (TEAB), Iodoacetamide,  
PhastGel® Blue R, Dulbecco's modiﬁed Eagle's medium (DMEM), Roswell Park 
Memorial Institute medium (RPMI), glutamine, pyruvate, penicillin, 
streptomycin, Foetal bovine serum (FBS), HPLC and LC-MS grade water, 
methanol, acetonitrile (ACN), acetone and formic acid (FA) were purchased 
from Sigma-Aldrich UK.   
Tween 20 (Tween), 2-mercaptoethanol, sodium azide, acetic acid, 
dimethyl sulfoxide (DMSO) and dithiothreitol (DTT), 30% w/v acrylamide, 
phosphate buffered saline pH 7.4 (PBS), trifluoroacetic acid (TFA) were 
purchased from Fisher Scientific UK. Multi-grade Developer and Rapid Fixer 
(Ilford Photo, Cheshire, U.K). Proteomics grade trypsin and protease inhibitor 
cocktail were purchased from Roche Diagnostics GmbH, Germany. iTRAQ 8-
plex isobaric labelling reagents were purchased from Sciex. 
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2.2 Cell culture 
2.2.1 Breast cell lines 
Breast cancer cell lines (MCF-7; ZR-75; MDA-MB-468; MDA-MB-231; 
MDA-MB-453) and Non-tumorigenic breast cells (MCF-10A) were obtained from 
American Type Culture Collection (Manassas, VA). Human mammary epithelial 
cells (HMEC) were isolated from biopsy material collected from a patient 
undergoing a double mastectomy for BRCA1 risk reduction at Bradford Royal 
Infirmary and determined by pathology to be essentially normal. Ethical approval 
was given by Leeds (East) Research Ethic Committee, reference 
07/H1306/98+5. HB2 non-tumorigenic cells were kindly provided by Professor 
Valerie Speirs from The Leeds Institute of Cancer and Pathology (University of 
Leeds).  
All cell lines were tested for mycoplasma contamination using 
MycoProbe mycoplasma detection kit (R&D Systems, Abingdon UK). Breast 
cancer cell lines (MCF-7, ZR-75; MDA-MB-468; MDA-MB-231; MDA-MB-453) 
were maintained in RPMI medium supplemented with 5% v/v L-glutamine, 5% 
v/v sodium pyruvate and10% v/v fetal bovine serum (FBS). HB2 breast cell lines 
were grown on DMEM medium containing 10% FBS supplemented with 
hydrocortisone (5 μg/mL) and insulin (10 μg/mL). MCF-10A normal breast cells 
were cultured in Mammary Epithelial Cell Growth Medium (MEGM) Bullet Kit 
(Lonza Walkersville, USA) and HMEC cells were cultured in MEGM™ Mammary 
Epithelial Cell Growth Medium (Lonza Walkersville, USA), referred to as 
standard growth medium.  All cells were cultured at 37°C and 5%CO2 and were 
harvested. Cell cultures were maintained for 8-10 passages, with cells typically 
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being harvested for analysis between 5 and 10 passages, then collected at log 
phase of growth, with density of 5x106 cells/ml.  
2.2.2 Cells washing for proteomics 
Cells were harvested by trypsin (Sigma-Aldrich, Poole, U.K.)-treatment 
once reaching 80-90% confluence. Cells were washed at least 3 time with sterile 
ice cold PBS, centrifuging at 1000 rpm for 5 minutes each time the supernatant 
was decanted and discarded after centrifugation at 1000 rpm (revolutions per 
minute) for 5 min, and the resulting cell pellet (5 × 106 cells) was stored at −20°C 
until required. Washing in PBS was repeated to remove cell debris, predominant 
FBS proteins and contaminants that may be bound to the cells. 
2.3 Breast tissues procurement 
The study protocol and patient consent forms were approved by the 
Cyprus National Bioethics Committee. Patients underwent surgery for removal 
of breast lesions and subsequent histopathological diagnosis. Following 
inspection by a histopathologist, resected specimens were snap frozen in 
isopentane cooled by liquid nitrogen and stored at -80oC. Tissues from the 
breast lesion and areas identified as normal, at least 5 cm apart, were obtained. 
Biopsies from patients with fibroadenoma, DCIS or invasive carcinoma were 
selected for proteomic analysis. Frozen sections were cut from matched blocks 
of normal and disease breast tissue using a Bright cryostat as described 
previously (Sutton et al., 2010).  
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2.4 Collection of serum samples 
Blood samples were collected as part of population-based case–control 
study of breast cancer in Cyprus after approval from the Cyprus National 
Bioethics Committee. Controls were women with no prior history of breast 
cancer and were active members of national mammography population 
screening programme. Each healthy volunteer and case gave written consent 
before sample collection. Blood samples were collected in no additive-
vacutainer tubes and kept on ice during transported to the laboratory. Then 
samples were centrifuged at 2000 rpm for 15 minutes at 4OC, to collect serum 
and stored at -800C until further use. 
2.5 NAF collection 
NAF samples were obtained from healthy volunteers and breast cancer 
patients, who presented to Bradford Teaching Hospitals NHS Trust, between 
2013 and 2016. All participants gave written informed consent to undergo 
bilateral nipple aspiration. The study protocol was approved by University of 
Bradford's Independent Scientific Advisory Committee (reference: 
application/13/051).  Ethical approval was given by Leeds (East) Research 
Ethics Committee, reference 07/H1306/98+5. Before aspiration was attempted, 
the nipple was initially cleansed with an alcohol pad to remove any keratin plugs. 
NAF collection from cancer patients was performed under general anaesthetic 
by the clinical team, prior to surgery for lumpectomy or mastectomy, assisted by 
massaging the breast and the liquid collected from the nipple using a sterile 
pipette. After collection, the samples were transferred to chilled, pre-labelled 
tubes containing a freeze-dried protease inhibitor cocktail mixture [Roche 
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Diagnostics, Germany], and frozen within 30 minutes of collection, at -20oC in 
dedicated fridge-freezers. Where possible, NAF samples were collected 
separately from both breasts to provide matched normal and disease samples. 
NAF from healthy volunteers was collected in a similar manner by the individual 
whilst conscious. A bank of more than 100 patient samples has been collected 
to date.  
2.6 Protein extraction  
2.6.1 Cell lines 
Each cell pellets (5 × 106 cells) were thawed, and 200 μl of urea 
extraction buffer (7 M urea, 2 M thiourea, 0.4% w/v CHAPS, 50 mM DTT in PBS 
pH7.4 containing protease inhibitor cocktail was added, and incubated on ice 
for thirty minutes and sonicated for 20 seconds on ice using a Status US70 
sonicating probe (Philips Harris Scientific, UK). The samples were centrifuged 
at 13,400 rpm for 20 minutes, 4oC and the liquid phase extracted to new tubes. 
The sonication and centrifugation steps were repeated if the sample remained 
cloudy. Lysates were stored at -20°C short term or -80°C long term. 
2.6.2 Tissue Biopsies  
Cryo-sections for matched normal and diseased tissues for four patients 
were prepared simultaneously using a dual lysis buffer method. For each 
sample, RIPA lysis buffer (50 µL, PBS pH 7.4, 0.1% w/v SDS, 0.25% w/v sodium 
deoxycholate containing EDTA-free protease inhibitor cocktail (Roche 
diagnostics GmbH, Germany) was added, subjected to vortexing for 30 minutes 
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at room temperature and sonicated for 20 seconds on ice using a Status US70 
sonicating probe (Philips Harris Scientific, UK). The samples were centrifuged 
at 13,400 rpm for 20 minutes, 4oC and the liquid phase extracted to new tubes. 
Urea lysis buffer (50 µL, 7M urea/2M thiourea/4% w/v CHAPS/50mM DTT in 
PBS containing EDTA-free protease inhibitor cocktail) was added to the pellet 
twice, each time treated with vortexing, sonication and centrifugation, and the 
resulting supernatant combined with the RIPA buffer protein extract.  
2.7 Protein quantification 
The protein concentration of each sample (NAF, serum and lysate from 
cell lines and tissues), was measured using the Bradford assay (Bradford, 1976) 
protein quantification kit (Bio-Rad Laboratories, Hemel Hempstead, U.K.), 
according to the manufacturer’s instructions.  The kit was used to calculate the 
protein concentration of unknown samples relative to a standard curve of bovine 
serum albumin (BSA – 0 to 2000g/ml). All samples were allowed to thaw on 
ice, before calculating the protein concentration, followed by vortexing for 1 
minute at room temperature. Samples were typically diluted 1-in-20 with HPLC 
grade water, and where appropriate, cell lysis buffer or 8M urea, was also used 
to determine background absorbance in the assay due to non-protein 
interferences. Bradford reagent (1.5 ml) was mixed with 50µL of samples and 
standards, and incubated for 10 minutes at room temperature. After incubation, 
1ml of reaction mixture was transferred to plastic cuvettes to measure the 
absorbance at 595nm by using a Multiskan Spectrum plate reader (Thermo 
Scientific), operated with Skanlt software. The equation of optical density 
relative to standard BSA concentration was calculated, and applied to the 
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unknown samples to determine the protein concentration. All measurements 
were performed in triplicate Wherever possible. 
2.8 SDS-PAGE and Western blotting 
2.8.1 SDS-PAGE 
Samples, equivalent to 20 μg of protein, were mixed with 10 μL of SDS 
reducing buffer (Laemmli buffer; 63mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 
0.0005% bromophenol blue and 0.1% β-mercaptoethanol) heated to 70°C for 
15 minutes. Denatured lysates were diluted with HPLC grade water to derive a 
consistent volume before loading to SDS polyacrylamide gels, with a 4% (v/v) 
stacking gel and 12% (v/v) separating gel in electrophoresis buffer (25mM Tris, 
193mM glycine, 0.1% SDS). Denatured lysates and 10 µL of Precision Plus 
Protein Standard (Fisher Scientific UK) 10-250 kDa were resolved with a Mini-
PROTEAN 3 Cell system (Bio-Rad) for 10 min at 80 V and then 1 hr for 150 V.  
2.8.2 Coomassie blue staining  
 After electrophoresis, the apparatus was disassembled and the gel 
transferred to a container and covered with 10 ml of the Coomassie blue 
reagent, for 1 hour at room temperature with gentle agitation. Then, the staining 
reagent was discarded and the gel was covered by 10 ml of destain solution 
(50% v/v methanol, 40% v/v water and 10% v/v acetic acid). The de-staining 
continued with gentle agitation until the protein bands became clear. Finally, the 
gels were scanned by Canon CanoScan 9000F MKII A4 Flatbed Colour 
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Scanner, operated through MP Navigator EX Ver. 5.0.2 software (Canon Tokyo, 
Japan).   
2.8.3 Western blotting 
Proteins were transferred by ‘wet transfer’ to nitrocellulose membrane 
(GE Healthcare) at 300 volts for 60 minutes at 4oCin transfer buffer (SDS-PAGE 
running buffer with 20% v/v methanol). The nitrocellulose membrane was first 
pre-activated for 5 minutes in HPLC grade water, then a protein transfer 
sandwich was made as follows: Positive electrode, sponge, filter paper, 
membrane, gel, filter paper, sponge, negative electrode (Figure 2-1).  
 
Figure 2-1: Representation of transfer “sandwich” assembly for Western 
blotting. 
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Coomassie blue staining was performed on residual gels to demonstrate 
successful protein transference. After transfer, membranes were washed in 
distilled water for 5 minutes. 
Nitrocellulose membranes were then blocked with 5% (w/v) non-fat milk 
in TBS-Tween-20 (0.05%) for 1 hour to prevent further, unwanted protein 
association. All immunoblotting was performed with primary antibodies diluted 
in blocking buffer (5% (w/v) non-fat milk in TBS Tween-20. Table 2-1 identifies 
the specific dilutions, manufacturer and the animal in which the antibody was 
produced. After incubation with primary antibodies, membranes were washed 3 
times for 5 minutes with TBS Tween-20. 
The appropriate secondary antibodies (Table 2-1), in blocking buffer, 
were incubated with the membrane for 45 min at room temperature. The 
residual secondary antibodies were removed with three TBS-Tween washes. 
All secondary antibodies were conjugated to an enzyme “horseradish 
peroxidase” (HRP) and proteins detected by the addition of ECL Plus Western 
Blotting reagent, then exposed to X-ray film (GE Healthcare, Amersham, U.K.). 
Relative quantification of band intensity was calculated using GelAnalyzer 
2010a software (http://www.gelanalyzer.com).   
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Table 2-1: Antibodies used for Western blotting. 
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2.9 Peptide preparation for LC-MS 
2.9.1 Trypsin digestion 
Each protein extract from cell lines and tissue biopsies (200 μg of 
protein) was precipitated overnight with 100% acetone at −20°C and centrifuged 
for 20 min at 13 400 rpm at 4°C. The pellet was resuspended in 8M urea in 
400mM ammonium bicarbonate (AMBIC) and protein concentration was again 
measured by Bradford assay (above section 2.7 Protein quantification) to check 
the efficiency of acetone precipitation. 
Sample amounts for proteomics were selected based on sample type 
and strategy; cell lines (80g for iTRAQ and 50g for MRM-MS), NAF (200g 
for label-free quantification and 50g for MRM-MS), tissue biopsies (50g for 
MRM-MS) and serum (50g for MRM-MS) Cell lines and tissue extracts were 
already in 8M urea, then reduced with 50 mM dithiothreitol (DTT) at 60oC for 15 
mins and alkylated with 100mM iodoacetamide (IAA) at ambient temperature, 
in the dark, for 15 min. MS-grade trypsin (Fisher Scientific UK) was used to 
digest proteins at a protease-to-protein ratio of 1:10 (w/w) at 37°C for 20 hrs. 
After digestion, each sample was desalted on an Isolute C18 desalting column 
and lyophilized. 
2.9.2 Checking the efficiency of tryptic digestion 
To check the efficiency of in-solution tryptic digestion, a 1µL aliquot of 
each digest was diluted 10-fold in 9µL 10% v/v acetonitrile (ACN). Then 0.5µL 
of each diluted sample was spotted between 2x 0.5µL saturated solution of α-
cyano-4-hydroxy-cinnamic acid (CHCA) in 30% v/v acetonitrile (ACN), on a 
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MALDI Target Plate (MTP Anchorchip 800/384 massive target T, Bruker 
Daltronics) for manual analysis by Ultraflex II. Peptide calibration mix II (Bruker 
Daltronics) was also spotted on to the target plate to calibrate the instrument. 
The dried droplets of calibrant and digested samples, were analysed on Ultraflex 
II, MS1 spectrum were acquired through FlexControl v3.4 and visualised in 
FlexAnalysis v3.4 (please see section 2.10 for further details of Ultraflex II). A 
complex MS1 spectrum indicated good efficiency of tryptic digestion. 
2.9.3 Isobaric tag peptide labelling 
All lyophilised peptides were resuspended in 1M TEAB (Sigma-Aldrich, 
Poole, U.K.), 0.1% SDS, and were incubated with iTRAQ 8-plex (Sciex, U.K.), 
according to the manufacturer’s instructions. The labelled peptides were then 
combined together, desalted on an Isolute C18 desalting column and the eluate 
was lyophilized (48°C, aqueous mode) until fully dry. 
2.9.4 OffGel fractionation  
The total iTRAQ-labelled sample was resuspended in OffGel peptide 
sample buffer (containing pH 3−10 ampholytes) and applied to an OffGel 3100 
(Agilent Technologies, Wokingham, U.K.) isoelectric focussing system using a 
pH 3−10 high-resolution strip, for 50 kV hours. Twenty-four fractions were 
collected, desalted on Isolute C18 RP cartridges, and then lyophilized until full 
dry and stored at -20oC. 
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2.9.5 SCX fractionation 
The combined sample was resuspended in 600µL SCX loading buffer 
(10mM KH2PO4 in 25% ACN, 0.01% w/v sodium azide, adjusted to pH3), added 
to an Isolute SCX column (Kinesis Ltd, UK) pre-wetted with HPLC grade water 
and allowed to flow through under passive hydrostatic pressure. Peptides were 
then eluted stepwise in 12 fractions with successive 500µL volumes of elution 
buffer, using a potassium chloride from 0 mM to 1000mM (Table 2-2). Sample 
fractions were diluted with 1.5ml Solvent A (2% v/v ACN, 0.05% v/v FA), 
desalted on an Isolute C18 desalting column and lyophilised (48°C, aqueous 
mode) until fully dry and stored at -20oC. 
 
Table 2-2: Strong Cation Exchange Elution Buffer (KCl) Concentrations.  
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2.10 LC-MS analysis 
2.10.1 Ultraflex II 
Each lyophilized sample was resuspended in 50 μL of 10% acetonitrile 
and 0.05% TFA (mobile phase A), 5 µL injected on to an LC Packings UltiMate 
3000 capillary HPLC system (ThermoFisher, Bremen, Germany), washed on a 
C18, 300 μm × 5 mm, 5 μm diameter, 100 Å PepMap pre-column (LC Packings, 
Sunnyvale, CA) before transfer to a C18, 75 μm × 15 cm, 3 μm diameter, 100 Å 
PepMap column (LC Packings). Peptides were eluted with a linear gradient of 
10-90% mobile phase B (80% acetonitrile, 0.05% TFA) over 95 min run time 
(Table 2-3). A total of 384, 75 nL fractions were co-deposited with 0.5 μL of a 
saturated -cyano-4-hydroxy cinnamic acid (CHCA) matrix (Bruker Daltonik, 
Bremen, Germany) solution onto a MTP AnchorChip 800/384 target plate 
(Bruker Daltonik) using a Proteineer FC fraction collector (Bruker Daltonik) and 
allowed to air-dry. Peptide Calibration Standard II (Angiotensin I, Angiotensin II, 
Substance P, Bombesin, ACTH clip 1−17, ACTH clip 18−39, Somatostatin 28, 
Bradykinin fragment 1−7 and Renin Substrate Tetradecapeptide porcine; 
covering the mass range 700−3200 Da, Bruker Daltonik) was applied between 
each group of four fractions. Mass spectrometric analysis was carried out using 
a MALDI−TOF/TOF UltraFlex II instrument (Bruker Daltonik) with a 200Hz 
Smartbeam laser (>250 μJ/pulse) in reflector mode. A fully automated workflow 
was performed using WarpLC software (version 1.3), which encompassed, (i) 
data acquisition (FlexControl v3.4), data-processing (FlexAnalysis v3.4 - 
TopHat baseline subtraction, Savitzky-Golay smoothing and SNAP peak 
detection algorithms), (ii) compilation of a non-redundant list of peptides from 
the 384 HPLC fractions, (iii) data-dependent MS/MS of each peptide using LIFT 
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mode, and (iv) compilation of the MS/MS fragment mass lists into a batch 
(WarpLC v1.3). Duplicate LC−MALDI analyses were performed for each OffGel 
fraction. 
2.10.2 Orbitrap Fusion 
Lyophilized peptide fractions were individually reconstituted in 10-30 μl 
of loading mobile phase (2% ACN, 0.1% FA) and 2-3 μl loaded by a Dionex 
Ultimate 3000 (Thermo Scientific) at 25 μl/minute for 4 minutes onto a C18 
PepMap100 trapping cartridge (5 mm × 300 µm ID, 5 μm particle) (Thermo 
Scientific) in loading mobile phase. After peptide loading, the trapping cartridge 
was brought in line with an Acclaim PepMap 100 column (25 cm or 50 cm × 75 
μm ID, 2 μm particle) at a flow rate of 300 nl/minute with 5% mobile phase B 
(80% CAN or 100% ACN, 0.1% FA) in mobile phase A (2% ACN, 0.1% FA). 
Several reverse phase elution gradient lengths were used, proportionally 
extrapolated from the 120-minute gradient from 5-90% solvent B (Table 2-3).   
Peptide elution was directly coupled to electrospray ionisation (ESI) at 
2.0 to 2.4 kV using a steel emitter (Thermo Scientific), and characterised with 
an Orbitrap Fusion mass spectrometer (Thermo Scientific). MS analysis of 
eluting peptides was conducted through Xcalibur 4.0 with Foundation 3.1 
SP1(Thermo Scientific) on Orbitrap Fusion, between 350 and 1500 m/z at 
120,000 mass resolution, with the maximum injection time was 100 ms. All 
MS/MS acquisition was performed on the Ion-trap, in top speed mode with 3s 
cycle time, a dynamic exclusion (±5 ppm) of 50-60 seconds, intensity threshold 
5000, with charge states 2+ to 7+ were sequentially fragmented by collision-
induced dissociation (CID) with a normalized collision energy (NCE) of 35%. A 
 87 
 
maximum of 200 ms ion injection time was allowed. Additionally, the 
Polysiloxane (C2H6SiO) at 445.12003 was used as a MS lock-mass. 
Automated Synchronous Precursor Selection (SPS) for MS3 setting was used 
for quantification of iTRAQ, a special feature of Orbitrap fusion which improves 
quantitative accuracy when using isobaric mass tags. All MS3 was performed 
on Orbitrap at 30000 resolutions, scan range 100-500 m/z, maximum injection 
time 105ms and with 65% high-energy collisional dissociation (HCD).  
2.10.3 MRM-MS 
All experiments were performed on a standard-ﬂow LC-MRM/MS 
platform with Xevo TQD, Quattro Premier XE and Quattro Ultima triple 
quadrupole mass spectrometers (Waters, Manchester, UK). Xevo TQD was 
coupled to a Waters Acquity I-Class UPLC separation system, Quattro Premier 
XE with Waters Acquity UPLC Separation system and Quattro Ultima with on-
line Waters Alliance 2695 HPLC Separation system. Instrument control was 
performed using MassLynx data system (details in Chapter 5). A two-stage 
UPLC gradient using solvent A and solvent B (Table 2-3) on Luna C18 column 
(2 mm ID x 25 cm length, 5µm particle size, Phenomenex Inc., Macclesfield, 
UK), was used for the separation of the target peptides. A linear gradient of 3 to 
90 % solvent B was applied for 40 minutes, followed by a column wash for 10 
minutes using solvent B and then a 10-min equilibration of column, total run time 
was 60 minutes (Table 2-3). The UPLC retention time, cone voltage and 
collision energy were optimized using synthetic reference peptides for target 
proteins. Calibration curves were prepared with the synthetic peptides (Chapter 
5) before quantitative analysis of protein extracts from cell lines and NAF 
samples. 
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Table 2-3:  List of instruments and columns optimised gradients for each experiment.
 89 
 
2.11 MS data processing 
MS/MS fragment mass lists were searched, via ProteinScape v3.0 for 
Ultraflex II (Bruker Daltonik) and Proteome Discoverer 2.1 for Orbitrap Fusion 
(Thermo Scientific), using Mascot software version 2.4 (Matrix Science, U.K.) 
against Swiss-Prot version 2016 containing 552,259 human protein sequences. 
A decoy search (based on automatically generated random sequences of the 
same length) was employed to determine the rate of false-positive identifications 
(Figure 2-2). Non-redundant protein profiles for each experiment were created in 
ProteinScape or Proteome Discoverer by combining the corresponding LC−MS 
datasets. The list of protein identifications was assessed manually, and all 
proteins defined as Master Protein Candidates, that could not be differentiated 
from the Master Protein (i.e. no unique peptides), were omitted for post 
processing of MS data. All stages involved in MS data processing on Proteome 
Discoverer and ProteinScape, from raw MS data file to final proteins list, are 
summarised in Figure 2-2. 
 90 
 
 
Figure 2-2: Overview of the different stages of Proteome discover and ProteinScape 
for LC-MS data processing. 
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2.12 Post-processing of MS data 
Peptide spectrum match data was exported from ProteinScape and 
Proteome Discoverer with the associated features: number of peptides, unique 
peptides, number of PSM, coverage, score Mascot, posterior error probability 
(PEP), charge states, precursor intensities and the reporter ion intensity values. 
2.12.1 Statistical analysis 
All the statistical analyses were undertaken using R Studio version 
0.99.903 (R Studio, Boston, MA) or PRISM version 6.0 software (GraphPad 
Software, San Diego, CA). 
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2.12.2 Hierarchical clustering 
R studio was used for hierarchical clustering of quantified proteome, 
using a similarity metric of Euclidian distance and complete linkage. The R 
script is given in Figure 2-3; 
 
Figure 2-3: R script for Hierarchical clustering. 
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2.12.3 Limma t-statistics 
Significantly up and down regulated proteins were defined by using 
Limma t- statistics in R- studio. The script for t-statistics is given in Figure 2-4.  
 
Figure 2-4: R script for Limma t-statistics. 
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2.12.4 Gene Ontology (GO) enrichment analysis 
All differentially expressed proteins were classified broadly into several 
groups according to the Gene Ontology (GO) annotation 
(www.geneontology.org). The over-representation analyses of GO terms, 
including the biological process, molecular function and enriched pathway 
analysis was performed using FunRich; Functional Enrichment Analysis Tool 
(www.funrich.org). Protein−protein interactions and network associations for 
significantly changed components were performed using STRING (version 9.05, 
www.string-db.org). Proteins identified in NAF samples were subjected to 
analysis in TMHMM Server v. 2.0 (http://www.cbs.dtu.dk/services/TMHMM/, 
(Krogh et al., 2001)), to determine those with transmembrane helical regions.  
2.13 Comparison of Western Blotting, iTRAQ and 
MRM-MS quantitation methods  
2.13.1 Processing of immune-blots 
Cell line extracts, equivalent to 20 μg of protein, were applied to SDS 
polyacrylamide gels. The blotted membrane was incubated in blocking buffer 
and then the appropriate primary antibodies; ACTB, CFL1, PTGES3 and 
HSPE1, in blocking buffer was incubated overnight at 4 °C. After removal of the 
primary antibody with three TBS-Tween buffer washes, the appropriate 
secondary antibodies and proteins detected by the addition of ECL Plus 
Western Blotting reagent, then exposed to X-ray film. For comparison, all 
immune blots were analysed by GelAnalyzer to calculate the intensity of bands 
then normalised with ACTB. The fold-change expression of proteins, was 
 95 
 
calculated against HMEC then converted into log2 value to simplify the 
interpretation of the dynamic range of expression. 
2.13.2 Processing of iTRAQ labelled peptides 
From iTRAQ Orbitrap Fusion data (Chapter 3), 4 proteins with 8 
peptides; Cofilin-1 (CFL-1-1, CFL-1-2, CFL-1-3), 10 kDa heat shock protein 
(HSPE1-1, HSPE1-2, HSPE1-3), Prostaglandin E synthase 3 (PTGES3-1) and 
Actin Cytoplasmic (ACTB-1); were selected because these peptides were 
common in both quantitation assay (iTRAQ and MRM). All peptides (high 
confident data p<0.05) were exported with non-normalised iTRAQ ratios then 
normalised with peptide ACTB-1 (GYSFTTTAER-iTRAQ labelled) and 
converted into log2 values to compare with MRM-MS and Western blotting. 
2.13.3 Processing of MRM peptides 
The amount of all eight peptides (CFL-1-1, CFL-1-2, CFL-1-3, HSPE1-
1, HSPE1-2, HSPE1-3, PTGES3-1), was normalised by using peptide ACTB-1 
(GYSFTTTAER). Only one peptide of PTGES3 was selected because of the 
limited availability of unique peptides. The fold-change expression of peptides, 
was calculated against HMEC then converted into log2 value. 
2.13.4 Calculating the amount of protein 
The average of three peptides (MRM-MS and iTRAQ data) was used to 
calculate the expression of CFL-1 and HSPE1 while expression of PTGES3 was 
determined from one peptide (PTGES3-1). 
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CHAPTER 3. PROTEOME PROFILING OF 
BREAST CANCER CELL LINES  
3.1 Introduction    
The aim of this study was two-fold (i) to establish the basis for precise 
protein quantification by iTRAQ (isobaric tags for relative and absolute 
quantification) mass spectrometry, and (ii) to understanding the heterogeneity 
of breast cancer at a molecular level and refine the taxonomy based on the 
presence of productive markers such as ER, PR and HER2. For these 
objectives, we applied iTRAQ based quantification approach on breast cancer 
cell lines. The iTRAQ labelled peptides were fractionated by isoelectric focusing 
and liquid chromatography and analysed by two mass spectrometry platforms; 
Orbitrap Fusion and MALDI-TOF/TOF (Ultraflex II). We have investigated how 
variance and bias in the iTRAQ reporter ions data are affected by MS platforms. 
Breast cancers which have similar histopathology behave differently in terms of 
disease progression and response to treatment. As such, there is still an unmet 
clinical need to develop biomarkers that can differentiate between different 
phenotypes of breast cancer. Proteomics provides the means to investigate the 
protein complement of biological systems and identify quantitative changes in 
specific components that can be further investigated by a range of independent 
methods as potential biomarkers.  
The advancement in proteomics techniques; methods and instruments, 
enabled quantitative analysis of complex samples with high sequence coverage 
of proteins. Several methods for quantification by mass spectrometry exist, both 
using isotopic labelling and label free approaches (Ong and Mann, 2005, 
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Bantscheff et al., 2007, Bantscheff et al., 2012). Quantification by isotopic 
labelling can be performed on precursor ion level like stable isotope labelling by 
amino acids in cell culture (SILAC) (Ong et al., 2002), or by quantifying isobaric 
label fragments like Isotope-coded affinity tag (Thompson et al., 2003) or 
isobaric tags for relative and absolute quantification (iTRAQ) (Ross et al., 2004), 
in fragment spectra.  
Isobaric mass tags are used for labelling of peptides and generate 
relative quantitative information in an isobaric labelling-based quantification 
approach. Isobaric labelling-based quantification, provides the ability to perform 
high-throughput quantiﬁcation by sample multiplexing compared to other stable 
isotope labelling techniques (Rauniyar and Yates III, 2014). A single multiplex 
experiment eliminates the need to compare multiple LC−MS2 data sets, and 
reduce overall analytical time and run-to-run variation. This type of analytical 
approach is ideal for studies; such as different stages of cell differentiation, 
comparisons of normal and diseased environment, comparisons of multiple drug 
treatments, measurement of inhibitor dose response, or time course 
comparisons, where whole proteome profiling is important to understand a 
biological condition (Zhang et al., 2005). 
Another advantage of isobaric labelling is dynamic range of 
identification and quantifications proteins; both high- and low-abundance, and 
with wide array of physiological properties (Bouchal et al., 2008). The identified 
and quantified proteome covers diverse molecular weight and pI ranges, 
functional categories, and cellular locations (Aggarwal et al., 2006, Trotter et al., 
2010). MS2/MS3 based quantification is better compared to MS based 
quantification, because the co-elution of light and heavy peptides in the latter, 
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can compromise sensitivity and occurrence of multiple precursor ion species 
create redundancy in MS2 data (Aggarwal et al., 2006, Trotter et al., 2010). The 
isobaric labelled peptides decreased the sample complexity during MS analysis. 
All peptide labelled with isobaric tags, have same chemical structure and 
molecular weight, same chromatographic time and with the same peptide mass, 
which improve the overall signal-to-noise ratios by merging the data of same 
peptide from different samples, producing good-quality MS2 data from low-copy-
number proteins (Hardt et al., 2005, Choi et al., 2009). In isobaric labelling based 
quantiﬁcation strategy, the peptides are labelled in vitro and can be applied in 
variety of sample; cell lines, human tissues, biofluid and animal tissue, which 
make it more efficient approach (Choi et al., 2009, Garbis et al., 2008, Zhou et 
al., 2009, Zhong et al., 2010, Sutton et al., 2010, Shaheed et al., 2013a).  
An isobaric mass tag has three parts; reactive group, balance group and 
reporter group. The reactive group mostly react with amine but tags react with 
cysteine residues and carbonyl groups are also present. To achieve the same 
mass of all tags with different isotopic variants, the balancing group adjusts for 
the mass difference in the reporter groups. The overall mass of reporter group 
and balance group of a tag, are kept constant using differential isotopic 
arrangements with 13C, 15N, and 18O atoms. The relative intensities of the 
reporter group provide the quantitative information about peptides between the 
different samples (Rauniyar and Yates III, 2014). Tandem mass tag (TMT) and 
isobaric tags for relative and absolute quantiﬁcation (iTRAQ), are two common 
commercially available mass tags. TMT reagents (Thermo Scientiﬁc), are 
available with different multiplex options; TMTzero, TMT duplex, TMT 6-plex, 
and TMT 10-plex, while iTRAQ reagents (AB Sciex) are available as set of 4-
plex and 8-plex mass tags.  
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The 4-plex iTRAQ reagents have reporter ion masses from m/z 114 to 
117 and a corresponding balance groups of 28−31 Da, to give a summed tag 
mass of 145 Da (Ross et al., 2004). The 8-plex reagents have reporter ion 
masses at m/z 113−119 and 121 with a balance groups to get final tag mass of 
305 Da (Sciex, 2017). The structure of the iTRAQ 8-plex balance group has not 
been published and tag mass 120 is excluded in iTRAQ 8-plex to avoid 
contamination from phenylalanine ammonium ion (m/z120.08) (Rauniyar and 
Yates III, 2014). The Figure 3-1 represents the chemical structured of iTRAQ 4-
plex, TMT 6-plex and iTRAQ 8-plex, with isotopic enrichment of 13C, 15N and 
18O (Ross et al., 2004, Pichler et al., 2010, Rauniyar and Yates III, 2014, 
ThermoFisher, 2016, Sciex, 2017). iTRAQ 8-plex allows relative quantification 
of up to 8 samples within a single experiment.  
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Figure 3-1: Chemical structures of iTRAQ 4-plex, TMT 6-plex and iTRAQ 8-plex 
reagents. 
Isobaric labelled peptides can be analysed on different type of mass 
spectrometers; MALDI-TOF/TOF (Wiese et al., 2007, Sutton et al., 2010) 
Quadrupole (Wolf-Yadlin et al., 2007), LTQ-FT (Köcher et al., 2009), LTQ-
Orbitrap (Bantscheff et al., 2008) and Orbitrap fusion (Williamson et al., 2016). 
The detection of low m/z fragment ions on TOF instruments, are ideal for 
acquisition of reporter ions but large ion selection window can result 
compression of signals from reporter ions because of background chemical 
noise (Keshamouni et al., 2006b). To avoid this type of compression effect on 
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reporter ions, MS3 mass spectrometry is performed on a hybrid ion trap Orbitrap 
platform (Ting et al., 2011). In this approach, after CID-MS2 fragmentation on an 
ion trap, the most intense product ion is selected from MS2, then analysed on 
Orbitrap by HCD-MS3 fragmentation (Senko, 2015). This type of instrument, 
provides an experimental solution to remove background interference, thus 
eliminating the ratio distortion problem.  
The goal of an iTRAQ-based biomarker discovery approach, is to 
measure quantitative expression of protein level between two or more clinical 
conditions. It is important to achieve accurate and precise quantitative 
information from the biological data, and correctly estimate the limitations of the 
quantification. This is particular relevant when selecting a protein as biomarker 
for a clinical condition, because further validation in other clinical material is time 
consuming and costly (White, 2011). 
Quantitative analysis of human proteome has some challenges; (a) 
large biological variations in expression of proteins in a cellular system (b) 
unknown complexity of proteome under a set of environmental conditions, and 
(c) large dynamic range for concentration of proteins. The factors contribute to 
large variety of peptides that can cause bias in the mass spectrometry analysis 
(Duncan et al., 2010, Hultin-Rosenberg et al., 2013). The precision and 
accuracy of a quantitation method is effected by systematic errors, that is, 
differences between true and observed values (bias). Several studies have 
proved that iTRAQ labelling is related with bias; proteome fold changes are 
compressed because of background chemical noise and this uncertainty in 
quantification is caused by co-eluting peptides with similar m/z values that are 
analysed together, creating mixed iTRAQ intensities in complex samples 
 102 
 
(Mahoney et al., 2011, Karp et al., 2010, Ow et al., 2009). The coefficient of 
variance (CV) of the iTRAQ signal depends on the intensity and results higher 
CV for low intensity peaks (Mahoney et al., 2011, Karp et al., 2010, Bantscheff 
et al., 2008, Griffin et al., 2007). The relative quantifications of proteins are 
calculated from iTRAQ intensities, which are obtained from MS2 spectra of 
peptides. There are different approaches to calculate a reliable protein ratio by 
combining the iTRAQ peptide data. Some of these methods to decrease 
uncertainty in protein quantification, are based on excluding low intensity 
peptide data (Hu et al., 2006a, Lin et al., 2006), stabilizing the variance (Karp et 
al., 2010) or weighting the peptide data according to intensity (Hu et al., 2006a, 
Gan et al., 2007, Li et al., 2012).  
Breast cancer is a heterogeneous disease which has more complex 
histological subtypes in term of disease progression, response to treatment and 
patient outcomes (Cadoo et al., 2013). Phenotyping by gene expression 
microarray has provided a powerful classification of breast cancer (Mackay et 
al., 2011) that correlate with the origins of normal breast cell development, 
elegantly portrayed by Prat and Perou in 2011, Figure 3-2 (Prat and Perou, 
2009, Prat and Perou, 2011).  
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Figure 3-2: Model of the human mammary epithelial grading linked to breast cancer subtypes (Prat and Perou, 2009). 
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Stratification has provided researchers and clinicians with valuable 
information to predict the risk of developing the disease, treatment regimen for 
patients, resistance to treatment and susceptibility to relapse thereby 
contributing towards improved personalised treatment with reduced side effects.  
Phenotyping, based on characteristic gene product profiles including unique 
classifier genes, initially identified four groups (Perou et al., 2000), which was 
subsequently increased to five classifications – luminal A, luminal B, HER2 
positive, basal-like and claudin-low (Holliday and Speirs, 2011).  
This not only applies to patient’s tumour profiles but categorisation of 
established breast cancer cell lines (Holliday and Speirs, 2011). Cell lines are 
an essential tool for the study of breast cancer biology, enabling development 
of in vitro (e.g. monolayers, 3D spheroids, co-cultures, drug resistance), in vivo 
(e.g. xenograft) and in situ (e.g. knock-in, knock-out) models, particularly in 
deciphering our understanding of molecular mechanisms. The ability to grow 
cell lines, under control conditions, provides researchers with a valuable 
resource for biological material. However, the artificial transformation/selection 
of cells for their ability to proliferate indefinitely is not without consequence in 
altering their molecular make-up, which may not fully reflect the original primary 
cells. At the time of publication/writing, there are approximately 55,084 
published articles (PubMed, (NCBI, 2017)) papers that reference breast cancer 
cell lines, some of which have played a fundamental part in disease stratification 
using comprehensive genomic and proteomic strategies. For example, the 
Cancer Cell Line Encyclopaedia includes comprehensive mRNA microarray 
profiling for 58 breast cancer cell lines (http://www.broadinstitute.org/ccle/home) 
(Barretina et al., 2012). Nevertheless, mRNA provides only one part of the 
picture in terms of the molecular events that describe cancer. Proteins, the 
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product of mRNA translation, play an integral role in the oncogenic processes 
that determine transformation, proliferation, survival, migration, invasion, and 
hence have been a rich seam of investigation to identify markers for early 
detection of the disease, disease stage, targets for drug development and 
indicators of response to treatment (toxicology).  However, there has been 
considerable debate regarding the relationship between expression at the 
mRNA and protein levels (Gry et al., 2009, Maier et al., 2009, Cifani et al., 2015), 
which for the most part has indicated limited quantitative correlation. The work 
of Cifani et al, in particular, concluded that there was no correlation between 
mRNA profiles that delineate the established phenotypes and the equivalent 
proteins using breast cancer cell lines, especially those genes defined as 
classifiers (Cifani et al., 2015). However, one challenge of this study was to use 
one cell type, MDA-MB-231, (a claudin-low subtype of the basal-like phenotype) 
as the reference cell line, which would distort potential profile aberrations 
constituted by cell line immortalisation.  
A recent study by Calderón-González and his co-workers 
identified  1,020 proteins in breast cell lines by iTRAQ 4-plex labelling and 
tandem mass spectrometry approach (Calderón-González et al., 2015). They 
compared the proteome of MCF7 and T47D (luminal A), MDA-MB-231 (claudin 
low) and SK-BR-3 (HER2+) breast cancer cell lines with MCF-10A (normal-like) 
and proposed BAG6, DDX39, ANXA8 and COX4 as putative biomarkers in 
breast cancer. A label free proteomics approach conducted by Laurence in 
2015, identified 12,000 different proteins in 20 breast cancer cell lines and 4 
tissues biopsies (triple negative) using mass spectrometry (Lawrence et al., 
2015). This study was focused on comparison of proteomes of triple negative 
breast cancer tissues with cell lines (tumour and normal-like). A recent study on 
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88 luminal-type breast cancer tissues, collected at different stages of breast 
progression, identified average of 5,439 proteins identified in each tissue 
(Pozniak et al., 2016). In this study, they also compared the quantitative 
proteome of MCF-7 (ER+) with normal mammary epithelial cells (HMEC), to 
understand the synthesis, degradation, and turnover of proteins in ER-positive 
cancer cells.  
To date, there has been no study to compare the proteome of different 
phenotype of breast cancer cell lines with normal mammary epithelial cells 
(HMEC), to identify phenotype specific signatures. This study was an iTRAQ 
experiment aimed at (a) identifying protein-specific profiles in human breast 
cancer cell lines representative of established phenotypes (luminal A, luminal 
B, HER2, basal-like and claudin-low), and (b) comparing the dynamics of iTRAQ 
quantification on two MS platforms (Ultraflex II and Orbitrap Fusion).   
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3.2     Materials and methods 
3.2.1    Breast cell lines 
Breast cancer cell lines (MCF-7; ZR-75; MDA-MB-468; MDA-MB-231; 
MDA-MB-453) and Non-tumorigenic breast cells (MCF-10A and HB2) were 
grown according recommended conditions (please refer to chapter 2 full 
details). Human mammary epithelial cells (HMEC) were isolated from biopsy 
material and ethical approval was given by Leeds (East) Research Ethic 
Committee, reference 07/H1306/98+5. All cell lines were tested for mycoplasma 
contamination using MycoProbe mycoplasma detection kit. The authenticity of 
MCF-7, MCF-10A, MDA-MB-468 and MDA-MB-231 cell lines, was confirmed by 
DNA typing (DDC Medical). All breast cancer cell lines were maintained in 
standard growth medium at 37°C and 5% CO2. 
3.2.2    Protein extraction from cell lines 
Cells were harvested by trypsin treatment on reaching 80-90% 
confluence and washed three times with PBS and resulting cell pellet (5 × 106 
cells) was resuspended in 100 μL of urea extraction buffer (7 M urea, 2 M 
thiourea, 4% w/v CHAPS, 50 mM DTT in PBS pH7.4 containing protease 
inhibitor cocktail) was added, vortexed, sonicated, and then centrifuged. The 
protein concentration of each cell line extract was measured using the Bradford 
assay (Bradford, 1976).  
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3.2.3 LC-MS analysis 
3.2.3.1 Trypsin digestion and iTRAQ labelling 
Each extract (200 μg of protein) was precipitated overnight with 100% 
acetone at −20°C and centrifuged for 20 min at 13 400 rpm at 4°C. The pellet 
was resuspended in 8M urea in 400mM ammonium bicarbonate (Ambic). After 
protein measurement by Bradford assay, each protein sample (80 μg of protein) 
was reduced with 50 mM dithiothreitol (DTT) for 15 min at 60°C, alkylated with 
100 mM iodoacetamide (IAA) at ambient temperature for 15 min, and digested 
with 3 μL of a 1 mg/mL solution of modified sequencing grade trypsin at 28°C 
for 20 hrs. After digestion, each sample was desalted on an Isolute C18 RP LC 
column, lyophilized, resuspended in 1M TEAB, 0.1% SDS and an iTRAQ 
reagent added as outlined in Table 3-1, for 2 hrs at room temperature. The 
labelled peptides were then combined, desalted on an Isolute C18 RP LC 
column, and the eluate lyophilized. 
3.2.3.2 Peptide fractionation 
The total iTRAQ-labelled peptide sample was resuspended in OffGel 
peptide sample buffer and applied to an OffGel 3100 isoelectric focussing 
system using a pH 3−10 high-resolution strip for 50 kV hours. Twenty-four 
fractions were collected, desalted on Isolute C18 RP cartridges and lyophilized. 
Figure 3-3 illustrates the workflow for the 2D Gel-LC-MS analysis of breast cell 
lines on two MS platforms. 
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Table 3-1: Breast cell lines attributes and iTRAQ labelling. 
3.2.3.3 Ultraflex II analysis 
Each lyophilized OffGel fraction was resuspended in 30 μL of 10% 
acetonitrile and 0.05% TFA, 5 µL injected on to an LC Packings UltiMate 3000 
nano HPLC system, washed on a C18 pre-column before transfer to analytical 
column. A total of 384, fractions were co-deposited with 0.4 μL of a saturated α-
cyano-4-hydroxy cinnamic acid (CHCA) matrix solution onto a MTP AnchorChip 
800/384 target plate using a Proteineer FC fraction collector and allowed to air-
dry. Peptide Calibration Standard II was applied between each group of four 
fractions. Mass spectrometric analysis was carried out using a 
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MALDI−TOF/TOF Ultraflex II instrument. A fully automated workflow was 
performed which encompassed data acquisition, data-processing, compilation 
of a non-redundant list of peptides from the 384 HPLC fractions. Duplicate 
LC−MALDI analyses were performed for each OffGel fraction (for full details, 
please see chapter 2, section 1.9.1). 
3.2.3.4 Fusion Orbitrap analysis 
Lyophilized peptide fractions were individually reconstituted in 30 μl of 
loading mobile phase and 2 μl loaded onto a Dionex Ultimate 3000 nanoLC for 
4 minutes on a C18 trapping cartridge (300 μm × 5 mm, 5 μm diameter, 100 Å 
PepMap pre-column), which was then brought in line with an analytical column 
(75 μm × 15 cm, 3 μm diameter, 100 Å PepMap column) at a flow rate of 300 
nl/minute. Several reverse phase elution gradient lengths were used (please 
see the details in chapter 2), proportionally extrapolated from the 120-minute 
gradient. MS characterisation of eluting peptides was conducted on an Orbitrap 
between 350 and 1500 m/z at 120,000 mass resolution and all MS2 acquisition 
was performed on the Ion-trap, in top speed mode with a 3s cycle time. 
Automated Synchronous Precursor Selection (SPS) for MS3 setting was used 
for quantification of iTRAQ, a special feature of the Orbitrap Fusion which 
improves quantitative accuracy when using isobaric mass tags (Chapter 2, 
Section 2.9.2 for details of the LC MS method).  
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Figure 3-3: Workflow illustrating the proteomics-based approach. 
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3.2.3.5 MS data processing 
Ultraflex II data was searched, via ProteinScape v3.0, and Orbitrap 
Fusion data was searched through Proteome Discoverer 2.1, by using same 
search method (Mascot software version 2.4 Matrix Science, U.K.) against 
SwissProt version 2016 containing 552,259 human protein sequences with 
search parameters: trypsin digestion, 2 missed cleavages, variable modification 
of methionine oxidation, fixed modifications of cysteine (carbamidomethylation) 
and iTRAQ (lysine and N-termini). For Ultraflex II; a precursor mass tolerance 
of 100 ppm, fragmentation mass tolerance of 0.7Da was used while on Orbitrap 
Fusion; a precursor mass tolerance of 10 ppm, fragmentation mass tolerance 
of 0.6 Da was selected. The confidence interval threshold was set to P value 
<0.05, which was equal to Mascot score ≥29 on Ultraflex II and was ≥22 on 
Orbitrap fusion. The schematic representation of the MS data processing 
workflow is shown in Figure 3-4. iTRAQ labelling efficiency was determined by 
searching MS/MS data using iTRAQ as a variable modification, and performing 
a survey of labelled and non-labelled peptides in the 20 highest scoring proteins 
from individual LC−MS experiments. Non-redundant protein profiles for each 
experiment were created in Proteome Discoverer/ ProteinScape by combining 
the corresponding LC−MS datasets. The list of protein identifications was 
assessed manually, and all proteins defined as Master Protein Candidates that 
could not be differentiated from the Master Protein (i.e. no unique peptides) 
were omitted. 
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Figure 3-4: Schematic representation of the MS data processing workflow. 
3.2.3.6 Statistical analysis  
For each dataset (Ultraflex II and Orbitrap Fusion), the median ratio was 
determined for each cell line, and individual protein ratios normalised (relative 
to the median ratio), to allow for experimental variation and enable comparison 
between cell lines and instruments. The ratios were converted to log2 and those 
components that were significantly changed, compared to primary human 
breast epithelial cells, were defined by using LIMMA statistics in R Studio (see 
Chapter 2, Section 2.13).  PRISM 6.0 software was used for graphical 
presentation of data. All differentially expressed proteins were classified broadly 
into several groups according to the Gene Ontology (GO) annotation. 
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Protein−protein interactions and network associations for significantly altered 
components were performed using STRING. 
3.2.4 Western blot analysis 
Cell line extracts, equivalent to 20 μg of protein, were mixed with 5 μL 
of SDS reducing buffer (Laemmli buffer), heated to 60°C for 15 min, and on 
cooling were applied to SDS polyacrylamide gels. Proteins were transferred to 
a nitrocellulose membrane by electro-blotting. The blotted membrane was 
incubated in blocking buffer and then the appropriate primary antibody (Chapter 
2, Table 2-2) in blocking buffer was incubated overnight at 4 °C. After removal 
of the primary antibody with three TBS-Tween buffer washes, the appropriate 
secondary antibodies (TABLE 2-2) and proteins detected by the addition of ECL 
Plus Western Blotting reagent, then exposed to X-ray film. (see Chapter 2, 
Section 1.7.4 for full details of western blot assay).  
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3.3 Results 
3.3.1 Comparison of protein and peptide identification from 
two MS platforms 
The experimental outline for data acquisition can be seen in Figure 3-3 
and results of protein identifications from Orbitrap Fusion and Ultraflex II are 
summarized in Table 3-2. A total of 2013 unique proteins were identified by 
using the Orbitrap Fusion with an average 6.25 peptides per protein whereas a 
total of 1884 unique proteins were identified on the Ultraflex II with an average 
of 4.94 peptides per protein. Hence, the results showed that the Orbitrap Fusion 
identified more proteins and at a greater depth of information content. There 
was a significance (p value <0.0001), on the performance of both instruments, 
for total number of PSMs, peptides, Mascot score and sequence coverage of 
identified proteins. The raw iTRAQ ratios (non-normalised), were also different, 
with p value of <0.0001, for all quantifiable proteins on both platforms (Table 
3-2). The MS acquisition time for each OffGel fraction was 2 hours on Orbitrap 
Fusion (online), while on Ultraflex II was 13 hours; 2 hours for fraction collection 
on MTP AnchorChip target (offline) and 11 hours for acquisition of average 
3,000 MS2 spectra from each OffGel fraction (Table 3-2). 
The average fold change range (log2) on Ultraflex II, was from -3.38 to 
2.12, while on Orbitrap Fusion was from -4.76 to 6.42 (Figure 3-6). iTRAQ ratios 
of all common proteins (n=1430) in both instruments (Figure 3-5), were median 
normalised and changed in to log2 values to compare the dynamic range of fold 
change. 
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Table 3-2: Proteome data comparison of instruments. 
 
Figure 3-5: Comparison of Ultraflex II and Orbitrap Fusion proteome. 
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After median normalisation of iTRAQ ratios for each sample; paired t-
test statistics was applied to compare fold change of each protein (common data 
only) on orbitrap Fusion and Ultraflex II. Dynamic range compression of iTRAQ 
ratios (113/121; p value 0.00242, 114/121; p value 0.00453, 115/121; p value 
<0.0001, 116/121; p value 0.00306, 117/121; p value <0.0001, 118/121; p value 
0.0131 and 119/121; p value <0.0001), was observed in MS2 data acquired on 
the Ultraflex II (Figure 3-6) compared to Orbitrap Fusion. The synchronous 
precursor selection (SPS) function of the Orbitrap Fusion for MS3 analysis of the 
reporter ions reduced ratio compression (increases dynamic range) (McAlister 
et al., 2014, Williamson et al., 2016) (Figure 3-6) and provided a more accurate 
picture of the protein expression changes compared to the Ultraflex II.  
Pearson correlation coefficient statistics was applied on both MS data 
sets (n=1430) to compare the slope of the linear regressions. Where SPS 
method is compared with MS2 method, good iTRAQ log2 ratio correlation was 
observed between the two instruments for all iTRAQ ratios except 118/121; 
(113/121 R2 = 0.603, 114/121 R2 = 0.595, 115/121 R2 = 0.600, 116/121 R2 = 
0.500, 117/121 R2 = 0.297, 118/121 R2 = 0.086, 119/121 R2 = 0.315) (Figure 
3-7). 
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Figure 3-6: Dynamic range of proteins identiﬁed with Ultraflex II vs Orbitrap Fusion. 
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Figure 3-7: Pearson correlation coefficient between log2 ratios of common proteins in both MS datasets – (MS/MS; Ultraflex ratio and 
SPS; Orbitrap Fusion ratios).
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3.3.2 Quantitative comparison of breast cell lines proteome 
A panel of breast cell lines was used to characterise the proteomes of 
Ultraflex II and Orbitrap Fusion, with the aim of identifying the dynamic range 
compression of MS2 data. Cell lines for each breast cancer subtype; luminal A 
represented by MCF-7, luminal B by ZR-75, HER2 by MDA-MB-453, basal-Like 
by MDA-MB-468, claudin-low by MDA-MB-231, were included, and 
premalignant cell lines were exemplified by MCF-10a (basal) and HB2 (luminal-
like). Primary human mammary epithelial cells (HMEC) were used to exemplify 
normal, healthy cells and as a reference for comparison of protein expression 
changes in cell lines in an iTRAQ-based proteomic analysis.  
To understand this effect, some pre-knowledge about the heat shock 
response in human cell lines was presumed i.e. the expression of certain heat 
shock proteins (HSPs), is changed under stressful conditions such as exposure 
to cold or heat, UV light and wound healing or tissue remodelling (Morimoto, 
1993, Jego et al., 2013, Lianos et al., 2015). The family of HSP consists of 29 
members, and many members of the family play a role as chaperone; folding or 
unfolding of proteins that were damaged by cell stress (Uniprot.org, 2015). 
Therefore, heat shock proteins are useful control proteins to compare SPS and 
MS2 quantitative method. A total of 15 heat shock proteins in all 7 cell lines and 
of the total ratios calculated by MS2 and SPS, 93% showed the same trend 
(Table 9-3). However, SPS generated 14 measurements that correlated with 
significant changes (median ± standard deviation) whereas only 4 were 
changed by MS2, indicating that greater dynamic range of the former compared 
to the latter.  
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Table 3-3:Median normalised iTRAQ ratios of heat shock proteins in breast cell lines, acquired on Orbitrap Fusion (SPS) and 
Ultraflex II (MS2). 
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3.3.3 Evaluation of Orbitrap Fusion data 
Overall there is a strong association between the two datasets, but SPS 
mode data with large dynamic range and protein IDs, was further evaluated for 
proteome profiling. In this study, breast cancer cell lines; MCF-7, ZR-75, MDA-
MB-453, MDA-MB-468, MDA-MB-231, were included, and premalignant cell 
lines were exemplified by MCF-10a and HB2. Primary human mammary 
epithelial cells (HMEC) were used to exemplify normal, healthy cells and as a 
reference for comparison of protein expression changes in cell lines in an 
iTRAQ-based proteomic analysis.  
A total of 2013 proteins from unique genes (excluding SNP and splicing 
variants) were identified with full iTRAQ ratios, of which 76% did not show a 
significant difference (within the Median range ± 1 standard deviation) in 
expression in any cell line compared to HMEC. An average of 480 proteins were 
significantly increased or decreased in at least one of the cell lines compared to 
HMEC. Those proteins that were changed in all cell lines compared to HMEC 
were identified; all increased - 18 proteins (Table 3-4) or all decreased - 56 
proteins (Table 3-5). Detailed GO-annotations for all up and down-regulated 
proteins are presented in supplementary data “All up and down compared to 
HMEC-Go-Analysis” as CD format. 
 123 
 
 
Table 3-4: Significantly up-regulated proteins in cancer and premalignant cell lines compared to primary human mammary epithelial 
cells. 
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Table 3-5, a: Significantly down-regulated proteins in cancer and premalignant cell lines compared to primary human mammary 
epithelial cells. 
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Table 3-5, b: Significantly down-regulated proteins in cancer and premalignant cell lines compared to primary human mammary 
epithelial cells. 
 126 
 
3.3.4 Hierarchical Clustering of breast cell lines 
Because of the heterogeneity of breast cancer, it is challenging to 
differentiate between each subtype based on a single gene or protein. 
Therefore, a group of markers are required that can serve as a signature for 
diagnosing different types of breast cancer. Gene expression profiling has 
played an important role in understanding the heterogeneity of breast cancer at 
a molecular level and refining the taxonomy based on the presence of 
productive markers like ER, PR and HER2 to more sophisticated grouping 
comprising luminal A, luminal B, basal-like, claudin-Low and HER2-positive 
phenotypes (Holliday and Speirs, 2011). Hierarchical clustering of breast cell 
lines proteome (SPS data), was performed by R Studio (method section for full 
details of R script), to compare the proteome of each cell lines. Luminal and 
basal cancer cell lines clustered together as expected, however the normal 
luminal (HB-2) and basal (MCF-10A) cell lines exhibited less similarity to their 
prospective lineages.  
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Figure 3-8: Hierarchical clustering of breast cell lines (cancer and normal-like) proteome compared to primary human mammary 
epithelial cells. 
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3.3.5 Breast cancer stratification using cancer cell line 
proteome profiles 
Statistical analysis was performed through R Studio software package; 
Bioconductor 3.4-Limma (section 2.12.3 above) to determine those proteins that 
were most significantly changed in specific cell lines (and therefore potentially, 
phenotype-specific) was used to determine unique protein signatures. The 
significant difference (both up- and down-regulated) of the iTRAQ ratio for one 
cell line relative to the ratios of the other cell lines (p<0.05) provides proteins 
that are unique protein classifiers for each phenotype (Figure 3-9). Interestingly, 
there number of proteins that were significantly different relative to HMEC 
increased relative to the stage of normal mammary development, with the 
smallest group of proteins defining differentiated Luminal A (MCF-7, (34 
proteins) and the largest signature (495 proteins) associated with the stem cell-
derived cancer cell line, MDA-MB-231, whose lineage is furthest removed from 
the mature differentiated healthy primary HMECs used as a control in this 
quantitative study. 
The expression of 57 proteins was significantly (p<0.05) changed in 
normal-like cell lines (MCF-10A and HB2) compared to Breast cancer cell lines 
(Detailed annotations for all signature proteins are presented in supplementary 
data, “Breast cancer specific-Go-Analysis” as CD format). Among these, 17 
proteins were down regulated and 40 proteins were up regulated in HB2 and 
MCF-10A breast cell lines. Cellular localisation (p value 0.004) and viral 
transcription process (p <0.0001) was up-regulated in normal- like cell lines 
compared to cancer cell lines. Four microRNAs in the Cancer pathway (p value 
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0.03); SERPINB5, CDKN2A, EGFR and FSCN1, were also up-regulated in HB2 
and MCF-10A.   
 
Figure 3-9: Venn diagram comparison of signature proteomes for breast cancer cell 
lines. 
3.3.5.1 Luminal vs Basal 
A group of 275 proteins (p<0.05) was significantly altered between 
luminal (MCF-7, ZR-75 and MDA-MB-453) vs basal (MDA-MB-468 and MDA-
MB-231) (Figure 3-10, Supplementary Table 3.1). One of the most significantly 
increased proteins in luminal cancer cell lines was anterior gradient protein 2 
homolog (AGR2), a proto-oncogene and protein disulphide isomerase, which 
plays a role post-transcriptional synthesis and secretion of mucins (Park et al., 
2009), not only in breast cells (ER positive) (Fritzsche et al., 2006), but many 
normal tissues (most strongly in the digestive tract, respiratory tissues, and male 
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and female reproductive organs) (Park et al., 2009). Using an iTRAQ approach, 
Chung et al, demonstrated elevated levels of AGR2 in lung carcinoma 
compared to adjacent normal tissues, which was verified by 
immunohistochemistry/tissue microarray of 268 cases, and proposed as a 
possible biomarker (CITY, 2012). 
 
 
Figure 3-10: Volcano plot analysis of differentially expressed proteins in Luminal vs 
Basal breast cancer cell lines. 
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3.3.5.2 Luminal A (MCF-7) 
For luminal A phenotype (MCF-7), a group of 34 proteins (p<0.05) were 
identified (Figure 3-11, Table 3-6), STRING analysis indicated that members 
were associated with fructose metabolism (1.640e-2, 3 components, all higher 
than in other cell lines relative to HMEC) and AMPK signalling pathway (4.80e-
2, 3 components all increased). The expression of kynureninase (KYNU) was 
significantly (p<0.001) higher in MCF-7 compared to all other cancer cell lines. 
Detailed annotations for all signature proteins are presented in supplementary 
data, “Breast cancer specific-Go-Analysis” as CD format. 
 
Figure 3-11: Volcano plot analysis of differentially expressed proteins in MCF-
7 (Luminal A). 
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Sr. 
no 
Accession Gene ID Description PSMs Peptides Coverage 
Unique 
Peptides 
Score 
Mascot 
MCF-7 
(logFC) 
MCF-7 
(P.Value) 
1 Q16719 KYNU Kynureninase 4 2 6 2 30 -3.75 0.0004 
2 P05161 ISG15 Ubiquitin-like protein ISG15 25 5 27 5 235 -4.27 0.0006 
3 Q9H6R3 ACSS3 Acyl-CoA synthetase short-chain family member 3, mitochondrial 2 2 5 2 39 -5.41 0.0028 
4 P42224 STAT1 Signal transducer and activator of transcription 1-alpha 49 14 23 14 559 -2.37 0.0037 
5 Q9H993 ARMT1 Protein-glutamate O-methyltransferase 3 3 5 3 51 -2.52 0.0056 
6 P09972 ALDOC Fructose-bisphosphate aldolase C 28 6 25 3 190 -2.17 0.0082 
7 Q9BTZ2 DHRS4 Dehydrogenase 8 5 28 5 137 -2.27 0.0087 
8 Q9BS40 LXN Latexin 4 1 8 1 208 -3.46 0.0090 
9 O60701 UGDH UDP-glucose 6-dehydrogenase 37 13 35 13 575 -2.55 0.0096 
10 P13797 PLS3 Plastin-3 11 6 11 3 70 2.65 0.0100 
11 Q96FQ6 S100A16 Protein S100-A16 18 4 45 4 391 2.68 0.0100 
12 Q6P1L8 MRPL14 39S ribosomal protein L14, mitochondrial 4 1 6 1 59 2.05 0.0111 
13 Q99439 CNN2 Calponin-2 18 6 23 5 143 2.46 0.0126 
14 P23443 RPS6KB1 Ribosomal protein S6 kinase beta-1 3 2 5 2 102 -2.25 0.0129 
15 Q9UJY1 HSPB8 Heat shock protein beta-8 5 2 9 2 43 -2.63 0.0173 
16 P05783 KRT18 Keratin, type I cytoskeletal 18 617 33 78 31 11934 -2.34 0.0196 
17 P36954 POLR2I DNA-directed RNA polymerase II subunit RPB9 4 2 14 2 33 -1.62 0.0216 
18 P20591 MX1 Interferon-induced GTP-binding protein Mx1 12 4 7 4 122 -2.67 0.0247 
19 Q15293 RCN1 Reticulocalbin-1 27 6 18 6 211 3.46 0.0282 
20 Q6IBS0 TWF2 Twinfilin-2 12 6 21 3 122 1.80 0.0303 
21 Q9C0C2 TNKS1BP1 182 kDa tankyrase-1-binding protein 12 6 5 6 124 1.67 0.0310 
22 P30536 TSPO Translocator protein 7 2 18 2 88 1.68 0.0340 
23 Q9H3N1 TMX1 Thioredoxin-related transmembrane protein 1 7 3 13 3 83 -1.42 0.0343 
24 Q6UB35 MTHFD1L Monofunctional C1-tetrahydrofolate synthase, mitochondrial 2 1 2 1 23 2.05 0.0367 
25 P07954 FH Fumarate hydratase, mitochondrial 36 11 28 11 770 1.48 0.0382 
26 Q15154 PCM1 Pericentriolar material 1 protein 3 2 1 2 31 1.80 0.0383 
27 P06280 GLA Alpha-galactosidase A 2 1 3 1 103 -1.86 0.0416 
28 P21266 GSTM3 Glutathione S-transferase Mu 3 10 4 17 4 157 -3.04 0.0421 
29 P17655 CAPN2 Calpain-2 catalytic subunit 36 8 15 8 733 1.86 0.0427 
30 P05787 KRT8 Keratin, type II cytoskeletal 8 672 46 83 38 7529 -2.13 0.0468 
31 P51159 RAB27A Ras-related protein Rab-27A 3 1 4 1 27 2.48 0.0475 
32 Q9NP61 ARFGAP3 ADP-ribosylation factor GTPase-activating protein 3 3 2 4 1 49 1.39 0.0475 
33 O00757 FBP2 Fructose-1,6-bisphosphatase isozyme 2 4 2 6 1 100 -2.91 0.0491 
34 P09467 FBP1 Fructose-1,6-bisphosphatase 1 12 6 23 5 178 -3.57 0.0493 
The table represents Uniprot Accession number, Gene ID, protein name, number of PSMs, total Peptides, unique peptides, protein coverage and Mascot score. LogFC: log fold 
change of MCF-7 vs all cancer cell lines. 
Table 3-6: Signature proteins for luminal A type breast cancer.
 133 
 
3.3.5.3 Luminal B (ZR-75)  
A group of 42 proteins (p<0.05) were observed to be uniquely increased 
or decreased in the luminal B cell line ZR-75 (Figure 3-12, Table 3-7) 
Glutathione metabolism pathway (3.71e-2, 3 components), was significantly 
altered, using Gene Ontology analysis. Detailed GO-annotations for all 
signature proteins are presented in supplementary data, “Breast cancer 
specific-Go-Analysis” as CD format. Programmed cell death protein 4 (PDCD4), 
a tumour suppressor gene and plays a role in apoptosis (Yang et al., 2006), was 
significantly decreased (p value 0.005) in luminal type breast cancer cell line 
ZR-75. The expression of proteasome assembly chaperone 2 (PSMG2), a 
negative regulation of apoptotic process (Uniprot.org, 2015), was increased (p 
value 0.01) in ZR-75 compared to all other breast cancer cell lines. 
 
Figure 3-12: Volcano plot analysis of differentially expressed proteins in ZR-75 
(Luminal B). 
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Table 3-7: Signature proteins for luminal B type breast cancer.  
The table represents Uniprot Accession number, Gene ID, protein name, number of PSMs, total Peptides, unique peptides, protein coverage and Mascot score. 
LogFC: log fold change of ZR-75 vs all cancer cell lines 
Sr. no Accession Gene ID Description PSMs Peptides Coverage 
Unique 
Peptides 
Score 
Mascot 
ZR-75 
(logFC) 
ZR-75 
(P.Value) 
1 P50238 CRIP1 Cysteine-rich protein 1 2 6 21 2 43 -5.72 0.0003 
2 O43491 EPB41L2 Band 4.1-like protein 2 1 2 1 1 27 3.43 0.0032 
3 P45877 PPIC Peptidyl-prolyl cis-trans isomerase C 3 7 13 2 99 2.08 0.0053 
4 Q8TE77 SSH3 Protein phosphatase Slingshot homolog 3 6 13 9 6 156 -2.62 0.0055 
5 Q53EL6 PDCD4 Programmed cell death protein 4 4 8 10 4 95 -2.46 0.0063 
6 Q5H9R7 PPP6R3 Serine/threonine-protein phosphatase 6 regulatory subunit 3 2 3 3 2 61 -2.30 0.0114 
7 Q13510 ASAH1 Acid ceramidase 7 15 13 7 68 -1.71 0.0120 
8 Q969U7 PSMG2 Proteasome assembly chaperone 2 1 8 5 1 131 2.38 0.0134 
9 Q9BV57 ADI1 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase 3 7 18 3 70 1.67 0.0162 
10 Q13232 NME3 Nucleoside diphosphate kinase 3 2 2 12 2 27 -1.91 0.0184 
11 Q8WVQ1 CANT1 Soluble calcium-activated nucleotidase 1 2 2 5 2 46 -1.53 0.0203 
12 P21291 CSRP1 Cysteine and glycine-rich protein 1 3 11 28 3 286 1.98 0.0220 
13 P52292 KPNA2 Importin subunit alpha-1 5 24 12 5 345 1.77 0.0221 
14 O94905 ERLIN2 Erlin-2 2 9 6 2 45 -1.52 0.0234 
15 P50897 PPT1 Palmitoyl-protein thioesterase 1 6 18 31 6 389 -1.74 0.0253 
16 P32322 PYCR1 Pyrroline-5-carboxylate reductase 1, mitochondrial 7 21 31 6 372 -1.92 0.0256 
17 Q9NSE4 IARS2 Isoleucine--tRNA ligase, mitochondrial 9 15 10 9 69 -2.21 0.0265 
18 Q9NUI1 DECR2 Peroxisomal 2,4-dienoyl-CoA reductase 3 6 12 3 102 -1.68 0.0278 
19 O75223 GGCT Gamma-glutamylcyclotransferase 4 10 24 4 135 -1.87 0.0293 
20 Q9Y277 VDAC3 Voltage-dependent anion-selective channel protein 3 9 45 34 8 406 -1.66 0.0297 
21 Q9NRF8 CTPS2 CTP synthase 2 2 3 4 1 76 -2.32 0.0298 
22 P52943 CRIP2 Cysteine-rich protein 2 4 10 36 4 156 -1.57 0.0305 
23 P01130 LDLR Low-density lipoprotein receptor 1 2 2 1 28 1.71 0.0305 
24 P08238 HSP90AB1 Heat shock protein HSP 90-beta 39 344 59 17 5782 1.53 0.0311 
25 Q12765 SCRN1 Secernin-1 3 7 10 3 67 -1.65 0.0327 
26 P50416 CPT1A Carnitine O-palmitoyltransferase 1, liver isoform 4 12 5 4 185 -3.88 0.0330 
27 P10620 MGST1 Microsomal glutathione S-transferase 1 2 4 17 2 38 2.23 0.0357 
28 Q8NFU3 TSTD1 Thiosulfate sulfurtransferase 2 8 14 2 50 -1.62 0.0365 
29 Q8IVL6 LEPREL2 Prolyl 3-hydroxylase 3 2 4 5 2 106 -2.04 0.0380 
30 Q9BR76 CORO1B Coronin-1B 10 25 16 10 170 -1.75 0.0385 
31 P11117 ACP2 Lysosomal acid phosphatase 2 5 5 2 30 -1.45 0.0423 
32 Q14155 ARHGEF7 Rho guanine nucleotide exchange factor 7 2 2 3 2 33 -1.46 0.0424 
33 O95801 TTC4 Tetratricopeptide repeat protein 4 2 3 7 2 73 1.75 0.0429 
34 O94919 ENDOD1 Endonuclease domain-containing 1 protein 2 5 4 2 45 -2.05 0.0430 
35 O00170 AIP AH receptor-interacting protein 3 4 10 3 69 -1.24 0.0452 
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Sr. no Accession Gene ID Description PSMs Peptides Coverage 
Unique 
Peptides 
Score 
Mascot 
ZR-75 
(logFC) 
ZR-75 
(P.Value) 
37 Q9BUP0 EFHD1 EF-hand domain-containing protein D1 3 4 13 2 33 -2.21 0.0470 
38 P02765 AHSG Alpha-2-HS-glycoprotein 2 5 5 2 84 1.27 0.0476 
39 O43447 PPIH Peptidyl-prolyl cis-trans isomerase H 2 7 8 1 80 1.46 0.0480 
40 Q9BXW7 CECR5 Cat eye syndrome critical region protein 5 3 5 12 3 78 -1.51 0.0481 
41 P48735 IDH2 Isocitrate dehydrogenase [NADP], mitochondrial 16 64 36 14 470 -2.56 0.0495 
42 P26641 EEF1G Elongation factor 1-gamma 12 96 27 12 911 1.31 0.0497 
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3.3.5.4 HER2 positive (MDA-MB-453) 
A HER2+ve signature was defined, comprising 40 proteins (p<0.05, 
Figure 3-13, Table 3-8), of which 9 were associated with metabolic pathways, 
including fatty acid metabolism and 10 proteins were regulator of oxidation and 
reduction process. Detailed GO-annotations for all signature proteins are 
presented in supplementary data, “Breast cancer specific-Go-Analysis” as CD 
format. The expression of podocalyxin (PODXL), a regulator of both adhesion 
and cell morphology as well as cancer progression (Somasiri et al., 2004), was 
4.7 fold higher (p value 0.01) in HER2 positive breast cancer cell lines MDA-
MB-453. The expression of cathepsin B (CTSB), which plays a role in tumour 
invasion and metastasis (Aggarwal and Sloane, 2014), was also higher (p value 
0.02) in MDA-MB-453 compared to all breast cancer cell lines. 
 
Figure 3-13: Volcano plot analysis of differentially expressed proteins in MDA-
MB-453 (HER2 positive).
 137 
 
Sr. no Accession Gene ID Description PSMs Peptides Coverage 
Unique 
Peptides 
Score 
Mascot 
MDA-
MB-453 
(logFC) 
MDA-
MB-453 
(P.Value) 
1 Q9NZT1 CALML5 Calmodulin-like protein 5 3 2 16 2 31 -3.79 0.0003 
2 Q9UFN0 NIPSNAP3A Protein NipSnap homolog 3A 2 1 6 1 56 2.81 0.0022 
3 Q9Y2G5 POFUT2 GDP-fucose protein O-fucosyltransferase 2 3 1 3 1 60 2.34 0.0074 
4 P33121 ACSL1 Long-chain-fatty-acid--CoA ligase 1 19 5 8 5 270 -2.70 0.0078 
5 P33316 DUT Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial 39 7 33 7 466 -2.41 0.0090 
6 Q9Y6N5 SQRDL Sulfide:quinone oxidoreductase, mitochondrial 37 15 45 15 719 -2.05 0.0093 
7 P43155 CRAT Carnitine O-acetyltransferase 7 5 8 5 36 -2.68 0.0098 
8 O00592 PODXL Podocalyxin 5 1 1 1 34 4.69 0.0105 
9 Q13641 TPBG Trophoblast glycoprotein 11 3 10 3 143 2.27 0.0108 
10 Q13509 TUBB3 Tubulin beta-3 chain 296 18 49 4 4106 2.30 0.0109 
11 P42765 ACAA2 3-ketoacyl-CoA thiolase, mitochondrial 7 4 12 4 145 2.29 0.0117 
12 Q13423 NNT NAD(P) transhydrogenase, mitochondrial 13 9 10 9 100 1.81 0.0119 
13 Q08380 LGALS3BP Galectin-3-binding protein 13 7 16 7 189 2.25 0.0132 
14 O15143 ARPC1B Actin-related protein 2 10 4 12 4 74 1.96 0.0134 
15 Q12797 ASPH Aspartyl 23 9 12 9 295 -2.18 0.0141 
16 P06396 GSN Gelsolin 42 12 19 12 261 1.89 0.0180 
17 P51812 RPS6KA3 Ribosomal protein S6 kinase alpha-3 4 1 1 1 45 1.76 0.0183 
18 P50995 ANXA11 Annexin A11 24 8 17 8 238 2.12 0.0196 
19 P07858 CTSB Cathepsin B 46 5 22 5 849 1.58 0.0209 
20 Q9BTE3 MCMBP Mini-chromosome maintenance complex-binding protein 6 2 3 2 27 -2.32 0.0216 
21 Q9UKE5 TNIK TRAF2 and NCK-interacting protein kinase 5 1 1 1 62 2.76 0.0239 
22 P04792 HSPB1 Heat shock protein beta-1 135 14 83 14 2315 2.49 0.0243 
23 Q9Y696 CLIC4 Chloride intracellular channel protein 4 15 5 25 5 90 1.69 0.0249 
24 O95479 H6PD GDH/6PGL endoplasmic bifunctional protein 6 4 7 4 37 1.75 0.0299 
25 P07711 CTSL Cathepsin L1 3 1 4 1 85 2.41 0.0300 
26 Q99797 MIPEP Mitochondrial intermediate peptidase 2 2 2 2 56 -1.79 0.0313 
27 P27105 STOM Erythrocyte band 7 integral membrane protein 18 7 29 7 132 -1.97 0.0320 
28 P12277 CKB Creatine kinase B-type 24 9 32 9 237 -3.07 0.0325 
29 O00151 PDLIM1 PDZ and LIM domain protein 1 15 6 23 6 224 1.68 0.0326 
30 Q14166 TTLL12 Tubulin--tyrosine ligase-like protein 12 19 9 20 9 205 -1.73 0.0332 
31 P33992 MCM5 DNA replication licensing factor MCM5 11 6 10 6 134 -1.54 0.0341 
32 P49748 ACADVL Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 25 11 19 11 284 1.62 0.0354 
33 Q13011 ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 40 9 34 9 448 1.98 0.0371 
34 Q8TD19 NEK9 Serine/threonine-protein kinase Nek9 2 1 1 1 47 -2.84 0.0383 
35 Q93062 RBPMS RNA-binding protein with multiple splicing 2 1 7 1 36 1.66 0.0385 
36 P07951 TPM2 Tropomyosin beta chain 50 11 23 1 725 1.63 0.0412 
37 P21266 GSTM3 Glutathione S-transferase Mu 3 10 4 17 4 157 3.05 0.0432 
38 P30038 ALDH4A1 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial 14 6 12 6 140 -2.20 0.0447 
39 Q00796 SORD Sorbitol dehydrogenase 20 7 28 7 455 -2.12 0.0494 
40 P12268 IMPDH2 Inosine-5'-monophosphate dehydrogenase 2 40 14 37 12 485 -1.29 0.0496 
The table represents Uniprot Accession number, Gene ID, protein name, number of PSMs, total Peptides, unique peptides, protein coverage and Mascot score. LogFC: log fold 
change of MDA-MB-453 vs all cancer cell lines. 
Table 3-8: Signature proteins for HER2 positive breast cancer. 
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3.3.5.5 Basal-like specific (MDA-MB-468) 
A group of 91 proteins (p<0.05) were observed to be uniquely 
expressed in the basal-like cell line MDA-MB-468 (Figure 3-14, Table 3-9), 
including organonitrogen compound biosynthetic process (4.29e-5, 13 
components) and cellular amino acid metabolic process (0.0004, 11 
components). The metabolic pathway (7.99e-6, 21 components) and synthesis 
of amino acids (0.002, 5 components) were two altered KEGG pathways. 
Detailed GO annotations for all signature proteins are presented in 
supplementary data, Breast cancer specific-Go-Analysis as CD format. The 
expression of Epidermal growth factor receptor (EGFR), a key regulator of cell 
growth, migration and proliferation, also plays role in DNA repair and replication 
by EGFR signalling pathway (Nicholson et al., 2001, Engelman and Cantley, 
2008), was down-regulated in basal-like breast cancer cell line MDA-MB-468. 
 
Figure 3-14: Volcano plot analysis of differentially expressed proteins in MDA-
MB-468 (Basal-Like).
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Table 3-9: Signature proteins for Basal-like breast cancer.  
The table represents Uniprot Accession number, Gene ID, protein name, number of PSMs, total Peptides, unique peptides, protein coverage and Mascot 
score. LogFC: log fold change of MDA-MB-468 vs all cancer cell lines.  
 
Sr. no Accession Gene ID Description PSMs Peptides Coverage 
Unique 
Peptides 
Score 
Mascot 
MDA-MB-
468 (logFC) 
MDA-MB-468 
(P.Value) 
1 Q8WUP2 FBLIM1 Filamin-binding LIM protein 1 4 1 3 1 88 -5.21 <0.0001 
2 P00533 EGFR Epidermal growth factor receptor 17 11 12 10 266 -4.94 0.0003 
3 Q9NS86 LANCL2 LanC-like protein 2 3 2 5 2 33 -3.26 0.0004 
4 P31944 CASP14 Caspase-14 5 4 18 4 24 -3.58 0.0005 
5 Q9UHW9 SLC12A6 Solute carrier family 12 member 6 3 2 2 2 26 -3.66 0.0005 
6 Q04695 KRT17 Keratin, type I cytoskeletal 17 280 33 70 18 3566 -3.19 0.0006 
7 P05109 S100A8 Protein S100-A8 6 3 33 3 91 -3.22 0.0006 
8 P13647 KRT5 Keratin, type II cytoskeletal 5 218 30 49 18 2285 -3.04 0.0006 
9 P42166 TMPO Lamina-associated polypeptide 2, isoform alpha 19 5 10 1 376 2.90 0.0007 
10 Q14956 GPNMB Transmembrane glycoprotein NMB 2 1 2 1 40 -3.26 0.0009 
11 Q3SY69 ALDH1L2 
Mitochondrial 10-formyltetrahydrofolate 
dehydrogenase 
5 3 5 3 45 -2.68 0.0010 
12 Q6UWP2 DHRS11 Dehydrogenase 5 2 11 2 96 -2.97 0.0012 
13 P06702 S100A9 Protein S100-A9 6 3 31 3 22 -2.61 0.0014 
14 P02511 CRYAB Alpha-crystallin B chain 7 3 16 3 71 -2.57 0.0018 
15 P08473 MME Neprilysin 9 6 9 6 222 -3.03 0.0018 
16 Q9P2K5 MYEF2 Myelin expression factor 2 2 2 4 2 26 2.91 0.0024 
17 Q9Y6K8 AK5 Adenylate kinase isoenzyme 5 8 2 4 1 59 -2.94 0.0025 
18 P04818 TYMS Thymidylate synthase 13 5 21 5 126 -3.01 0.0027 
19 O95340 PAPSS2 
Bifunctional 3'-phosphoadenosine 5'-phosphosulfate 
synthase 2 
11 6 13 4 85 -3.23 0.0028 
20 Q71DI3 HIST2H3A Histone H3.2 36 4 40 1 258 2.13 0.0036 
21 Q07020 RPL18 60S ribosomal protein L18 8 2 13 2 144 -2.16 0.0036 
22 P54578 USP14 Ubiquitin carboxyl-terminal hydrolase 14 42 8 17 8 657 -2.89 0.0036 
23 P30519 HMOX2 Heme oxygenase 2 3 2 12 2 119 2.25 0.0049 
24 Q8IWA5 SLC44A2 Choline transporter-like protein 2 4 2 3 2 25 -2.34 0.0051 
25 P47895 ALDH1A3 Aldehyde dehydrogenase family 1 member A3 40 13 31 12 267 -2.14 0.0055 
26 Q9NQG5 RPRD1B 
Regulation of nuclear pre-mRNA domain-containing 
protein 1B 
5 1 2 1 31 -2.20 0.0056 
27 P26358 DNMT1 DNA (cytosine-5)-methyltransferase 1 7 4 3 4 78 -2.18 0.0064 
28 P07738 BPGM Bisphosphoglycerate mutase 2 1 4 1 59 -2.67 0.0065 
29 P04350 TUBB4A Tubulin beta-4A chain 454 21 70 1 5780 1.79 0.0077 
30 Q16643 DBN1 Drebrin 4 4 8 4 39 -1.97 0.0079 
31 Q96DG6 CMBL Carboxymethylenebutenolidase homolog 5 2 7 2 23 2.52 0.0082 
32 P78330 PSPH Phosphoserine phosphatase 18 4 20 4 335 -3.14 0.0083 
33 Q9H1E3 NUCKS1 
Nuclear ubiquitous casein and cyclin-dependent 
kinase substrate 1 
3 1 4 1 35 2.28 0.0099 
34 P67870 CSNK2B Casein kinase II subunit beta 8 2 12 2 163 -1.78 0.0115 
35 P49585 PCYT1A Choline-phosphate cytidylyltransferase A 5 2 7 2 130 2.04 0.0120 
36 O00425 IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 13 5 10 3 154 -3.24 0.0153 
37 P07686 HEXB Beta-hexosaminidase subunit beta 5 4 10 4 61 1.91 0.0153 
38 O43175 PHGDH D-3-phosphoglycerate dehydrogenase 67 15 34 15 945 -2.15 0.0154 
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Sr. no Accession Gene ID Description PSMs Peptides Coverage 
Unique 
Peptides 
Score 
Mascot 
MDA-MB-
468 (logFC) 
MDA-MB-468 
(P.Value) 
40 Q86UU0 BCL9L B-cell CLL 2 1 1 1 33 -1.59 0.0174 
41 Q86WC4 OSTM1 Osteopetrosis-associated transmembrane protein 1 2 1 4 1 50 2.12 0.0174 
42 P15924 DSP Desmoplakin 34 14 5 14 380 -1.64 0.0178 
43 P68371 TUBB4B Tubulin beta-4B chain 510 25 82 1 6906 1.49 0.0200 
44 Q9Y2J8 PADI2 Protein-arginine deiminase type-2 13 4 6 4 144 -3.16 0.0208 
45 P36915 GNL1 Guanine nucleotide-binding protein-like 1 5 2 4 2 162 -1.73 0.0217 
46 P61970 NUTF2 Nuclear transport factor 2 5 3 45 3 74 1.59 0.0217 
47 O60936 NOL3 Nucleolar protein 3 6 3 18 3 77 1.51 0.0222 
48 P20962 PTMS Parathymosin 5 2 22 2 101 2.33 0.0236 
49 Q99584 S100A13 Protein S100-A13 21 5 49 5 142 1.97 0.0236 
50 Q9NVS9 PNPO Pyridoxine-5'-phosphate oxidase 3 2 9 2 57 1.58 0.0236 
51 O15382 BCAT2 
Branched-chain-amino-acid aminotransferase, 
mitochondrial 
6 4 13 4 163 1.51 0.0237 
52 Q6ZVX7 NCCRP1 F-box only protein 50 2 2 6 2 29 -2.19 0.0246 
53 P04264 KRT1 Keratin, type II cytoskeletal 1 52 13 21 8 554 1.71 0.0248 
54 P04040 CAT Catalase 14 6 13 6 66 -1.64 0.0248 
55 Q9ULZ3 PYCARD 
Apoptosis-associated speck-like protein containing a 
CARD 
9 3 13 3 58 1.54 0.0256 
56 P07305 H1F0 Histone H1.0 7 3 15 3 58 1.69 0.0266 
57 Q9GZP4 PITHD1 PITH domain-containing protein 1 3 2 8 2 65 -1.48 0.0266 
58 Q02338 BDH1 
D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial 
12 3 11 3 80 2.36 0.0280 
59 P04062 GBA Glucosylceramidase 2 2 4 2 50 1.32 0.0282 
60 Q16543 CDC37 Hsp90 co-chaperone Cdc37 17 2 5 2 122 -1.36 0.0285 
61 P22102 GART Trifunctional purine biosynthetic protein adenosine-3 31 11 14 11 378 -1.84 0.0290 
62 Q04828 AKR1C1 Aldo-keto reductase family 1 member C1 25 7 28 7 203 -2.18 0.0298 
63 Q14344 GNA13 Guanine nucleotide-binding protein subunit alpha-13 13 2 6 1 235 1.96 0.0299 
64 P07108 DBI Acyl-CoA-binding protein 16 5 63 5 117 1.50 0.0307 
65 P80188 LCN2 Neutrophil gelatinase-associated lipocalin 3 2 14 2 37 -2.67 0.0308 
66 P62330 ARF6 ADP-ribosylation factor 6 12 3 23 3 139 2.02 0.0311 
67 Q6P5R6 RPL22L1 60S ribosomal protein L22-like 1 2 1 10 1 26 1.70 0.0311 
68 Q9UKS6 PACSIN3 
Protein kinase C and casein kinase substrate in 
neurons protein 3 
2 1 2 1 89 -1.51 0.0312 
69 Q9BZL1 UBL5 Ubiquitin-like protein 5 5 1 12 1 32 -1.58 0.0343 
70 P14209 CD99 CD99 antigen 5 2 13 2 53 1.47 0.0350 
71 Q8IVT2 MISP Mitotic interactor and substrate of PLK1 2 2 3 2 38 3.58 0.0351 
72 P05187 ALPP Alkaline phosphatase, placental type 5 2 4 2 35 -1.89 0.0354 
73 P08240 SRPR Signal recognition particle receptor subunit alpha 6 4 8 4 62 -1.33 0.0361 
74 P48507 GCLM Glutamate--cysteine ligase regulatory subunit 2 1 5 1 70 -1.60 0.0373 
75 O43570 CA12 Carbonic anhydrase 12 2 2 9 2 118 3.83 0.0380 
76 Q15046 KARS Lysine--tRNA ligase 10 4 7 4 60 -1.53 0.0395 
77 Q86SX6 GLRX5 Glutaredoxin-related protein 5, mitochondrial 12 4 32 4 212 1.22 0.0396 
78 Q99426 TBCB Tubulin-folding cofactor B 14 5 21 5 152 -1.37 0.0407 
79 P35520 CBS Cystathionine beta-synthase 4 3 6 3 36 -2.09 0.0410 
80 Q9H8Y8 GORASP2 Golgi reassembly-stacking protein 2 7 2 8 2 159 1.64 0.0412 
81 O95571 ETHE1 Persulfide dioxygenase ETHE1, mitochondrial 14 5 31 5 213 -1.54 0.0414 
82 Q8IUE6 HIST2H2AB Histone H2A type 2-B 53 4 35 1 405 1.31 0.0416 
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Sr. no Accession Gene ID Description PSMs Peptides Coverage 
Unique 
Peptides 
Score 
Mascot 
MDA-MB-
468 (logFC) 
MDA-MB-468 
(P.Value) 
84 P45954 ACADSB Short 2 2 7 2 53 2.27 0.0433 
85 Q8NE86 MCU Calcium uniporter protein, mitochondrial 5 2 3 2 123 -1.37 0.0444 
86 P26640 VARS Valine--tRNA ligase 45 17 16 17 566 -1.68 0.0448 
87 Q9HD26 GOPC 
Golgi-associated PDZ and coiled-coil motif-
containing protein 
5 2 5 2 110 -1.41 0.0460 
88 P07477 PRSS1 Trypsin-1 15 1 4 1 115 1.77 0.0472 
89 P31153 MAT2A S-adenosylmethionine synthase isoform type-2 38 9 29 9 610 -1.19 0.0477 
90 P07237 P4HB Protein disulfide-isomerase 161 33 70 33 1376 1.21 0.0495 
91 P09758 TACSTD2 Tumor-associated calcium signal transducer 2 4 3 11 3 59 -1.21 0.0496 
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3.3.5.6 Stem cell characteristics of Claudin-low cell line MDA-MB-
231 
Vimentin and CD44, which are markers of mesenchymal and stem 
cell-like properties in claudin-low tumours had the highest levels in MDA-
MB-231 compared to the other cancer cell lines. CD44, a marker for breast 
cancer stem cells, plays an essential role in cell migration, tumour growth 
and progression by formation of invadopodia (Vikesaa et al., 2006). The 
expression of CD44 is reported to be higher in myoepithelial cells from basal 
tumours compared to those from luminal–derived malignancies (Charafe-
Jauffret et al., 2005). The proteomics data correlated with these findings, 
exhibiting low expression in Luminal cells and higher expression in basal-
like and Claudin-low subtypes. A signature, comprising 499 proteins 
(p<0.05), was defined for claudin-low phenotype of breast cancer (Figure 
3-15, Table 3-10Error! Reference source not found., Supplementary 
Table 3.2). The String analysis of these signature proteins reveal 468 
biological process including intercellular transporters (140 components, 
1.28e-11), cellular localization (103 components, 1.7e-12), Cell surface 
receptor signalling pathway ((68 components, 0.01), regulation of cell death 
(64 components, 2.1e-05) and apoptotic process (80 components, 0.0001). 
Detailed GO annotations for all signature proteins are presented in 
supplementary data, “Breast cancer specific-Go-Analysis” as CD format. 
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Figure 3-15: Volcano plot analysis of differentially expressed proteins in MDA-MB-231 cell line (Claudin-Low). 
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Table 3-10: Signature proteins for Claudin-Low breast cancer.  
The table represents Uniprot Accession number, Gene ID, protein name, number of PSMs, total Peptides, unique peptides, protein coverage and Mascot score. 
LogFC: log fold change of MDA-MB-231 vs all cancer cell lines. 
Sr. no Accession Gene ID Description PSMs Peptides Coverage 
Unique 
Peptides 
Score 
Mascot 
MDA-
MB-231 
(logFC) 
MDA-MB-
231 
(P.Value) 
1 P08670 VIM Vimentin 448 47 88 44 5307 -4.85 <0.0001 
2 P29373 CRABP2 Cellular retinoic acid-binding protein 2 43 7 61 7 498 3.2 0.0001 
3 Q9BYT8 NLN Neurolysin, mitochondrial 5 1 1 1 66 4.74 0.0001 
4 P42285 SKIV2L2 Superkiller viralicidic activity 2-like 2 4 2 2 2 38 3.41 0.0001 
5 P35754 GLRX Glutaredoxin-1 3 2 11 2 41 -2.83 0.0002 
6 Q8N201 INTS1 Integrator complex subunit 1 2 2 1 2 45 5.45 0.0002 
7 P21980 TGM2 Protein-glutamine gamma-glutamyltransferase 2 14 8 14 8 131 -3.29 0.0003 
8 Q15269 PWP2 Periodic tryptophan protein 2 homolog 8 3 3 3 119 3.72 0.0004 
9 P46821 MAP1B Microtubule-associated protein 1B 4 3 2 3 31 -3.54 0.0005 
10 Q09666 AHNAK Neuroblast differentiation-associated protein AHNAK 227 82 36 82 1961 -2.58 0.0005 
11 P40261 NNMT Nicotinamide N-methyltransferase 6 2 7 2 81 -2.52 0.0005 
12 P08758 ANXA5 Annexin A5 110 16 48 15 1162 -2.33 0.0006 
13 Q9HD20 ATP13A1 Manganese-transporting ATPase 13A1 6 3 3 3 81 2.9 0.0006 
14 Q9HCU5 PREB Prolactin regulatory element-binding protein 2 2 9 2 76 2.49 0.0006 
15 Q6P1N9 TATDN1 Putative deoxyribonuclease TATDN1 2 1 3 1 36 3 0.0006 
16 O43852 CALU Calumenin 28 6 17 6 316 -2.58 0.0007 
17 Q03135 CAV1 Caveolin-1 8 2 12 2 210 -4.73 0.0007 
18 P09211 GSTP1 Glutathione S-transferase P 37 9 61 9 360 -4.59 0.0007 
19 P07195 LDHB L-lactate dehydrogenase B chain 74 12 43 10 653 -3.81 0.0007 
20 P09382 LGALS1 Galectin-1 116 9 81 9 1437 -2.61 0.0008 
21 Q13330 MTA1 Metastasis-associated protein MTA1 4 2 3 1 36 -2.34 0.0008 
22 Q15437 SEC23B Protein transport protein Sec23B 22 6 9 4 325 2.6 0.0008 
23 P55209 NAP1L1 Nucleosome assembly protein 1-like 1 26 6 18 5 518 -2.2 0.001 
24 Q9UJZ1 STOML2 Stomatin-like protein 2, mitochondrial 7 4 16 4 112 -2.57 0.001 
25 P26006 ITGA3 Integrin alpha-3 12 4 5 4 158 -2.1 0.0013 
26 Q6UW68 TMEM205 Transmembrane protein 205 10 2 16 2 92 3.08 0.0013 
27 Q96QK1 VPS35 Vacuolar protein sorting-associated protein 35 25 7 9 7 469 2.26 0.0013 
28 Q16531 DDB1 DNA damage-binding protein 1 13 9 10 9 106 2.54 0.0014 
29 Q8N6R0 METTL13 Methyltransferase-like protein 13 4 3 3 3 38 2.22 0.0014 
30 O14976 GAK Cyclin-G-associated kinase 3 2 2 2 41 3.69 0.0015 
31 P67936 TPM4 Tropomyosin alpha-4 chain 76 19 54 8 855 -2.67 0.0016 
32 Q6P9B9 INTS5 Integrator complex subunit 5 3 2 2 2 46 1.89 0.0017 
33 Q15691 MAPRE1 Microtubule-associated protein RP 3 2 10 2 42 -2.36 0.0017 
34 P78527 PRKDC DNA-dependent protein kinase catalytic subunit 93 35 9 35 940 1.92 0.0019 
35 P43490 NAMPT Nicotinamide phosphoribosyltransferase 31 11 27 11 228 -2.91 0.0019 
36 Q92973 TNPO1 Transportin-1 15 9 12 9 193 1.95 0.0019 
37 P62158 CALM3 Calmodulin 37 7 49 7 328 -2.05 0.002 
38 P40121 CAPG Macrophage-capping protein 15 5 18 5 151 -3.21 0.002 
39 O14950 MYL12B Myosin regulatory light chain 12B 60 7 52 3 1098 -2.43 0.002 
40 A3KMH1 VWA8 von Willebrand factor A domain-containing protein 8 4 2 1 2 55 2.59 0.002 
41 P62942 FKBP1A Peptidyl-prolyl cis-trans isomerase FKBP1A 22 4 41 4 424 -1.99 0.0021 
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Sr. no Accession Gene ID Description PSMs Peptides Coverage 
Unique 
Peptides 
Score 
Mascot 
MDA-
MB-231 
(logFC) 
MDA-MB-
231 
(P.Value) 
43 P13640 MT1G Metallothionein-1G 22 3 34 3 174 -3.28 0.0022 
45 P30405 PPIF Peptidyl-prolyl cis-trans isomerase F, mitochondrial 6 4 26 3 24 -1.71 0.0025 
46 P58107 EPPK1 Epiplakin 97 28 27 23 1634 2.45 0.0026 
47 Q86Y46 KRT73 Keratin, type II cytoskeletal 73 28 5 5 1 168 5.34 0.0026 
48 Q9H299 SH3BGRL3 SH3 domain-binding glutamic acid-rich-like protein 3 26 4 39 4 335 -1.8 0.0026 
49 Q9BV44 THUMPD3 THUMP domain-containing protein 3 6 4 8 4 41 2.21 0.0029 
50 P04179 SOD2 Superoxide dismutase [Mn], mitochondrial 35 9 51 9 285 -2.04 0.0031 
51 O00186 STXBP3 Syntaxin-binding protein 3 3 2 5 2 26 2.35 0.0033 
52 Q6P1M0 SLC27A4 Long-chain fatty acid transport protein 4 6 2 3 2 37 3.78 0.0034 
53 Q9NRP0 OSTC Oligosaccharyltransferase complex subunit OSTC 3 1 8 1 32 1.9 0.0035 
54 Q96RP9 GFM1 Elongation factor G, mitochondrial 6 2 2 2 36 1.77 0.0036 
55 Q9HD45 TM9SF3 Transmembrane 9 superfamily member 3 6 2 4 2 99 3.56 0.0038 
56 O60664 PLIN3 Perilipin-3 46 10 39 10 956 -1.6 0.0039 
57 Q04941 PLP2 Proteolipid protein 2 8 2 18 2 207 -2.81 0.0039 
58 Q03252 LMNB2 Lamin-B2 43 15 26 13 352 -1.88 0.004 
59 P27816 MAP4 Microtubule-associated protein 4 32 14 15 14 428 -1.52 0.0042 
60 Q6P2Q9 PRPF8 Pre-mRNA-processing-splicing factor 8 12 9 4 9 160 1.67 0.0042 
61 Q9ULA0 DNPEP Aspartyl aminopeptidase 12 4 11 4 196 2.07 0.0045 
62 Q8N766 EMC1 ER membrane protein complex subunit 1 4 3 4 3 23 1.79 0.0046 
63 Q9H6S3 EPS8L2 
Epidermal growth factor receptor kinase substrate 8-like 
protein 2 
6 2 3 2 54 -2.05 0.0047 
64 P42704 LRPPRC 
Leucine-rich PPR motif-containing protein, 
mitochondrial 
53 20 16 20 640 1.77 0.0047 
65 Q8WWI5 SLC44A1 Choline transporter-like protein 1 3 1 2 1 61 1.99 0.0048 
66 P07814 EPRS Bifunctional glutamate 64 21 16 21 649 1.99 0.0049 
67 Q6UWP7 LCLAT1 Lysocardiolipin acyltransferase 1 2 2 4 2 35 1.69 0.0049 
68 Q9BVQ7 SPATA5L1 Spermatogenesis-associated protein 5-like protein 1 4 3 3 3 43 1.46 0.0053 
69 P53992 SEC24C Protein transport protein Sec24C 7 4 5 4 109 1.81 0.0054 
70 Q9UGP8 SEC63 Translocation protein SEC63 homolog 4 2 3 2 140 2.81 0.0054 
71 Q7Z2K6 ERMP1 Endoplasmic reticulum metallopeptidase 1 5 2 3 2 85 2.61 0.0055 
72 Q15121 PEA15 Astrocytic phosphoprotein PEA-15 10 1 9 1 248 -2.55 0.0056 
73 O95671 ASMTL N-acetylserotonin O-methyltransferase-like protein 3 1 2 1 98 4.41 0.0056 
74 Q9P2E9 RRBP1 Ribosome-binding protein 1 47 20 22 20 215 -1.55 0.0056 
75 P62258 YWHAE 14-3-3 protein epsilon 138 16 69 13 1806 -1.57 0.0057 
76 Q9BQ69 MACROD1 O-acetyl-ADP-ribose deacetylase MACROD1 7 3 14 3 187 1.6 0.006 
77 P78417 GSTO1 Glutathione S-transferase omega-1 23 6 24 6 234 -2.01 0.0061 
78 O94826 TOMM70A Mitochondrial import receptor subunit TOM70 5 3 5 3 50 1.88 0.0061 
79 Q8WV74 NUDT8 Nucleoside diphosphate-linked moiety X motif 8 3 1 4 1 44 2.78 0.0061 
80 O43399 TPD52L2 Tumor protein D54 29 6 31 6 475 -1.77 0.0063 
81-499 Full list of 499 proteins for claudin low breast cancer cell lines is given in supplementary data. 
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3.3.6 Western blot analysis 
CD44 antigen (CD44), Aldehyde dehydrogenase, mitochondrial 
(ALDH2), calreticulin (CALR), prostaglandin E synthase 3 (PTGES3) and 
10kDa heat shock protein, mitochondrial (HSPE1), were analysed by western 
blot (Figure 3-16). All immunoblots were analysed by GelAnalyzer 2010, to 
determine the quantitative expression of target proteins in all breast cell lines 
(Table 3-11). 
 
Figure 3-16: Western blot analysis of ACTB, CD44, ALDH2, CALR, PTGES3, 
HSPE1 in breast cell lines. 
ACTB is a house-keeping protein and was used as a loading control in 
Western blotting. Its molecular weight is approximately 42 kDa (Uniprot.org, 
2015). CD44 was only detected in basal-like (MDA-MB-468) and Claudin-low 
(MDA-MB-231) breast cancer cell lines, but with distinctly different molecular 
weights of 74 and 81kDa respectively. ALDH2 exhibited differential 
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expression and extensive heterogeneity with 6 bands between 50kDa and 
58kDa, with protein absent completely in only MCF-10A (Figure 3-16). The 
expression of ALDH2 (combine quantification of Isoforms 1 and 2), was 
increased in HER2 positive cell lines (ZR-75 and MDA-MB-453) but 
decreased in basal type breast cancer (MDA-MB-468 and MDA-MB-231). 
Calreticulin was expressed in all cell lines tested with one major band 
(48kDa), but less intense bands present up to 52kDa in a cell line-specific 
manner (Figure 3-16). Post-translational modifications, N6-acetyllysine and 
glycosylation have been reported for calreticulin and may contribute to this 
heterogeneity (Uniprot.org, 2015). PTGES3 was observed as a band at 
18kDa with stronger expression in MCF-7, normal breast cell lines (HB-2 and 
MCF-10A), and primary epithelial cells (Figure 3-16).  
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Table 3-11: Quantitative expression of ACTB, CD44, ALDH2, CALR, 
PTGES3 and HSPE1 in breast cell lines. 
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3.4    Discussion 
3.4.1 MS2 and SPS quantification 
Proteomics has the potential to study the expression of proteins in 
complex biological samples. Developments in protein fractionation and 
labelling techniques have also improved identification of less abundant 
proteins in biological samples. The enzymatic digestion of proteins prior 
labelling, increase the complexity of samples and result inherent drawback 
of reporter ions technology (Zieske, 2006). The focus of this quantitative 
approach was to understand the fact that co-isolation of multiple precursors 
in iTRAQ experiments compromises the dynamic range of reported ratios 
(Savitski et al., 2013, Ting et al., 2011). Different data acquisition schemes 
are used on Ultraflex II and Orbitrap Fusion in quantitative proteomics. Every 
full MS scan is followed by data-dependent CID MS2 scans in the Ultraflex II 
analysis, both identification and quantification of peptides/ proteins are 
derived from MS2 spectra. A key challenge in MS2 based iTRAQ 
quantification, is underestimation of fold change because of compression of 
the iTRAQ ratio. The propensity for underestimation was noted in 
comparative biological profiling, where confirmation of differential expression 
of selected targets was analysed through other methods such as western 
blotting (Keshamouni et al., 2006a, Glen et al., 2008). 
10 kDa heat shock protein, mitochondrial (HSPE1), is a chaperone that 
interacts in a two-step folding mechanism of protein biogenesis in the 
mitochondria (Corrao et al., 2010) . In SPS data, we found that HSPE1 was 
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up-regulated in MDA-MB-231 and MCF-10A cell lines (Table 3-3, Figure 
3-17) while no significant different was observed in MS2 data (Table 3-3) and 
WB analysis; a single band at 10kDa was detected in all cell lines (Table 
3-11, Figure 3-16, Figure 3-17). The over expression of HSPE1, a cancer 
related gene, has been reported in glioma, breast, head and neck, liver, 
lungs, melanoma, prostate ovarian, cervical, renal, testis and thyroid 
(Shaheed et al., 2015, Cappello et al., 2007).  In our previous study, Shaheed 
et al 2013, we found the increased expression of HSPE1 in tissue biopsies 
collected from invasive carcinoma patients compared to normal (Shaheed et 
al., 2013a).  
 
Figure 3-17: Comparison of western blot analysis and MS results for 
HSPE1 in breast cell lines. 
When the data for highest scoring peptide of HSPE1, 
(VLQATVVAVGSGSK), acquired on Orbitrap Fusion (Mascot Score; 71) and 
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Ultraflex II (Mascot score; 64); was evaluated, similar fragmentation patterns 
was observed on both instruments (Figure 3-18, A, B).  The low dynamic 
range for iTRAQ ratios were observed in MS2 spectra, acquired on Ultraflex 
II (Figure 3-18, C). The synchronous precursor selection (SPS)-based MS3 
is a unique feature of Fusion, where SPS mode alleviates dynamic range 
compression compared to MS2-based analysis. In SPS mode reporter ions 
are isolated from multiple MS2 fragment ions in parallel and analysed in MS3 
fragmentation (Ting et al., 2011). The reporters’ ions acquired through SPS 
mode of MS analysis, had wider dynamic range compared to MS2 
quantifications were also observed in our data (Figure 3-6, Figure 3-18, D). 
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Figure 3-18 Comparison of MS2 fragmentations for a peptide of HSPE1 and 
dynamic range of reporter ions on Orbitrap Fusion and Ultraflex II. 
3.4.2 Immortalised cell lines compared to primary cells  
In this study, the proteomes of five phenotypes of breast cancer; 
luminal A (MCF-7), luminal B (ZR-75), basal-like (MDA-MB-468), claudin-low 
(MDA-MB-231) and HER2-positive (MDA-MB-453), two normal breast cell 
lines; MCF-10A and HB2, and human mammary epithelial cells (HMEC) were 
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compared. Significantly up-regulated or down-regulated proteins were 
clustered according to types of cell lines compared to HMEC. GO enrichment 
analysis was performed by calculating a p-value, if an annotation term is 
enriched in certain set of gene products relative to all genes in the genome, 
providing biological significance to the data (Cox and Mann, 2012). 
Gene ontology enrichment for proteins up-regulated in all cell lines 
compared to HMEC indicated a strong correlation (PPI enrichment p-value, 
1.96e-09, Figure 3-19), with DNA replication (KEGG Pathways, p-value 
<0.001, 3 proteins). The histone family (Histone H2B type 1-K, H2AFZ, 
Histone H2A.Z, Histone H2B type 3-B), involved in transcription regulation, 
DNA repair, DNA replication and chromosomal stability, expression is 
increased in all cell lines compared to HMEC (Geiger et al., 2012). Three 
components (MCM2, MCM3 and MCM5) of the toroidal hexameric MCM 
(mini-chromosome complex) ring complex (p-value 5.23e-05, 3 proteins), a 
helicase required for DNA replication and elongation, and associated with 
replication specific DNA polymerase alpha (Remus, 2016, Raynaud et al., 
2014), were increased in expression across all the cell lines. Cyclin-
dependent kinase 1 (CDK1),  responsible for cell proliferation, DNA 
replication and apoptosis was also increased in both cancer and transformed 
normal cells compared to HMEC (Castedo et al., 2002). However, the 
increased level of the MCM complex and CDK1, in normal-like breast cell 
lines (MCF-10A and HB2), indicates the change in expression was not due 
to oncogenic processes but transformation-related processes. 
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Figure 3-19: Up-regulated DNA replication protein-protein interactions ubiquitous 
to all cell lines compared to HMEC  
Down-regulated in all cell lines indicated that protein processing in 
the extracellular matrix organization (p-value 3.38e-8, 13 components), focal 
adhesion (p-value 9.2e-7, 9 components), ECM-receptor interaction 
pathways (p-value 1.52e-5, 6 components) and multicellular organismal 
development (p-value 5.61e-6, 28 components) were the main biological 
functions suppressed (Figure 3-20). Normal myoepithelial cells secrete 
extracellular matrix (ECM) components and express high level of adhesion 
proteins, to provide structural and biochemical support in tissue formation 
(Adriance et al., 2005). Hence the expression of ECM and adhesion proteins 
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was generically decreased in transformed and tumour cells grown as cell 
cultures. The most dramatic changes occurred in cell adhesion proteins such 
as integrin alpha-2 (ITGA2), integrin alpha-V (ITGAV), and integrin beta-4 
(ITGB4), highlighting their importance for detachment of the tumour cells 
from the original tissue. This correlated with previous studies that showed 
low expression of ITGA2 and ITGB4 in metastatic sites of breast cancers 
(Geiger et al., 2012). The loss of adhesion proteins in the cancer cell lines, 
reflected the general collapse of normal tissue architecture, which is a known 
feature of the development of carcinomas. Conversely, the ability of cells to 
grow singularly has reduced cell-cell interaction functionality and lowered 
expression of adhesion/ extracellular matrix interaction receptors and 
cytoskeletal proteins that would have provided discrete morphology within 
the normal tissues environment. Adenoviral and lentiviral vectors are 
commonly used for virus-mediated transfection because it is highly efficient 
and easy to achieve sustainable transgene expression. However, virus-
mediated transfection has a drawback; it may cause an inflammatory reaction 
and insertional mutations such as activation of oncogenes by disrupting 
tumour suppressor genes (Kim and Eberwine, 2010). Not surprisingly, the 
transformation of cells to immortalisation, with dysregulation of the molecular 
processes which control replication, results in increased expression of 
proteins responsibly for DNA replication. That these changes were observed 
in virally-transfected normal breast cell lines as well as cancer cell lines 
indicates that caution is required when considering the use of the latter in the 
study of distinct oncologic responses, as they may not be cancer-specific at 
all.  
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Figure 3-20: Protein-protein interaction map of down regulated proteins for 
all cell lines compared to HMEC. 
Cell lines are widely used in cancer research as in vitro models 
because they are easy to handle and provide unlimited supply of a relatively 
homogeneous cell population. On the other hand, when these cell lines are 
cultured on plastic in two dimensions, they lack the complex inter-
relationships that exist between cells in vivo and also continual culturing can 
introduce genotypic and phenotypic drift in cell lines (Holliday and Speirs, 
2011). These drawbacks can be controlled by using primary cultures derived 
directly from tumour or normal tissues.  
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3.4.3 Breast cancer classifiers 
Because of the heterogeneity of breast cancer, it is challenging to 
differentiate between each subtype on the basis of a single gene or protein. 
Therefore, a group of markers are required that can serve as a signature for 
diagnosing different types of breast cancer. Gene expression profiling has 
played an important role in understanding the heterogeneity of breast cancer 
at a molecular level and refining the taxonomy based on the presence of 
productive markers like ER, PR and HER2 to more sophisticated grouping 
comprising luminal A, luminal B, basal-like, claudin-low and HER2-positive 
phenotypes (Holliday and Speirs, 2011).  
Two of the four main phenotype classifiers (HER2 and EGFR) were 
detected and interestingly exhibited diametrically opposite expression, with 
luminal cancer cell lines expressing HER2 (highest levels in HER2-positive 
MDA-MD-453) and low levels of EGFR and vice versa in basal cancer cell 
lines (highest levels of EGFR in MDA-MB-468, Figure 3-21) (Holliday and 
Speirs, 2011). In lung cancer cell lines EGFR has been shown to play an 
important role in the delivery of Mucin-4 to the plasma membrane from the 
endoplasmic reticulum, and hence a direct impact on EGFR-mediated 
proliferation (Li et al., 2014c). Furthermore, it has been proposed as a 
candidate serum biomarker in pancreatic ductal carcinoma (Makawita et al., 
2013).  
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Figure 3-21: Expression of HER2 and EGFR in breast cancer cell lines. 
The well-known markers of Luminal type breast cancer; ER and PR, were 
not detected in luminal-type cells (MCF-7, ZR-75, MDA-MB-453) which is a 
limitation of the iTRAQ qualification approach. By combining the proteome of 
8 samples after iTRAQ labelling, the increased complexity of the sample 
results in identification of fewer peptides and proteins (Hultin-Rosenberg et 
al., 2013).  
The most significantly increased protein in luminal-type (MCF-7, ZR-
75, MDA-MB-453 and HB2) consisted of Anterior gradient protein 2 homolog 
(AGR2), which is involved in cell migration, cell differentiation (Wang et al., 
2008), whereas three tumour related proteins; Integrin alpha-3 (ITGA3), 
involved in breast metastasis (Seguin et al., 2015), epidermal growth factor 
receptor (EGFR) and cellular tumour antigen p53 (TP53), were decreased in 
luminal compare to basal-type (MDA-MB-468 and MDA-MB-231). 
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Total 19 members of Keratin family were detected in Orbitrap data; 
12 of these components (KRT5, KRT6A, KRT6B, KRT7, KRT10, KRT14, 
KRT15, KRT16, KRT17, KRT77, KRT80, KRT81) expression was decreased 
in all cell lines as compared to HMEC. The expression of Keratins; KRT1, 
KRT2, KRT8, KRT9, KRT18, KRT19, and KRT73 was higher in luminal A 
(MCF-7) and luminal B (ZR-75) cell lines, whereas for all other cell lines, the 
expression was unique; KRT1, KRT 2, KRT 9, were decreased in MDA-MB-
468 and KRT73 was down-regulated in HER2 (MDA-MB-453) and claudin-
low (MDA-MB-231) cell lines. Interestingly, keratin family have been 
considered as basal markers (Shao et al., 2012), but our results show that 
their expression demarcates cancer stage rather than subtype.  
Prostaglandin E synthase 3 (PTGES3) is a multifunctional protein 
that modulates the activity of aryl hydrocarbon receptor and, in conjunction 
with HSP90, increases the affinity of steroid hormone receptors for their 
respective ligands (Sullivan et al., 1997, Oxelmark et al., 2006). It is also 
involved in the recruitment of steroid receptors and telomerase to the nucleus 
where they regulate transcriptional expression of target genes (Toogun et al., 
2008); it stabilizes specific kinases and has glutathione-dependent 
cytoplasmic prostaglandin E synthase 3 enzyme activities (Tanioka et al., 
2003). Overexpression of PTGES3 in breast cancer enhances ER-
dependent transcriptional events including promoting transition from non-
invasive to invasive cells through activation of metastasis-related genes, and 
has been established as a potential target to prevent development of 
secondary tumours. Proteomics analysis indicated that PTGES3 was 
increased in all cell lines, including normal cell lines compared to HMECs, 
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with highest levels in MCF-7 (luminal A) (Figure 3-16, Figure 3-22 and Table 
3-11).  
 
Figure 3-22: Comparison of SPS analysis and MS results for PTGES3 in breast 
cell lines. 
Gene encoding for isocitrate dehydrogenases 2 (IDH2) was 
observed at higher levels in Luminal B (ZR-75) as compared to luminal A 
(MCF-7), with no change in other breast cancer phenotypes. IDH2 is 
frequently mutated in enchondroma (benign tumour of bones) and glioma 
cancer, resulting in abnormal histone and DNA methylation, a common 
feature of tumorigenesis (Yang et al., 2012). The expression of programmed 
cell death protein 4 (PDCD4), involved in apoptosis and negative regulator 
of tumour invasion by inhibiting mitogen-activated protein kinases 85 
(MAPK85) (Frankel et al., 2008), was higher in ZR-75 as compare to all other 
cancer cell lines. A study on 420 patients with ER-positive breast cancer 
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found that down-regulation of PDCD4 was associated with a lower rate of 
disease-free survival and high histologic grade of breast tumours (Chen et 
al., 2015). Calmodulin-like protein 5 (CALML5) was significantly (p<0.0001) 
up-regulated gene in HER2 positive phenotype. CALML5 binds with HER2 
and stimulates neoplastic transformation and tumour progression(White et 
al., 2011). The increase expression of both proteins (CALML5 and HER2) in 
HER2+ (MDA-MB-453) breast cancer cell line was observed in our data.   
The high expression of aldehyde dehydrogenase (ALDH) isoforms is 
associated with poor clinical outcome in human cancer; breast, colon, bone, 
head and neck, lung, liver, brain, thyroid, pancreas, skin (melanoma), cervix, 
prostate and bladder (Rodriguez-Torres and Allan, 2016). A 
Immunohistochemistry based analysis of tissues from 160 patients with 
breast cancer, found higher expression of ALDH4A1 but no significance 
difference for ER, PR and HER2 status (Qiu et al., 2014). Aldehyde 
dehydrogenase family 1 member A3 (ALDH1A3) and Mitochondrial 10-formyl 
tetra hydro folate dehydrogenase (ALDH1L2) decreased in all cell lines.  
Different studies reported the low expression of ALDH2 in oropharyngeal, 
laryngeal and esophageal cancers, with increased risk of alcohol-associated 
cancer (Seitz and Stickel, 2010). The levels of ALDH2 were significantly 
decreased in invasive cancer breast tissues comparing with normal tissues 
and adenoma breast cancer tissues (Shaheed et al., 2013a). In iTRAQ data, 
the expression of ALDH2 was decreased in all transformed cell lines 
compared to HMEC but Western blot results showed the increase expression 
in HER2 (MDA-MB-453) and Luminal B (ZR-75) cell types (Figure 3-16). 
iTRAQ quantification does not discriminate between different isoforms of a 
protein or heterogeneity that may be caused by post translation modification 
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but western blot can differentiate these factors. This may in part be due to 
variable expression of two isoforms; isoform-1 (expected molecular weight = 
56.38kDa) and isoform-2, which lacks a sequence of 47 amino acid residues 
within the N-terminal region of the protein (expected molecular weight = 
50.99kDa), but may also be due to processing of an N-terminal transit peptide 
or N6-acetyllysine PTMs. The right isoform of ALDH2 can be further validated 
by analysing the 56.38kDa and 50.99kDa bands by GEL-LC-MS analysis 
(Shevchenko et al., 1996).These observations highlight the value of Western 
blotting in identifying molecular weight variation of the intact protein that was 
not detected by MudPIT proteomics. 
S100 protein family performs a wide range of intracellular and 
extracellular functions; (i) cell proliferation, (ii) apoptosis, (iii) cytoskeleton 
interactions, (iv) regulation of calcium homeostasis, (v) protein 
phosphorylation, (vi) cell invasion and motility, (vii) regulation of 
transcriptional factors, (viii) inflammation, (ix) chemotaxis and (x) 
autoimmunity (Chen et al., 2014). The altered expression of S100 proteins, 
was associated with tumour progression and prognosis (Chen et al., 2014). 
S100A proteins comprise 21 subunits (Chen et al., 2014), of which 9 were 
detected in Orbitrap Fusion analysis. Of these, 3 exhibited the opposite 
expression in basal-like cell line compare to other breast cancer cell lines. 
The expression of S100A13 was decreased but S100A8 and S100A9 was 
increased in MDA-MB-468. The S100A13 is involved in cancer cell motility, 
invasion and migration (Chen et al., 2014). The S100A8 and S100A9 work 
as single unit and play role in cancer cell differentiation, apoptosis, cell cycle 
and growth (Chen et al., 2014).  
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Basal type cells showed increased level of CD44 antigen (CD44) 
compared to other cells, and is involved in cell migration, evasion of 
apoptosis, tumour growth, angiogenesis and progression (Vikesaa et al., 
2006, Louderbough and Schroeder, 2011). CD44 performed these functions 
independently or in conjunction with other cellular components. CD44 has 
dual functionality; either it can activate tumour growth by Rho GTPases, Ras-
MAPK and PI3K/AKT pathways, or can inhibit angiogenesis and invasion by 
promoting apoptosis(Louderbough and Schroeder, 2011). High expression 
of CD44 has been reported in Head and neck cancer, melanoma, pancreatic, 
breast, cervical, lymphoma, colorectal and lungs cancer. CD44 is an 
accepted marker for breast cancer stem cells (BCSCs) and high expression 
of CD44 in BCSCs, promote tumorigenesis and metastasis (Smith and Cai, 
2012). In this study, higher expression of CD44 in claudin low (MDA-MB-231) 
and basal-like (MDA-MB-468), compared to luminal-type breast cancer, was 
observed. Western blot analysis of same samples; showed increased 
expression of CD44 in basal type cell lines, verifying iTRAQ-based 
quantification (Figure 3-15 and Figure 3-16, Table 3-11, Figure 3-23). So, 
higher expression of CD44 in MDA-MB-468 and MDA-MB-231, confirmed the 
stem cell like origin of these cell lines. 
  
164 
 
 
Figure 3-23: Comparison of SPS analysis and MS results for CD44 in breast 
cell lines. 
The high expression of vimentin (VIM), a marker of epithelial-to-
mesenchymal transition (EMT), is related with chemo-resistance and high 
tumour invasion and metastasis (Makki et al., 2015, Thompson et al., 1992). 
Macrophage-capping protein (CapG), has been reported as an oncogene 
with increased expression in breast, colorectal, pancreatic and ovarian 
cancer (Glaser et al., 2014, Thompson et al., 2007, Neumann et al., 2014). 
Caveolin-1 (CAV1), is not only involved in tumour invasion and metastasis 
but also plays a role in Ras-ERK pathway by promoting cell cycle (Sloan et 
al., 2004). The increased expression of CAV1 inhibits primary breast tumour 
growth and spontaneous metastasis of breast cancer (Sloan et al., 2004) and 
plays important role in EGR induced migration and proliferation of stem cells 
(Park et al., 2005). Cytoskeleton-associated membrane protein 4 (CKAP4) is 
an epithelial cell surface receptor for anti-proliferative factor signalling and 
elevated level has been reported in breast, cervical, lungs, liver, ovarian and 
pancreatic cancer (Li et al., 2014a, Kimura et al., 2016, Li et al., 2014b). The 
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expression of VIM, CAV1, CKAP4 and CapG, was high in MDA-MB-231 
compared to all other breast cancer cell lines, indicate high level of tumour 
invasion and metastasis associated with claudin-low breast cancer. 
Calreticulin (CALR) is a chaperone protein located in the 
endoplasmic reticulum, which induces a variety of cellular functions, including 
the control of calcium function as part of cell signalling, operating exclusively 
through Integrin alpha 3 subunit (Coppolino et al., 1997). In this iTRAQ 
proteomics approach, the expression of CALR was decreased in MCF-7 
breast cancer cell line as compare to HMEC and was also verified by Western 
blotting (Figure 3-16 and Figure 3-24, Table 3-11). But high level of CALR 
was observed in claudin-low (MDA-MB-231) breast cancer.  Over expression 
of CALR has been proposed as a biomarker due to the high levels observed 
in urine of bladder cancer patients (Kageyama et al., 2009) and increased 
expression was observed with the progression of breast cancer from 
fibroadenoma to invasive carcinoma (Shaheed et al., 2013a). An 
immunohistochemical study of gastric cancer also showed that CALR was 
found to be correlated with high micro-vessel density, serosal and perineural 
invasion, lymph node dissemination, and poor patient survival (Chen et al., 
2009). However, in neuroblastoma, the most common malignancy in infants, 
positive immunohistochemical staining for CALR was correlated with 
improved prognosis and patient survival (Hsu et al., 2005). The low 
expression of CALR in lung cancer cell lines was associated with a 
stimulating effect on rate of proliferation (Bergner et al., 2009). Higher 
expression of CALR is also reported in oesophageal squamous carcinoma 
cells and plays important role in cell migration and metastasis (Shi et al., 
2014). 
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Figure 3-24: Comparison of SPS analysis and MS results for Calreticulin in breast 
cell lines.  
In Summary, this study builds on other deep proteome 
characterisation of breast cancer (Geiger et al., 2012, Lawrence et al., 2015, 
Tyanova et al., 2016) and represent the first deep iTRAQ based-proteome 
characterization the breast cancer phenotypes compared to primary human 
mammary epithelial cells. The proteome profiling of breast cancer cell line 
introduced here provides the research community with an additional resource 
to select the most appropriate MS instrument and model for their research.  
  
167 
 
3.5     Conclusions 
Current developments in proteomics techniques allow high-throughput 
analyses for the detection, identification, and functional investigation of 
proteome. Using an Orbitrap Fusion operated in CID-MS2-Ion trap and HCD-
MS3 (SPS)-Orbitrap configuration, improved the number of PSMs, peptides, 
Mascot score, protein sequence coverage, number of unique proteins 
detected compared to Ultraflex II.  SPS mode acquisition on Orbitrap Fusion 
also decreased the dynamic range compression of iTRAQ ratios, due to 
background proteome and noise signals 
Our proteomics approach on breast cell lines, captured the general 
biological processes that are altered in cancer and premalignant cell lines 
compared primary human mammary epithelial cells. Signature proteins for 
five different phenotypes of breast cancer; luminal A (MCF-7, 32 proteins), 
luminal B (ZR-75, 40 proteins), HER2 (MDA-MB-453, 38 proteins), basal like 
(MDA-MB-468, 89 proteins) and largest signature (495 proteins) associated 
with the stem cell-derived cancer cell line, MDA-MB-231, were found. These 
markers can be further investigated in biofluids on larger scale, to define their 
diagnostics and prognostic values for human breast cancer. The quantitative 
proteomics data presented here, obtained from 5 breast cancer cell lines, will 
yield biomarkers discoveries that will help in the diagnosis and prognosis of 
breast cancers. The biological characterisation of biofluids also provides a 
unique insight into tumour microenvironment such as immune system 
responses, regulation of cellular interactions and tumour related proteins 
secretion and shedding. 
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CHAPTER 4. PROTEOME PROFILING OF 
NIPPLE ASPIRATE FLUID. 
4.1 Introduction    
There remains an unmet need to provide high risk premenopausal 
women with a regular and convenient means of breast cancer screening. 
Breast secretions (nipple discharge [ND] and nipple aspirate fluid [NAF]), 
collectively herein described as NAF, were investigated, as they are 
produced by epithelial cells lining breast ducts and lobules which are most 
commonly associated with the disease. These secretions are protein-rich and 
therefore ideally suited for biomarker discovery. My aim, in this study, was to 
investigate the protein composition of breast secretions from stage-specific 
patients using state-of-the-art proteomics techniques and determine if the 
profiles provided diagnostic value. 
Although the number of women, aged 40 or less, diagnosed with 
breast cancer is relatively low, they experience a more aggressive forms of 
the disease (frequently defined by triple negative or HER2 positive 
phenotypes) with poorer clinical outcome (Azim and Partridge, 2014, Copson 
et al., 2013). They are often at higher risk due to a genetic predisposition 
towards the disease, of which mutations in BRCA1 and BRCA2 breast cancer 
susceptibility genes are the best characterised, accounting for approximately 
15% of all breast cancer cases (Aloraifi et al., 2015). Awareness of these 
variants, by germ line genetic testing, informs the patient of the life-time risk 
of susceptibility to the disease compared to the general population, but it 
does not tell the patient when the disease will occur (Rieder et al., 2016). 
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Unfortunately, the discovery of a mutation can result in preventative 
intervention by elective surgery to remove both breasts or prophylactic 
administration of tamoxifen before the disease has occurred (Davies et al., 
2015).  
Mammography has been very successful in detecting breast cancer 
in post-menopausal women (98% sensitivity), but less so in younger women 
due to image obfuscation by breast density (30 to 48% sensitivity) (Kolb et 
al., 2002, Mandelson et al., 2000). An inaccurate diagnosis leads to high call-
back rates, elevated costs of unnecessary biopsies, increased radiation dose 
exposure and patient anxiety during re-screening. For successful diagnosis 
by mammography, a substantial mass is required, which may have already 
metastasised in aggressive forms of the disease. Also, mammography 
cannot differentiate between benign micro-calcifications associated with low 
risk DCIS, which do not require surgery, and higher risk DCIS that will 
progress to an invasive tumour (Espina and Liotta, 2011), thereby resulting 
in over-diagnosis and over-treatment (Francis et al., 2015).  
Therefore, new methods that can be used, safely and routinely, for 
the early detection of breast cancer are required to support high risk younger 
women. The search for diagnostic biomarkers of breast cancer has been 
extensive and proteomics strategies increasingly employed as part of the 
discovery process (Zeidan et al., 2015). Plasma is by far the most common 
biofluid used, but putative markers are massively diluted relative to the site 
of origin of the cancer, thereby reducing sensitivity (Loo et al., 2010). As an 
alternative, I have chosen to analyse nipple aspirate fluid (NAF), which is 
collected by massage or breast pump, and differentiating them from liquid 
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biopsies collected by lavage or using needles). NAF originates from cells 
associated with 85% of breast carcinomas and comprises a diverse range of 
endogenous substances such as micronutrients (tocopherols,, cholesterols, 
carotenes) (Djuric et al., 2007), hormones (estradiol, estrone, progesterone 
and testosterone)  (Chatterton et al., 2010), carbohydrate (Thomsen 
Friedenreich and Tn) antigens (Deutscher et al., 2010b), microRNA (Canto 
et al., 2016), and microbes (Chan et al., 2016b).  NAF has multiple 
advantages as a liquid biopsy for detection of breast cancer: (i) pre-
menopausal women are more likely to produce NAF than post-menopausal 
women where ductal atrophy may be prevalent (Baltzell et al., 2006), (ii) NAF 
expression is non-invasive, causing minimal discomfort compared to other 
breast cancer screening procedures (De Groot et al., 2015) (iii) enables 
procurement of matched pairs of samples which may provide an intra-
individual control for comparing disease with healthy, (iv) biomarkers remain 
highly concentrated for analysis (compared to blood and urine), and (v) 
minimal sample preparation is required, compared to tissues, therefore 
excluding yield-reducing protein extraction steps. NAF volumes are small, 
but protein concentrations are high and more than sufficient for replicate 
analyses with state-of-the-art mass spectrometric techniques.  
A number of studies have been undertaken to characterise the NAF 
proteome many of which have been summarised by Pavlou et al, as part of 
a comparison with their own dataset of 854 proteins (Pavlou et al., 2010). In 
that study, 3 healthy individuals and 3 patients, was analysed on Orbitrap 
mass analyser coupled to a linear ion trap, after Multiple fractionation 
methods (size-exclusion and anion-exchange chromatography). Another 
deep proteome study of NAF was conducted by Brunoro et al 2015, which 
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again based on different fractionation methods such as strong cation-
exchange (SCX) and pI-based OFFGEL fractionation (Brunoro et al., 2015). 
The fractionated samples were analysed on an LTQ-Orbitrap XL and 
identified 4466 peptides corresponded to a total of 557 proteins. A more 
recent study by Kurono et al 2016 identified 372 proteins in breast cancer 
patients and healthy volunteers (n = 19 and 12, respectively) (Kurono et al., 
2016). In this study, the samples were fractionated; first at high pH, then on 
low pH before MS analysis. All these studies were optimisation of 
fractionation techniques, to increase protein IDs and sequences coverage in 
NAF samples. 
My objective in this study, was to deal with the fundamental 
definitions of NAF composition and determine if the proteins present 
constitute biologically and physiologically relevant information for diagnosing 
breast health.  In so doing I will identify if NAF has the potential to be a 
suitable liquid biopsy for biomarker discovery. Following preliminary 
characterisation by protein determination and SDS PAGE, I used a semi-
quantitative (label-free) comparison of proteomic profiles of matched pairs 
from four cases, (1) a healthy volunteer (HV), and patients with (2) benign 
phyllodes (PB), (3) DCIS (PD) and (4) invasive carcinoma (PI). The 
proteomic profiles were subject to statistical and gene ontological analysis to 
glean significant expression changes relating to disease state.    
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4.2 Materials and methods 
4.2.1 Patients and sample collection 
NAF samples were obtained from healthy volunteers and breast 
cancer patients, who presented to Bradford Teaching Hospitals NHS Trust, 
between 2013 and 2016. All participants gave written informed consent to 
undergo bilateral nipple aspiration. The study protocol was approved by 
University of Bradford's Independent Scientific Advisory Committee 
(reference: application/13/051).  Ethical approval was given by Leeds (East) 
Research Ethics Committee, reference 07/H1306/98+5. Before aspiration 
was attempted, the nipple was initially cleansed with an alcohol pad. NAF 
collection from cancer patients was performed under general anaesthetic by 
the clinical team, prior to surgery, assisted by massaging the breast and the 
liquid collected from the nipple using a sterile pipette. After collection, the 
samples were transferred to chilled, pre-labelled tubes containing a freeze-
dried protease inhibitor cocktail mixture (Roche Diagnostics), and frozen 
within 30 minutes of collection. Where possible, NAF samples were collected 
separately from both breasts. NAF from healthy volunteers was collected in 
a similar manner by the individuals whilst conscious. From a bank of 100 
patient samples, 15 NAF pairs were selected on the basis of a utilisable 
volume of sample, right and left breast expression and disease stage, in 
order to optimise LC-Ms assay.(Table 4-1). 
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Table 4-1: Healthy volunteer and patient parameters and NAF characteristics.
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4.2.2 Sample preparation 
The samples were centrifuged for 1 minute to remove particulate 
matter and the supernatants collected. The protein concentration was 
measured using the Bradford assay (Bio-Rad Laboratories) and paired 
samples (20µg) analysed by SDS PAGE as described previously chapter 2; 
materials and methods. Gels were stained with PhastGel Blue R (in 5% 
acetic acid, 50% methanol) for protein detection. 
4.2.3 Proteomic analysis 
An aliquot of each sample (200 µg) was reduced with 50 mM 
dithiothreitol (DTT) for 15 minutes at 60°C, alkylated with 100mM 
iodoacetamide (IAA) at ambient temperature for 15 minutes, and digested by 
modified sequencing grade trypsin (Fisher Scientific); protease-to-protein 
mass ratio of 1:20 (w/w) at 37°C for 20 hrs. After digestion, each sample was 
desalted on an Isolute C18 RP LC column (Kinesis Ltd) and lyophilized. 
4.2.3.1 SCX Peptide fractionation 
Trypsin-digested NAF samples were re-suspended in SCX loading 
buffer (10mM KH2PO4 in 25% v/v acetonitrile [ACN], 0.01% w/v sodium 
azide, adjusted to pH3) and added to an Isolute SCX column (Kinesis), 
equilibrated with SCX loading buffer. Peptides were eluted in 12 fractions 
with stepwise increasing potassium chloride concentration from 0 to 1000mM 
(see chapter 2 for full details). Eluted fractions were diluted with 2% v/v ACN, 
0.05% v/v formic acid (FA), desalted on an Isolute C18 RP LC column 
(Kinesis) and lyophilised. 
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4.2.3.2 Fusion Orbitrap analysis 
The lyophilised SCX fractions were re-suspended in 10μl of 0.1% of 
FA and analysed in triplicate (3µL/injection) on a nano-LC UltiMate 3000 
capillary HPLC system coupled to an Orbitrap Fusion™ Tribrid™ Mass 
Spectrometer (Chapter 2, section 2.10.2 for full details). Samples were 
applied at 25 µL/minute and washed on a C18, 300 μm × 5 mm, 5 μm 
diameter, 100 Å PepMap pre-column (ThermoFisher) before transfer to a C18, 
75 μm × 50 cm, 2 μm diameter, 100 Å PepMap column, (ThermoFisher) 
(please see Table 2-3 for full details). The Orbitrap Fusion parameters were 
as follows: for full MS spectra, the scan range was m/z 350–1500 with a 
resolution of 120,000 at m/z 200. All MS/MS acquisition was performed on 
Ion-trap, in top speed mode with 3 second cycle time, a dynamic exclusion 
(±5 ppm) of 60 seconds, intensity threshold 5000, with ions of charge states 
2+ to 7+ sequentially fragmented by collision-induced dissociation (CID) with 
a normalized collision energy (NCE) of 35%. A maximum of 200 ms ion 
injection time was allowed. 
4.2.3.3 Data Analysis 
MS/MS fragment mass lists were searched, via Proteome Discoverer 
version 2.1 (ThermoFisher) using Mascot software version 2.4 (Matrix 
Science) with a percolator (strict FDR of 0.01 and a relaxed FDR of 0.05) 
against SwissProt version 2016 containing 552,259 human protein 
sequences with search parameters: trypsin digestion, 2 missed cleavages, 
variable modification of methionine oxidation, fixed modifications of cysteine 
(carbamidomethylation), precursor mass tolerance of 10 ppm, MS/MS 
fragmentation mass tolerance of 0.5 Da and a 95% confidence interval 
  
177 
 
threshold (p < 0.05, Mascot score ≥23). Non-redundant protein profiles for 
each NAF sample were created by combining the corresponding LC−Fusion 
datasets. The list of protein identifications, was assessed manually, and only 
Master Proteins (i.e. contain unique peptides) were accepted. 
Protein quantitation was defined as the sum of the peak areas of the 
three strongest parent signals. To allow comparison of sample protein 
profiles, quantitation of each protein was normalised relative to the median 
peak area sum of the whole protein complement in the sample. Pearson 
correlation coefficient was calculated using PRISM 6.0 software (GraphPad 
Software), to determine gross similarities of paired samples. To identify 
cases-specific (healthy vs disease [HV vs PB, PD, PI], benign vs healthy and 
cancer [PB vs HV, PD, PI], non-cancer vs cancer [[HV, PB vs PD, PI]) protein 
expression, averaged data of paired (left and right breast) samples was used. 
Student t-tests were undertaken using Excel 2010 to identify significantly 
(p<0.05) expressed proteins. A functional Enrichment analysis tool, FunRich 
2.1.2 (http://www.funrich.org/) was used to compare proteomes of NAF 
samples. Proteins which met the required thresholds for identification were 
submitted to Database for Annotation, Visualization and Integrated Discovery 
(DAVID, version 6.8) analysis. Default settings were used for functional 
annotation with Benjamini-corrected p-values of <0.05, deemed significant. 
Protein-protein interaction analysis was performed using STRING version 
10.0 (http://string-db.org/). Proteins were also subject to analysis in TMHMM 
Server v. 2.0 (http://www.cbs.dtu.dk/services/TMHMM/ (Krogh et al., 2001), 
to determine those with transmembrane helical regions. 
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4.2.4 Western blot analysis 
NAF samples, equivalent to 20μg of protein, were analysed by 
Western blotting blotting (see Chapter 2 section 2.8) using primary 
antibodies; anti-beta-actin mouse monoclonal, anti-EGFR mouse 
monoclonal, anti-vimentin mouse monoclonal, anti-CYP3A4 rabbit 
monoclonal, and anti-CD44 rabbit monoclonal, then followed by appropriate 
secondary antibodies (rabbit anti-mouse IgG-conjugated with horse radish 
peroxidase, or goat anti-rabbit IgG-conjugated with horse radish peroxidase 
(Table 2-1 for full details of antibodies). All immuno-blots were analysed by 
GelAnalyzer 2010a software (http://www.gelanalyzer.com). 
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4.3 RESULTS 
4.3.1  NAF sample characterisation 
My preliminary objective was to characterise matched pairs of NAF 
samples using basic biochemical procedures, measuring total protein 
amount, concentration and matched pairs visualisation by SDS PAGE, which 
has not been reported previously. NAF samples were collected from 100 
breast cancer patients and healthy volunteers and grouped into 4 clinical 
stages - invasive carcinoma (IC), ductal carcinoma in situ (DCIS), benign 
lesions and healthy. From these, 15 pairs (13 with cancer and 2 non-cancer) 
were characterised for volume (varying from 4 to 500µL) and protein 
concentration (3 to 70mg/ml (Table 4-1). Samples were analysed by SDS 
PAGE demonstrating that, in the majority of cases, pairs from the same 
person had similar profiles (Figure 4-1, A to D). Some cases exhibited a 
dominant serum albumin band, suggesting a high plasma content (Figure 
4-1, A, Case 2), whilst others had a relatively low albumin presence (Figure 
1, A Cases 1, 3 and 4). Based on sample colour there was no indication of 
blood in the latter group, no apparent correlation with disease compared to 
healthy, and hence was not indicative of tissue damage or tumour 
invasiveness. Four matched pairs, a healthy volunteer (Case 4, HV), a 
patient with benign phyllodes tumour (Case 9, PB), a patient with DCIS (Case 
10, PD) and a patient with invasive carcinoma (Case 12, PI) (Table 4-1), were 
selected for proteomic analysis, based on similar protein concentration (to 
minimise samples preparation variation) and protein quantity (providing 
sufficient material for validations studies).  
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Figure 4-1: SDS PAGE analysis of matched pairs of NAF samples.  
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4.3.2 NAF proteomic analysis 
For NAF to be a useful clinical sample it was important to establish 
the quality and complexity of proteomic data that can be achieved using a 2D 
LC separation approach as this had implications on sensitivity and analysis 
time. From 1D LC analyses of the 8 NAF samples, a total of 661 different 
proteins were identified (p<0.05). An average of 389 proteins was detected 
per sample, with 134 common to all the samples (Figure 4-2, A). From 2D 
LC MS analysis, a total of 1990 proteins were identified (p<0.05), with an 
average of 1265 proteins (Figure 2A) and 567 found in all the samples (Figure 
4-2, B).  At a qualitative level, 644 of the proteins were identified in both 1D 
and 2D approaches, with 17 proteins uniquely detected by 1D LC MS and 
1346 additional proteins were observed in 2D LC MS (Figure 4-2, D).  Of the 
proteins identified by both 1D and 2D analysis, 117 were found in all samples. 
Comparison of this subset of common proteins indicated that 2D LC analysis 
provided more confident identification, with an average 19 unique peptides 
per protein (compare to 14 with 1D LC), 25% increase in sequence coverage 
and 4-fold more spectra associated with each protein to improve label-free 
quantification.  The Coefficient of variation (CV%) of Mascot score, peptides, 
and PSMs, was less in 2D proteome as compare to 1D proteome for 117 
common proteins (Figure 4-2, C). Therefore, despite the longer analysis time 
of 2D LC MS (48 hrs per NAF sample, compared to 9 hours for 1D), it 
provided a much richer source of information for NAF characterisation, hence 
only the proteomic content of the 2D LC dataset will be described further. 
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Figure 4-2: Comparison of 1D and 2D NAF proteome profiling. 
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4.3.3 Comparison of identified 2D NAF proteome  
Comparison of pairs of proteomics profiles from 2D LC analysis showed greater than 50% similarity in protein composition (Figure 4-3). 
The matched pair of NAF have higher correlation (average 77%) while healthy volunteer has less similarity (average 52%) compared to 
NAF collected from patients with benign, DCIS and IC.  
 
Figure 4-3: Comparison of NAF proteome acquired by 2D-LC/MS analysis.
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NAF profiles for matched pairs from each individual, showed the 
greatest similarity with 1017 out of a total of 1282 proteins, 1374/1685, 
948/1350 and 1082/1382 common for HV, PB, PD and PI pairs, respectively 
(Figure 4-4, A, B, C, D).  
 
Figure 4-4: Comparison of the matched 2D NAF protein profiles. 
When taking into account the quantitative data in terms of normalised 
peak areas for those proteins common to all the profiles (567), the natural 
pairs again showed greatest positive correlation (Pearson correlation 
coefficient values of 0.90 to 0.99) (Figure 4-5).  
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Figure 4-5: Pearson correlation coefficient for each NAF profile compared 
to each other, based on median normalised peak area of each protein. 
4.3.4 Cellular localisation of NAF Proteome 
The proteins common to all eight 2D LC analyses were manually 
categorised based on their normal cellular location using Uniprot (release 
1026_07), into (i) intracellular, (ii) extracellular stroma (surrounding the 
breast cells) or (iii) plasma (Supplementary Figure 3). Intracellular proteins 
were further sub-divided into cytoplasmic, membrane-linked (i.e. containing 
transmembrane domain, GPI or lipid anchors), or organelle-specific location. 
Of the common proteins, 25% are normally found in plasma, 14% function 
within the extracellular space and 61% are from cell components. Of the 346 
cellular proteins, 45% are normally found in the cytoplasm, 36% are 
membrane-associated, 7% lysosome, 8% endoplasmic reticulum/Golgi 
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apparatus, 2% mitochondrion and 2% in the nucleus. The nuclear and 
mitochondrial proteins were particularly under-represented, which have been 
estimated to represent 14% and 6% of the total human proteome respectively 
(Fink et al., 2008, Calvo et al., 2016). Submission of the total proteome profile 
to TMHMM transmembrane protein search engine identified 415 proteins 
with transmembrane regions (Figure 4-6) and a further 147 proteins with GPI-
anchors, N-terminal or cys-modified lipid attachments were identified from 
UniProt.  
 
Figure 4-6:  Normal cellular localisation of the 567 proteins common to all the 
NAF samples. 
Therefore, 27% of the NAF proteins identified are normally found 
permanently anchored in membranes and provide a valuable source of 
information regarding cellular integrity. Using STRING analysis, 74 of the 
membrane proteins were linked to cell adhesion (FDR 2.88e-24), 50 proteins 
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involved in glycoprotein metabolism (FDR 2.88e-24) and 86 proteins have 
receptor activity (FDR 1.04e-21). 
4.3.5 Functional annotation of NAF Proteome 
Functional annotation of the proteins identified in the total NAF 
complement was performed using the DAVID bioinformatics resource. The 
application of the functional annotation clustering tool, which reduces 
redundancy in annotation of closely related biological functions across 
different ontological fields, identified secreted glycoproteins (enrichment 
score 101.14), cell-cell adhesion (41.97), antigen binding and immune 
response (24.46), lysosome (23.48), ribosomal protein interactions (14.93) 
and peptidase/protease activity (13.64).  
A diverse range of cell adhesion proteins (193 components, 
Bonferroni p value 8.55E-25) were also detected in the NAF samples including 
CEACAMs 1, 6 and 8, NCAM2, BCAM, ALCAM, ECAM, MCAM and ICAM1, 
14 cadherin and protocadherin proteins and 5 integrin subunits (Table 4-2). 
Furthermore, 24 protein kinases (in addition to those categorised as 
receptors) and 18 protein phosphatases were identified which play a role in 
signal transduction. Stem cell (CD44) and epithelial-mesenchymal transition 
markers (cadherin 1, fibronectin, vimentin, cytokeratin 8 and cytokeratin 18), 
myoepithelial markers (cytokeratin 14 and cytokeratin 17) were also detected 
in all NAF samples. 
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Table 4-2: List of cell adhesion (GO:0007155; GO Biological Process) proteins identified in the NAF 
samples. 
 Table represents Gene ID, Protein name, UniProt accession number, Mascot score, Sequence 
coverage of protein, number of spectra identified in MS analysis, number of unique peptides, Frequency 
of detection in samples.   
Gene ID Protein Name 
UniProt 
Accession 
Spectra Coverage 
Unique 
Peptides 
Score 
Mascot 
Frequency 
ACTB Actin, cytoplasmic 1 P60709 3351 58.9 10 48916 8 
ACTN1 Alpha-actinin-1 P12814 1957 60.8 31 32234 8 
ADAM15 
Disintegrin and metalloproteinase 
domain-containing protein 15 
Q13444 55 11.9 6 630 7 
ADAM9 
Disintegrin and metalloproteinase 
domain-containing protein 9 
Q13443 17 9.9 5 152 5 
ALCAM CD166 antigen Q13740 391 41.5 17 4716 8 
AMBP Protein AMBP P02760 449 40.6 10 6588 8 
ANTXR1 Anthrax toxin receptor 1 Q9H6X2 9 1.6 1 107 4 
ANXA1 Annexin A1 P04083 362 49.4 16 9026 8 
ANXA2 Annexin A2 P07355 1250 64.3 22 21847 8 
APOA4 Apolipoprotein A-IV P06727 578 50.3 18 6813 8 
APP Amyloid beta A4 protein P05067 419 25.6 12 2776 8 
ARF6 ADP-ribosylation factor 6 P62330 107 41.7 6 1506 8 
ATP1B1 
Sodium/potassium-transporting 
ATPase subunit beta-1 
P05026 3 3.6 1 38 0 
AZGP1 Zinc-alpha-2-glycoprotein P25311 42340 74.2 44 746399 8 
B4GALT1 Beta-1,4-galactosyltransferase 1 P15291 1478 43 10 20579 8 
BAIAP2 
Brain-specific angiogenesis 
inhibitor 1-associated protein 2 
Q9UQB8 258 31 12 1968 8 
BAIAP2L1 
Brain-specific angiogenesis 
inhibitor 1-associated protein 2-like 
protein 1 
Q9UHR4 26 11 3 150 3 
BCAM Basal cell adhesion molecule P50895 67 18.3 8 926 7 
CADM4 Cell adhesion molecule 4 Q8NFZ8 395 40.2 10 4722 8 
CD22 B-cell receptor CD22 P20273 45 1.4 1 87 6 
CD2AP CD2-associated protein Q9Y5K6 10 2.8 1 39 1 
CD36 Platelet glycoprotein 4 P16671 752 27.5 11 15576 8 
CD44 CD44 antigen P16070 161 4.6 4 3385 8 
CD47 Leukocyte surface antigen CD47 Q08722 15 2.8 1 51 5 
CD58 
Lymphocyte function-associated 
antigen 3 
P19256 23 10.8 3 258 4 
CD63 CD63 antigen P08962 35 13.4 2 441 7 
CD9 CD9 antigen P21926 707 20.6 4 8242 8 
CDC42 
Cell division control protein 42 
homolog 
P60953 306 51.3 7 2652 8 
CDH1 Cadherin-1 P12830 590 22.6 14 10468 8 
CEACAM1 
Carcinoembryonic antigen-related 
cell adhesion molecule 1 
P13688 271 15.8 4 3613 8 
CEACAM5 
Carcinoembryonic antigen-related 
cell adhesion molecule 5 
P06731 104 10 2 1328 0 
CELSR2 
Cadherin EGF LAG seven-pass G-
type receptor 2 
Q9HCU4 69 2.4 4 310 7 
CIB1 
Calcium and integrin-binding 
protein 1 
Q99828 314 51.3 9 4534 8 
CLCA2 
Calcium-activated chloride channel 
regulator 2 
Q9UQC9 212 19.3 12 2570 6 
CLIC1 
Chloride intracellular channel 
protein 1 
O00299 320 42.3 7 4249 8 
CLSTN1 Calsyntenin-1 O94985 29 8.1 5 356 2 
CLSTN3 Calsyntenin-3 Q9BQT9 17 3.1 2 157 4 
CNTN1 Contactin-1 Q12860 49 9.2 6 409 6 
CNTNAP3 Contactin-associated protein-like 3 Q9BZ76 13 2.8 3 97 2 
COL12A1 Collagen alpha-1(XII) chain Q99715 27 4.5 7 219 4 
COL14A1 Collagen alpha-1(XIV) chain Q05707 13 4.8 5 211 3 
COL18A1 Collagen alpha-1(XVIII) chain P39060 38 4.5 6 225 4 
COL6A1 Collagen alpha-1(VI) chain P12109 1251 32.7 22 15932 8 
COL6A2 Collagen alpha-2(VI) chain P12110 341 18.4 14 3170 8 
COL6A3 Collagen alpha-3(VI) chain P12111 11 0.4 1 164 3 
CORO1A Coronin-1A P31146 14 13.2 3 130 3 
CRISP2 Cysteine-rich secretory protein 2 P16562 8 7.8 1 75 1 
CSRP1 Cysteine and glycine-rich protein 1 P21291 39 25.9 4 474 7 
CSTA Cystatin-A P01040 45 52 3 476 7 
CTNNA1 Catenin alpha-1 P35221 39 12.9 7 466 5 
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CTTN Src substrate cortactin Q14247 7 5.1 2 73 2 
CX3CL1 Fractalkine P78423 72 4.5 1 439 4 
DAG1 Dystroglycan Q14118 480 23.5 12 3883 7 
DCHS1 Protocadherin-16 Q96JQ0 5 0.4 1 61 2 
DCHS2 Protocadherin-23 Q6V1P9 38 2.9 5 230 2 
DDR1 
Epithelial discoidin domain-
containing receptor 1 
Q08345 267 13.1 9 3444 8 
DPP4 Dipeptidyl peptidase 4 P27487 21 5.1 4 124 4 
DSC2 Desmocollin-2 Q02487 406 10.3 9 4006 8 
DSC3 Desmocollin-3 Q14574 18 7 4 57 5 
DSG1 Desmoglein-1 Q02413 5 1.5 1 82 1 
DSG2 Desmoglein-2 Q14126 38 9.3 7 227 6 
DSP Desmoplakin P15924 11 2.2 4 144 2 
DST Dystonin Q03001 12 0.1 1 130 7 
EFNA1 Ephrin-A1 P20827 140 8.8 1 1131 8 
EGFR Epidermal growth factor receptor P00533 18 3.1 3 132 4 
ENG Endoglin P17813 196 18.2 9 2738 8 
ENTPD1 
Ectonucleoside triphosphate 
diphosphohydrolase 1 
P49961 39 12.2 5 328 6 
EPCAM Epithelial cell adhesion molecule P16422 8 22 4 83 2 
EPHB3 Ephrin type-B receptor 3 P54753 21 3.6 4 313 4 
EPHB4 Ephrin type-B receptor 4 P54760 38 5.5 4 188 5 
EZR Ezrin P15311 1588 38.7 15 19419 8 
F11R Junctional adhesion molecule A Q9Y624 58 22.7 4 885 8 
FAT2 Protocadherin Fat 2 Q9NYQ8 549 22 57 4655 7 
FBLN5 Fibulin-5 Q9UBX5 114 14.1 5 1130 8 
FBLN7 Fibulin-7 Q53RD9 14 5.2 2 95 4 
FERMT3 Fermitin family homolog 3 Q86UX7 20 7.6 3 173 4 
FGA Fibrinogen alpha chain P02671 97 13.4 9 811 8 
FGB Fibrinogen beta chain P02675 628 46.6 15 6466 8 
FGG Fibrinogen gamma chain P02679 503 53 16 5667 8 
FLNA Filamin-A P21333 269 14.3 22 3296 8 
FLOT2 Flotillin-2 Q14254 72 28 9 930 8 
FN1 Fibronectin P02751 402 24.1 32 5270 8 
FZD7 Frizzled-7 O75084 44 5.2 2 631 8 
GAS6 Growth arrest-specific protein 6 Q14393 3 1.1 1 47 1 
GNAS 
Guanine nucleotide-binding protein 
G(s) subunit alpha isoforms XLas 
Q5JWF2 300 19.9 14 2299 8 
GPNMB Transmembrane glycoprotein NMB Q14956 315 4.7 2 8738 8 
GPR56 G-protein coupled receptor 56 Q9Y653 54 6.5 3 650 4 
GPR98 G-protein coupled receptor 98 Q8WXG9 4 0.5 2 53 1 
HABP2 Hyaluronan-binding protein 2 Q14520 6 5.5 2 83 2 
HAPLN3 
Hyaluronan and proteoglycan link 
protein 3 
Q96S86 46 21.4 6 322 2 
HBB Hemoglobin subunit beta P68871 952 88.4 7 11220 5 
HSPB1 Heat shock protein beta-1 P04792 164 40 5 1587 8 
ICAM1 Intercellular adhesion molecule 1 P05362 337 32.3 12 5942 8 
IGFALS 
Insulin-like growth factor-binding 
protein complex acid labile subunit 
P35858 110 17.2 8 1287 6 
IGFBP7 
Insulin-like growth factor-binding 
protein 7 
Q16270 2 7.1 1 44 1 
ISLR 
Immunoglobulin superfamily 
containing leucine-rich repeat 
protein 
O14498 377 27.1 8 4596 8 
ITGAM Integrin alpha-M P11215 49 4 3 793 5 
ITGAV Integrin alpha-V P06756 9 5.1 3 40 1 
ITGAX Integrin alpha-X P20702 25 7.2 4 211 2 
ITGB1 Integrin beta-1 P05556 7 4.6 2 32 2 
ITGB2 Integrin beta-2 P05107 49 12.7 7 715 7 
JUP Junction plakoglobin P14923 45 12.6 3 249 5 
KIF14 Kinesin-like protein KIF14 Q15058 3 2.3 3 37 1 
KIT 
Mast/stem cell growth factor 
receptor Kit 
P10721 39 4.6 4 301 4 
KRT18 Keratin, type I cytoskeletal 18 P05783 412 33.3 9 3448 8 
LAMA3 Laminin subunit alpha-3 Q16787 8 0.7 1 46 2 
LAMA5 Laminin subunit alpha-5 O15230 129 7.1 17 671 7 
LAMB2 Laminin subunit beta-2 P55268 172 13.3 15 1647 8 
LAMC1 Laminin subunit gamma-1 P11047 39 4.7 5 1221 7 
LAMC2 Laminin subunit gamma-2 Q13753 35 7.2 5 310 6 
LGALS3BP Galectin-3-binding protein Q08380 6960 55.4 25 112765 8 
Gene ID Protein Name 
UniProt 
Accession 
Spectra Coverage 
Unique 
Peptides 
Score 
Mascot 
Frequency 
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MCAM Cell surface glycoprotein MUC18 P43121 16 1.5 1 128 2 
MFGE8 Lactadherin Q08431 3120 74.9 24 44479 8 
MPDZ Multiple PDZ domain protein O75970 5 3.5 4 67 1 
MSN Moesin P26038 1139 43.3 13 14451 8 
MUC16 Mucin-16 Q8WXI7 3150 11.2 56 31323 8 
MUC4 Mucin-4 Q99102 799 19.4 23 12749 6 
MYH10 Myosin-10 P35580 374 7 2 2702 1 
MYH9 Myosin-9 P35579 1231 33.3 42 12532 8 
NCAM2 Neural cell adhesion molecule 2 O15394 84 12.2 6 1174 6 
NEO1 Neogenin Q92859 22 4.2 4 167 5 
NME1 Nucleoside diphosphate kinase B P22392 60 27 1 249 3 
NOV Protein NOV homolog P48745 38 14.3 3 426 7 
NPNT Nephronectin Q6UXI9 114 19.5 8 1114 8 
NPTN Neuroplastin Q9Y639 2 4.5 1 29 1 
NRXN3 Neurexin-3 Q9Y4C0 24 3.2 3 90 4 
NT5E 5'-nucleotidase P21589 245 40.4 16 3462 7 
OLFM4 Olfactomedin-4 Q6UX06 3540 49.4 20 58285 8 
PAK4 
Serine/threonine-protein kinase 
PAK 4 
O96013 2 2.5 1 43 1 
PCDHA10 Protocadherin alpha-10 Q9Y5I2 31 6.3 1 489 2 
PCDHA4 Protocadherin alpha-4 Q9UN74 21 6.9 3 245 2 
PCDHB14 Protocadherin beta-14 Q9Y5E9 30 9 4 165 3 
PCDHB4 Protocadherin beta-4 Q9Y5E5 34 5.3 1 452 1 
PCDHB5 Protocadherin beta-5 Q9Y5E4 51 7.7 2 596 3 
PCDHGA12 Protocadherin gamma-A12 O60330 4 1 1 57 3 
PCDHGA3 Protocadherin gamma-A3 Q9Y5H0 2 1.3 1 29 1 
PCDHGB7 Protocadherin gamma-B7 Q9Y5F8 17 6.9 4 110 2 
PCDHGC3 Protocadherin gamma-C3 Q9UN70 21 6.9 4 369 2 
PDLIM1 PDZ and LIM domain protein 1 O00151 13 4 1 90 4 
PDLIM5 PDZ and LIM domain protein 5 Q96HC4 28 9.6 4 357 4 
PLXNB2 Plexin-B2 O15031 93 7.2 10 764 8 
PLXNB3 Plexin-B3 Q9ULL4 10 2.3 2 67 3 
PLXNC1 Plexin-C1 O60486 9 3.6 4 91 2 
PODXL Podocalyxin O00592 156 5.6 3 1364 8 
PODXL2 Podocalyxin-like protein 2 Q9NZ53 22 10.1 3 127 3 
POSTN Periostin Q15063 85 17.9 8 919 6 
PPP1CA 
Serine/threonine-protein 
phosphatase PP1-alpha catalytic 
subunit 
P62136 120 26.7 1 1752 4 
PTK7 Inactive tyrosine-protein kinase 7 Q13308 64 7.9 5 882 4 
PTPRF 
Receptor-type tyrosine-protein 
phosphatase F 
P10586 240 16 18 2480 7 
PTPRK 
Receptor-type tyrosine-protein 
phosphatase kappa 
Q15262 166 9.5 8 1739 7 
PTPRS 
Receptor-type tyrosine-protein 
phosphatase S 
Q13332 58 6.2 6 516 7 
PVR Poliovirus receptor P15151 64 12.9 4 465 6 
PVRL1 Nectin-1 Q15223 49 16.6 5 245 5 
PVRL2 Nectin-2 Q92692 82 10.6 4 918 6 
PVRL4 Nectin-4 Q96NY8 54 9.4 4 360 7 
RAB10 Ras-related protein Rab-10 P61026 194 22.5 2 2867 8 
RAB1A Ras-related protein Rab-1A P62820 245 51.2 2 3099 4 
RAC1 
Ras-related C3 botulinum toxin 
substrate 1 
P63000 177 39.6 5 1097 8 
RAC2 
Ras-related C3 botulinum toxin 
substrate 2 
P15153 43 12.5 1 543 2 
RAP2B Ras-related protein Rap-2b P61225 26 29 3 366 4 
RGMB RGM domain family member B Q6NW40 20 4.3 1 85 6 
RPSA 40S ribosomal protein SA P08865 81 38.6 7 843 6 
S100A11 Protein S100-A11 P31949 310 63.8 4 7761 8 
S100A8 Protein S100-A8 P05109 827 45.2 6 8206 8 
S100A9 Protein S100-A9 P06702 3300 75.4 8 54496 8 
SHC1 SHC-transforming protein 1 P29353 6 2.1 1 24 3 
SIRPA 
Tyrosine-protein phosphatase non-
receptor type substrate 1 
P78324 470 28.8 9 4641 8 
SLURP1 
Secreted Ly-6/uPAR-related 
protein 1 
P55000 3 24.3 1 47 1 
SPP1 Osteopontin P10451 982 55.1 13 11049 3 
STXBP1 Syntaxin-binding protein 1 P61764 14 7.2 3 62 3 
TGFB2 Transforming growth factor beta-2 P61812 12 12.8 3 71 3 
TGFBI 
Transforming growth factor-beta-
induced protein igh3 
Q15582 327 30.7 13 2474 8 
THBS1 Thrombospondin-1 P07996 1294 40.9 31 17622 8 
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THBS3 Thrombospondin-3 P49746 6 2.8 2 55 2 
THY1 Thy-1 membrane glycoprotein P04216 14 24.2 3 93 4 
TINAGL1 
Tubulointerstitial nephritis antigen-
like 
Q9GZM7 31 13.9 5 212 5 
TLN1 Talin-1 Q9Y490 60 3.6 6 860 7 
TM9SF4 
Transmembrane 9 superfamily 
member 4 
Q92544 6 3 1 44 3 
TMEM8A Transmembrane protein 8A Q9HCN3 23 7.8 5 181 3 
TNC Tenascin P24821 3757 57.7 81 56044 8 
TOR1A Torsin-1A O14656 17 6.9 2 112 6 
TSTA3 GDP-L-fucose synthase Q13630 9 11.5 2 43 5 
VCAN Versican core protein P13611 158 3.4 7 1918 6 
VCL Vinculin P18206 75 15.3 11 945 8 
VTN Vitronectin P04004 491 26.4 9 8572 8 
VWA2 
von Willebrand factor A domain-
containing protein 2 
Q5GFL6 6 3.7 2 72 1 
VWF von Willebrand factor P04275 89 7.2 15 783 2 
4.3.6 Expression of cancer related proteins 
The normalised peak area mean for each protein for each matched 
pair was calculated to establish significant expression changes between 
individuals. Whilst many proteins detected are case/patient specific, there 
were some important trends observed that reflect changes in disease-related 
physiology. The proteomic profiles from the healthy volunteer (Case 1) had 
distinctly different protein compositions from the other 3 cases. A Student t-
test was applied to identify proteins that were significantly different compared 
to the other three cases. A comparison of non-cancer (healthy/benign) to 
malignancies (DCIS/invasive carcinoma), identified 225 proteins 
(Supplementary Table 4.3) that were differentially expressed (p<0.05). Of 
these 76 are normally found in the extracellular space, including basement 
membrane and extracellular matrix proteins (STRING, 28 proteins, FDR – 
6.68e-14, DAVID, 33 proteins, 2.4e-19, Benjamini corrected), focal adhesion 
(DAVID, 35 proteins, 8.8e-18, Benjamini corrected) and those involved in 
wound healing (STRING 40 proteins, FDR – 4.48e-15) cell-cell adherens 
junction (DAVID, 18 proteins, 7.7e-6, Benjamini corrected). 
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In this study, 15 growth factors were also identified including insulin-
like growth factor I and II (IGF1 and IGF2), interleukin-8, 9 and 34, 
transforming growth factor beta 1, 2, and 3, and vascular endothelial growth 
factor A (VEGFA) (Table 4-3). Although some are case-specific, amongst the 
receptors detected were those associated with tumour growth, including 
epidermal growth factor receptor (EGFR), transforming growth factor beta 
receptor type II and III (TGFβR 2 and 3), hepatocyte growth factor receptor 
(HGFR), vascular endothelial growth factor receptor (VEGFR1), mast/stem 
cell growth factor receptor (KIT) and receptor tyrosine-protein kinase Erbb-3 
(HER3) (Table 4-4). Furthermore, a number of cancer associated ligands 
were also detected including pro-epidermal growth factor (EGF), platelet-
derived growth factors C and D (PDGF-C and PDGF-D), placenta growth 
factor, neuropilin-1 and pleiotropin (Table 4-4).  
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Table 4-3: Selected mitogenic factors identified in NAF 
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Table 4-4: Selected mitogenic receptors identified in NAF. 
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The IGF signalling pathway plays an important role in regulating cell 
proliferation and inhibiting apoptosis in breast and prostate cancer. 
Expression of IGF1 and insulin-like growth factors-binding proteins 3 
(IGFBP3) may be related to mammographic density, a high-risk factor for 
breast cancer as it correlates with the volume of ductal/lobule anatomy and 
consequentially the epithelial cell content which in turn is connected with 
proliferation and possibly mutagenesis [24]. Circulating IGF1 has been 
shown to be positively associated with ER-positive breast cancer risk [25]. In 
this study, IGF1 was only detected in the invasive carcinoma patient, 
however, IGFBP3 was detected in all samples and exhibited increasing 
levels with disease stage. Basic fibroblast growth factor, a marker of 
angiogenesis in tumour growth and metastatic breast cancer, has been 
measured in NAF by immunoassay [26], but was not detected in our samples. 
However, three other proteins (MMP9, collagen alpha-2(IV) and VEGFR1) 
associated with angiogenesis, were detected. 
A subgroup of extracellular matrix proteins exhibited a variation on 
the above profile with a decrease in DCIS (PD) expression compared to 
benign (PB) but with highest levels in invasive carcinoma (PI) - glypicans-1 
(GPC1) and -4 (GPC4), and syndecan-1 (SDC1), and junctional adhesion 
molecule A (F11R). The degradation of the ductal lining, is most likely due to 
the action of the large number of proteases present in NAF. We have 
previously observed that laminin beta2 decreases in invasive carcinoma 
tissue (Shaheed et al., 2013b), most likely due to proteolytic degradation and 
I was now able to see these products secreted in NAF.  
Mannello et al identified the importance of exploring NAF for 
established biomarkers such as urokinase-dependent plasminogen activator 
  
196 
 
(uPA) and  plasminogen activator inhibitor (PAI-I), particularly for their role in 
extracellular matrix turnover, which might be expected from processes 
associated with cancer invasiveness (Mannello and Ligi, 2013). Analysis of 
NAF identified nearly 233 proteolytic enzymes and inhibitors (1.94 fold 
enriched, p value 58E-18), many of which are naturally secreted by cells to 
modulate stromal composition. Within this group were 10 members of the 
kallikrein family, including prostate specific antigen (PSA/KLK3) (Table 4-5). 
An inverse correlation of KLK3 levels in NAF with breast cancer stage (DCIS 
to metastatic) has previously been described (Alexander et al., 2004, Sauter 
et al., 2004b). KLK3 was detected in 3 NAF samples (Table 4-5), most 
significantly representing a decrease in DCIS compared to the matched 
normal. Of the other kallikreins, KLK5, KLK6, KLK8, KLK11 were detected in 
all NAF samples. 
There were 6 proteins (kallikrein 6, ATP-binding cassette sub-family 
C member 11, secretoglobin family 3A member 1, mammaglobin-A, 
prolactin-inducible protein [PIP], and mucin-like protein 1) strongly 
associated with breast tissue expression (compared to all other tissues). The 
expression of PIP, was also verified by western blot in NAF samples (Figure 
4-8). Although these proteins are not cancer-specific, changes in these 
proteins may prove useful indicators of breast health. 
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Table 4-5: List of proteolysis proteins identified in the NAF samples.  
Table represents Gene ID, Protein name, UniProt accession number, Mascot score, Sequence coverage of 
protein, number of spectra identified in MS analysis, number of unique peptides, Frequency of detection in 
samples. 
Gene ID Protein Name 
UniProt 
Accession 
# 
Spectra 
Coverage 
# Unique 
Peptides 
Score 
Mascot 
Frequency 
ABHD5 
1-acylglycerol-3-phosphate O-
acyltransferase ABHD5 
Q8WTS1 45 14.3 3 721 3 
ACE Angiotensin-converting enzyme P12821 1813 33.1 34 22210 8 
ACE2 Angiotensin-converting enzyme 2 Q9BYF1 74 22.0 12 690 6 
ADAM10 
Disintegrin and metalloproteinase domain-
containing protein 10 
O14672 4 2.3 1 83 1 
ADAM15 
Disintegrin and metalloproteinase domain-
containing protein 15 
Q13444 55 11.9 6 630 7 
ADAM9 
Disintegrin and metalloproteinase domain-
containing protein 9 
Q13443 17 9.9 5 152 5 
ADAMDEC1 ADAM DEC1 O15204 8 10.2 3 92 1 
AGA 
N(4)-(beta-N-acetylglucosaminyl)-L-
asparaginase 
P20933 335 34.7 5 8616 8 
AGT Angiotensinogen P01019 734 31.5 10 14508 8 
ANPEP Aminopeptidase N P15144 4833 48.6 41 80648 8 
APEH Acylamino-acid-releasing enzyme P13798 13 3.1 2 166 4 
APOH Beta-2-glycoprotein 1 P02749 1245 53.3 12 14435 8 
ARRB1 Beta-arrestin-1 P49407 13 7.9 2 31 3 
ASPRV1 Retroviral-like aspartic protease 1 Q53RT3 4 3.8 1 62 2 
ATP6AP2 Renin receptor O75787 88 26.9 6 1159 5 
AZU1 Azurocidin P20160 271 48.6 7 3268 5 
BLMH Bleomycin hydrolase Q13867 27 7.9 2 207 4 
BMP1 Bone morphogenetic protein 1 P13497 5 5.2 3 118 2 
C1QA 
Complement C1q subcomponent subunit 
A 
P02745 2 9.4 1 24 1 
C1QB 
Complement C1q subcomponent subunit 
B 
P02746 4 5.5 1 73 1 
C1QC 
Complement C1q subcomponent subunit 
C 
P02747 17 8.6 2 77 3 
C1R Complement C1r subcomponent P00736 335 39.0 16 4114 8 
C1RL 
Complement C1r subcomponent-like 
protein 
Q9NZP8 287 16.8 4 2220 8 
C1S Complement C1s subcomponent P09871 198 28.9 12 4227 8 
C2 Complement C2 P06681 167 18.9 11 1666 8 
C3 Complement C3 P01024 18775 77.6 113 297198 8 
C4A Complement C4-A P0C0L4 32891 65.6 5 556429 8 
C4B Complement C4-B P0C0L5 33808 65.9 6 572440 8 
CAPN1 Calpain-1 catalytic subunit P07384 43 11.5 7 394 7 
CAPN2 Calpain-2 catalytic subunit P17655 31 8.0 4 136 5 
CAPN7 Calpain-7 Q9Y6W3 5 3.3 2 29 3 
CAPNS1 Calpain small subunit 1 P04632 24 28.7 4 223 4 
CASP14 Caspase-14 P31944 178 39.3 10 2406 7 
CD2AP CD2-associated protein Q9Y5K6 10 2.8 1 39 1 
CD46 Membrane cofactor protein P15529 22 3.8 1 32 7 
CFB Complement factor B P00751 1977 46.1 27 20896 8 
CFD Complement factor D P00746 572 53.0 10 5978 8 
CFI Complement factor I P05156 900 40.5 19 17877 8 
CHMP4B Charged multivesicular body protein 4b Q9H444 34 25.4 3 636 8 
CLCA2 
Calcium-activated chloride channel 
regulator 2 
Q9UQC9 212 19.3 12 2570 6 
CLCA4 
Calcium-activated chloride channel 
regulator 4 
Q14CN2 360 35.5 20 4336 8 
CLN5 Ceroid-lipofuscinosis neuronal protein 5 O75503 60 24.0 7 457 7 
CNDP2 Cytosolic non-specific dipeptidase Q96KP4 161 56.2 16 1574 8 
COPS4 COP9 signalosome complex subunit 4 Q9BT78 3 3.4 1 34 1 
CORIN 
Atrial natriuretic peptide-converting 
enzyme 
Q9Y5Q5 7 2.1 1 67 1 
CPA1 Carboxypeptidase A1 P15085 52 5.3 1 679 0 
CPA4 Carboxypeptidase A4 Q9UI42 15 5.0 2 67 4 
CPB1 Carboxypeptidase B P15086 2045 78.9 24 30392 8 
CPD Carboxypeptidase D O75976 65 3.6 4 1644 7 
CPE Carboxypeptidase E P16870 128 21.0 6 2328 8 
CPM Carboxypeptidase M P14384 111 16.5 5 1376 8 
CPNE1 Copine-1 Q99829 2 1.7 1 47 1 
CPQ Carboxypeptidase Q Q9Y646 122 19.3 6 2421 8 
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Spectra 
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CSNK1A1 Casein kinase I isoform alpha P48729 7 3.0 1 62 3 
CTNNB1 Catenin beta-1 P35222 31 6.4 1 150 2 
CTSA Lysosomal protective protein P10619 14 7.9 3 200 5 
CTSB Cathepsin B P07858 594 38.1 10 9400 8 
CTSC Dipeptidyl peptidase 1 P53634 383 22.0 7 4139 8 
CTSD Cathepsin D P07339 1842 48.1 16 31145 8 
CTSF Cathepsin F Q9UBX1 6 6.4 2 38 2 
CTSG Cathepsin G P08311 167 39.6 7 1646 6 
CTSH Pro-cathepsin H P09668 60 9.0 3 459 8 
CTSL Cathepsin L1 P07711 10 8.4 2 44 3 
CTSO Cathepsin O P43234 11 13.1 3 81 4 
CTSS Cathepsin S P25774 137 30.8 6 2146 7 
CTSZ Cathepsin Z Q9UBR2 206 38.0 7 1272 8 
CUL3 Cullin-3 Q13618 4 4.9 2 32 2 
CUL4B Cullin-4B Q13620 9 0.9 1 82 2 
DAG1 Dystroglycan Q14118 480 23.5 12 3883 7 
DCD Dermcidin P81605 36 12.7 2 370 5 
DDB1 DNA damage-binding protein 1 Q16531 13 4.3 3 48 6 
DHCR24 Delta(24)-sterol reductase Q15392 22 7.4 3 227 2 
DNAJB2 DnaJ homolog subfamily B member 2 P25686 2 4.6 1 37 1 
DNAJC3 DnaJ homolog subfamily C member 3 Q13217 28 11.5 4 220 5 
DNPEP Aspartyl aminopeptidase Q9ULA0 14 5.1 2 43 2 
DPP3 Dipeptidyl peptidase 3 Q9NY33 21 7.6 4 165 5 
DPP4 Dipeptidyl peptidase 4 P27487 21 5.1 4 124 4 
DPP7 Dipeptidyl peptidase 2 Q9UHL4 161 26.4 10 1944 7 
ELANE Neutrophil elastase P08246 313 36.7 6 4135 5 
ERAP1 Endoplasmic reticulum aminopeptidase 1 Q9NZ08 662 32.8 25 7162 8 
ERAP2 Endoplasmic reticulum aminopeptidase 2 Q6P179 17 2.9 2 97 2 
F12 Coagulation factor XII P00748 95 15.6 6 653 7 
F2 Prothrombin P00734 650 43.6 21 7797 8 
F9 Coagulation factor IX P00740 3 2.0 1 47 2 
FAM125A Multivesicular body subunit 12A Q96EY5 101 34.1 6 1960 8 
FCN2 Ficolin-2 Q15485 34 14.7 3 352 6 
FGA Fibrinogen alpha chain P02671 97 13.4 9 811 8 
FGB Fibrinogen beta chain P02675 628 46.6 15 6466 8 
FGG Fibrinogen gamma chain P02679 503 53.0 16 5667 8 
FOLH1 Glutamate carboxypeptidase 2 Q04609 56 13.1 6 690 4 
FURIN Furin P09958 19 9.9 4 80 3 
GAS6 Growth arrest-specific protein 6 Q14393 3 1.1 1 47 1 
GCA Grancalcin P28676 4 4.6 1 42 1 
GGH Gamma-glutamyl hydrolase Q92820 291 35.2 8 2786 8 
GGT1 Gamma-glutamyltranspeptidase 1 P19440 1852 34.8 11 33170 8 
GGT5 Gamma-glutamyltransferase 5 P36269 591 33.8 13 7608 8 
GGT6 Gamma-glutamyltransferase 6 Q6P531 47 16.0 4 519 4 
GGTLC3 
Putative gamma-glutamyltransferase light 
chain 3 
B5MD39 231 19.1 2 4964 1 
GTSE1 G2 and S phase-expressed protein 1 Q9NYZ3 6 1.8 1 78 4 
HABP2 Hyaluronan-binding protein 2 Q14520 6 5.5 2 83 2 
HP Haptoglobin P00738 1339 56.7 11 17693 8 
HPN Serine protease hepsin P05981 54 13.2 3 374 6 
HPR Haptoglobin-related protein P00739 457 27.9 2 7609 4 
HSP90B1 Endoplasmin P14625 243 18.8 11 3487 8 
HSPA5 78 kDa glucose-regulated protein P11021 440 39.4 20 5711 8 
HTRA1 Serine protease HTRA1 Q92743 32 4.0 2 594 5 
ITCH E3 ubiquitin-protein ligase Itchy homolog Q96J02 9 7.9 4 107 1 
KIF14 Kinesin-like protein KIF14 Q15058 3 2.3 3 37 1 
KLK10 Kallikrein-10 O43240 71 14.1 3 364 7 
KLK11 Kallikrein-11 Q9UBX7 394 46.8 9 3633 8 
KLK13 Kallikrein-13 Q9UKR3 12 4.0 1 32 5 
KLK14 Kallikrein-14 Q9P0G3 129 50.9 9 2439 5 
KLK2 Kallikrein-2 P20151 3 6.5 1 45 1 
KLK3 Prostate-specific antigen P07288 294 55.6 8 2457 3 
KLK5 Kallikrein-5 Q9Y337 164 27.3 5 1503 8 
KLK6 Kallikrein-6 Q92876 558 48.4 8 5116 8 
KLK7 Kallikrein-7 P49862 7 9.9 1 36 3 
KLK8 Kallikrein-8 O60259 136 20.8 4 1029 8 
KLKB1 Plasma kallikrein P03952 8 4.2 2 146 2 
LAP3 Cytosol aminopeptidase P28838 48 16.8 6 328 7 
LGMN Legumain Q99538 263 41.6 11 2064 8 
LNPEP Leucyl-cystinyl aminopeptidase Q9UIQ6 2 1.3 1 31 1 
LONP2 Lon protease homolog 2, peroxisomal Q86WA8 17 8.8 4 78 2 
  
199 
 
Gene ID Protein Name 
UniProt 
Accession 
# 
Spectra 
Coverage 
# Unique 
Peptides 
Score 
Mascot 
Frequency 
LTF Lactotransferrin P02788 76302 94.9 106 
137915
3 
8 
MAN1B1 
Endoplasmic reticulum mannosyl-
oligosaccharide 1,2-alpha-mannosidase 
Q9UKM7 42 11.7 6 192 5 
MBTPS1 
Membrane-bound transcription factor site-
1 protease 
Q14703 100 3.8 2 705 7 
MME Neprilysin P08473 182 31.2 17 2828 3 
MMP7 Matrilysin P09237 203 34.1 6 1606 8 
MMP9 Matrix metalloproteinase-9 P14780 32 9.5 5 503 4 
MYH9 Myosin-9 P35579 1231 33.3 42 12532 8 
NCSTN Nicastrin Q92542 205 18.3 7 2392 8 
NPEPPS Puromycin-sensitive aminopeptidase P55786 52 7.6 6 997 7 
OS9 Protein OS-9 Q13438 11 10.9 5 115 2 
OTUB1 Ubiquitin thioesterase OTUB1 Q96FW1 26 18.1 4 107 6 
PAPPA2 Pappalysin-2 Q9BXP8 13 4.2 4 43 1 
PARK7 Protein deglycase DJ-1 Q99497 171 64.6 8 2073 8 
PCBP2 Poly(rC)-binding protein 2 Q15366 4 4.4 1 25 3 
PCOLCE Procollagen C-endopeptidase enhancer 1 Q15113 35 12.2 4 172 8 
PCYOX1 Prenylcysteine oxidase 1 Q9UHG3 22 11.9 4 476 4 
PDCD6 Programmed cell death protein 6 O75340 76 40.8 5 981 8 
PDCD6IP 
Programmed cell death 6-interacting 
protein 
Q8WUM4 1354 50.9 33 20305 8 
PDIA3 Protein disulfide-isomerase A3 P30101 277 34.9 13 2729 8 
PEF1 Peflin Q9UBV8 6 8.5 2 119 2 
PEPD Xaa-Pro dipeptidase P12955 64 22.7 6 1243 5 
PGC Gastricsin P20142 163 5.2 2 2189 6 
PIP Prolactin-inducible protein P12273 56864 77.4 21 122387 8 
PLAT Tissue-type plasminogen activator P00750 1229 58.0 23 15190 8 
PLAU Urokinase-type plasminogen activator P00749 8 4.4 2 30 3 
PLG Plasminogen P00747 927 49.0 26 8068 8 
PROS1 Vitamin K-dependent protein S P07225 65 12.6 7 321 8 
PRSS1 Trypsin-1 P07477 7 8.1 1 56 3 
PRSS22 Brain-specific serine protease 4 Q9GZN4 66 18.6 4 414 7 
PRSS23 Serine protease 23 O95084 20 10.2 3 248 4 
PRSS8 Prostasin Q16651 1340 41.4 7 18478 8 
PRTN3 Myeloblastin P24158 356 27.7 4 4200 7 
PSMD1 
26S proteasome non-ATPase regulatory 
subunit 1 
Q99460 12 1.3 1 161 5 
PSMD2 
26S proteasome non-ATPase regulatory 
subunit 2 
Q13200 12 1.7 1 37 2 
PSMD3 
26S proteasome non-ATPase regulatory 
subunit 3 
O43242 5 2.4 1 28 2 
PSMD5 
26S proteasome non-ATPase regulatory 
subunit 5 
Q16401 10 9.7 3 89 3 
PSMD6 
26S proteasome non-ATPase regulatory 
subunit 6 
Q15008 9 9.3 3 71 2 
PSME1 Proteasome activator complex subunit 1 Q06323 16 24.1 4 303 5 
PSME2 Proteasome activator complex subunit 2 Q9UL46 3 5.9 1 111 1 
RAD23B 
UV excision repair protein RAD23 
homolog B 
P54727 9 2.7 1 69 2 
RFFL E3 ubiquitin-protein ligase rififylin Q8WZ73 4 5.8 1 40 1 
RHOA Transforming protein RhoA P61586 364 65.3 2 3306 8 
RNPEP Aminopeptidase B Q9H4A4 170 32.6 13 1500 8 
RPS27A Ubiquitin-40S ribosomal protein S27a P62979 537 30.1 4 6930 8 
RUVBL1 RuvB-like 1 Q9Y265 3 3.5 1 45 2 
SCPEP1 
Retinoid-inducible serine 
carboxypeptidase 
Q9HB40 158 21.0 7 1582 8 
SFRP1 Secreted frizzled-related protein 1 Q8N474 485 42.7 9 3313 8 
SHMT1 
Serine hydroxymethyltransferase, 
cytosolic 
P34896 25 15.1 5 360 2 
SPPL2A Signal peptide peptidase-like 2A Q8TCT8 11 4.4 2 201 2 
SRI Sorcin P30626 7 6.1 1 110 2 
ST14 Suppressor of tumorigenicity 14 protein Q9Y5Y6 130 16.1 8 1623 8 
TBC1D10A TBC1 domain family member 10A Q9BXI6 6 10.6 3 130 1 
TGFB1 Transforming growth factor beta-1 P01137 2 3.3 1 41 1 
THSD4 
Thrombospondin type-1 domain-
containing protein 4 
Q6ZMP0 3 1.1 1 61 2 
TINAGL1 Tubulointerstitial nephritis antigen-like Q9GZM7 31 13.9 5 212 5 
TMEM59 Transmembrane protein 59 Q9BXS4 38 7.4 2 134 5 
TMPRSS11E Transmembrane protease serine 11E Q9UL52 4 8.7 2 56 2 
TMPRSS13 Transmembrane protease serine 13 Q9BYE2 52 12.1 6 450 4 
TMPRSS2 Transmembrane protease serine 2 O15393 32 15.4 5 288 6 
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Gene ID Protein Name 
UniProt 
Accession 
# 
Spectra 
Coverage 
# Unique 
Peptides 
Score 
Mascot 
Frequency 
TOM1L1 TOM1-like protein 1 O75674 73 13.2 5 374 7 
TOR1A Torsin-1A O14656 17 6.9 2 112 6 
TPP1 Tripeptidyl-peptidase 1 O14773 185 30.9 9 2260 8 
TPSAB1 Tryptase beta-2 P20231 190 22.9 5 1274 5 
TRABD2B Metalloprotease TIKI2 A6NFA1 16 5.2 2 113 2 
TSG101 Tumor susceptibility gene 101 protein Q99816 140 20.0 7 1419 8 
UBA3 
NEDD8-activating enzyme E1 catalytic 
subunit 
Q8TBC4 3 3.2 1 82 3 
UBE2L3 Ubiquitin-conjugating enzyme E2 L3 P68036 24 24.0 2 86 6 
UBE2N Ubiquitin-conjugating enzyme E2 N P61088 51 34.2 4 132 7 
UQCRC1 
Cytochrome b-c1 complex subunit 1, 
mitochondrial 
P31930 7 14.2 3 44 2 
UQCRC2 
Cytochrome b-c1 complex subunit 2, 
mitochondrial 
P22695 10 11.0 3 90 3 
USP5 Ubiquitin carboxyl-terminal hydrolase 5 P45974 4 1.5 1 28 2 
VCP 
Transitional endoplasmic reticulum 
ATPase 
P55072 129 25.8 15 1336 8 
VPS25 
Vacuolar protein-sorting-associated 
protein 25 
Q9BRG1 41 21.6 4 155 6 
VPS28 
Vacuolar protein sorting-associated 
protein 28 homologs 
Q9UK41 126 37.6 9 1966 8 
VPS36 
Vacuolar protein-sorting-associated 
protein 36 
Q86VN1 8 14.5 4 100 2 
VPS4A 
Vacuolar protein sorting-associated 
protein 4A 
Q9UN37 50 14.9 3 377 3 
VPS4B 
Vacuolar protein sorting-associated 
protein 4B 
O75351 106 21.8 5 735 7 
WFDC2 WAP four-disulfide core domain protein 2 Q14508 1142 67.7 6 18605 8 
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4.3.7 Pathway analysis of differently expressed proteins in the NAF proteome. 
The KEGG pathway (http://www.genome.jp/kegg/) analysis of NAF proteome identified 11 significant proteins 
(highlighted in red) which play a role in breast cancer proliferation, survival, and progression. These proteins control four 
important pathways in breast cancer; MAPK signalling pathway, PI3k-Akt signalling pathway, Notch signalling pathway and 
Wnt signalling pathway. The cellular interaction of these proteins is shown in Figure 4-7. 
 
Figure 4-7: NAF proteins detected in breast cancer signalling pathways. 
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4.3.8 Verification of presence of selected targets by Western 
blot. 
The expression of prolactin-inducible protein (PIP), CD44 antigen 
(CD44), vimentin (VIM), actin, cytoplasmic 1 (ACTB), cofilin-1 (CFL1), 
calreticulin (CALR), epidermal growth factor receptor (EGFR), and 
cytochrome P450 3A4 (CYP3A4), was verified in NAF by Western blotting. 
All immunoblots were analysed by GelAnalyzer 2010, to determine the MW 
of proteins (Figure 4-8). The target proteins; CD44, CALR, EGFR, ACTB and 
cofilin-1, were detected with single band at 81kDa, 48kDa, 44kDa, 42kDa 
and 18kDa respectively.  
The theoretical mass of EGFR is 134kDa (Uniprot.org, 2015) but in 
NAF samples was detected at 44kDa. EGFR has 4 isoforms; P00533-1 
(134kDa), P00533-2 (44kDa), P00533-3 (77kDa) and P00533-4 (69kDa) 
(Uniprot.org, 2015). On this basis, anti-EGFR antibody seems to be detecting 
isoform 2 at 44kDa, which can be further verified by GEL-LC-MS analysis of 
the 44kDa band (Shevchenko et al., 1996) VIM was detected with 2 bands 
at 53kDa and 51kDa while theoretical mass of VIM is 53.65kDa. PIP was 
present in all NAF samples at 16kDa (theoretical MW-16.57kDa) except 
those of the healthy volunteers, while a weak band at 14kDa was also 
detected in Patient with DCIS and patient with invasive carcinoma (Figure 
4-8). Actin cytoplasmic 1 (ACTB) was used a control for western blot assay, 
but ACTB was observed at different level in NAF samples (Figure 4-8). There 
was also a difference for expression in left and right breasts of same patient. 
These findings suggest that ACTB is not the right control for analysis of NAF 
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samples by Western blot analysis. The limited volume of NAF also makes 
Western blot a less than ideal approach for validation of breast cancer 
biomarkers. Therefore, a multiplex assay like MRM-MS, will be ideal to 
validate and quantify potential biomarkers in NAF samples.  
 
Figure 4-8: Western blot analysis of ACTB, CD44, CYP3A4, VIM, CALR, 
EGFR, CFL1 and PIP in NAF.
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4.4 DISCUSSION 
4.4.1 Comparison of identified NAF proteome with 
published NAF data. 
Prior to this study, the most complete proteomics profile of NAF was 
that of Pavlou et al (Pavlou et al., 2010). A total of 854 proteins were identified 
from 3 healthy volunteers and 3 cancer patients (2 samples from the 
cancerous breast and one from the non-cancer breast). Comparison with our 
dataset, based on gene identity (691 entries Pavlou et al, and 1919 for our 
set), indicated an overlap of 563 proteins Figure 4-9: Overlapping identities 
with the data from the NAF study by Pavlou et al 2010.(Figure 4-9), however 
our current study illustrated substantial progress in NAF characterisation 
identifying 1374 new proteins not previously seen in NAF. 
 
Figure 4-9: Overlapping identities with the data from the NAF study by 
Pavlou et al 2010.  
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4.4.2 Comparison of NAF proteome with Plasma proteome 
As plasma is by far the most commonly used and most completely 
characterised liquid biopsy, including many breast cancer biomarker studies 
(Zeidan et al., 2015), I wanted to establish if the NAF proteome is likely to 
provide unique insights. The Plasma Proteome Database comprises the 
collated quantitative data for 10546 proteins that have been detected in 
plasma and serum (http://www.plasmaproteomedatabase.org/) (Omenn et 
al., 2005). A comparison of the NAF profile with the Plasma Proteome 
Database identified 1578 proteins in common (Figure 4-10), but 332 proteins 
(21% of the total NAF profile) were unique to NAF indicating it has great 
potential to provide molecular information specific to breast health. 
 
Figure 4-10: overlapping identities with the Human Plasma Proteome 
database. 
In this study, the high plasma composition was interpreted as blood 
contamination of the tissue during surgery as high levels of haemoglobin 
isoforms were also detected. Interestingly, haemoglobin alpha and beta 
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isoforms were only detected in patient NAF samples, and with significant 
higher levels in the diseased breast compared to the normal.  
4.4.3 Phenotype specific protein expression changes 
A two-tailed Student t-test of HV, using the average normalised sum 
of the three strongest peak areas for each protein, from two breast analyses, 
compared to the equivalent data for the three cancer samples, identified 331 
proteins that were present at significantly different levels (p<0.05) 
(Supplementary Table 4.1). The proteomic profile of Case 1 (healthy 
volunteer, HV), indicated high levels of milk proteins (Figure 4-11). Of the 40 
most abundant proteins observed by Beck et al, the most complete proteome 
study of human milk to date, identifying 1606 gene products, 25 were also 
the most abundant in the NAF samples of case 1 (Beck et al., 2015).  Case 
1 presented at the outpatient clinic with a spontaneous milky-pus discharge 
when either nipple was squeezed. The reproductive history of the volunteer, 
aged 48, indicated, she had achieved parity 3 times (with the first birth at age 
38). Small amounts of milk or serous fluid expression can persist for months 
or years after weaning, but Case 1 did not engage in breastfeeding. Further 
investigation of her medical records, however, indicated that she had been 
prescribed amitriptyline, for depression and stress-management, and 
omeprazole and lansoprazole for gastric oesophageal reflux. In rare cases, 
these may cause breast tissue enlargement and nipple discharge, which is 
associated with galactorrhea rather than cancer (Pipaliya et al., 2016). 
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Figure 4-11: Significantly increased in the healthy volunteer (HV), compared to diseased samples. 
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Phyllodes tumours constitute less than 1% of all breast tumours and 
are characterised by atypical stromal histological features. The phyllodes 
patient (Case 9, PB) investigated here was a benign form (Figure 4-1). Of the 
462 proteins (Supplementary Table 4.2) previously identified as benign 
phyllodes markers, predominantly through immunohistochemistry methods, 
EGFR (malignant phyllodes marker) (Tse et al., 2009), neprilysin (CD10) 
(Vilela et al., 2014), VEGF (Tse et al., 2004), alpha catenin and beta-catenin 
(Ho et al., 2013, Tsang et al., 2012, Lacroix-Triki et al., 2010) were most 
abundant in the NAF samples from Case 9 confirming previous observations. 
High expression of EGFR was also observed in patients with benign 
phyllodes and ductal carcinoma in situ (DCIS), by Western blot analysis 
(Figure 4-8). E-cadherin or cadherin 1 has also been linked to benign 
phyllodes, and was significantly high in the benign patient, but was also high 
in the invasive cancer patient. c-kit (CD117) another marker of benign 
phyllodes (Sawyer et al., 2003) was detected in NAF, but only in the healthy 
and invasive cases. Other important markers of benign phyllodes, p53 and 
Ki-67 (CD34) were not detected in NAF, but as they are found in the nucleus 
and nuclear component of NAF is under-represented compared to normal, 
this would be expected. Ubiquitin carboxy-terminal hydrolase L1 has been 
associated with the tumour development including benign phyllodes (Lien et 
al., 2013). Although not detected in this study, a related isoform Ubiquitin 
carboxy-terminal hydrolase 5, which has a role in p53 de-ubiquitination, was 
solely detected in the benign case. 
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4.4.4 Cancer specific protein expression changes 
In this study, the proteome of health volunteer/benign was compared 
against DCIS/IC, to understand cancer specific protein expression changes. 
Laminins form a complex and constitute a key component of basement 
membranes and have an essential role the structure and function of 
extracellular matrix (Glentis et al., 2014). Each complex comprising a 
heterotrimer of subunits (alpha, beta and gamma) linked by disulphide 
bridges. Of the 5 laminin isoforms detected in NAF samples, the three most 
abundant were alpha5, beta2 and gamma1, which suggests the expression 
of the specific heterotrimer laminin-11 (or laminin-521) normally 
expressed/found in the glomerular basement membrane in the kidney, the 
neuromuscular synaptic cleft and placenta (Miner and Patton, 1999). Laminin 
alpha5, beta2 and gamma1, along with collagen alpha 1(VI), alpha 2(VI), 
fibulin(s), versican were increased in absolute levels from healthy volunteer 
to invasive carcinoma suggesting increasing disruption of the basement 
membrane with disease progression (Figure 4-12). Extracellular matrix 
proteins, including ICAM1 (which has been implicated in cell migration and 
metastasis), mucin-1 (MUC1), mucin-like protein-1 (MUCL1), E-cadherin 
(cadherin-1, CDH1), cell adhesion molecule 4 (CADM4), extracellular 
superoxide dismutase (SOD3), moesin (MSN), tenascin (TNC), 
thrombospondins-1 (THBS1) and -2 (THBS2), vitronectin (VTN), ezrin (EZR), 
olfactomedin-4 (OLFM4), extracellular matrix protein 1 (ECM1), EGF-
containing fibulin-like extracellular matrix protein 1 (EFEMP1) and 
Ly6/PLAUR domain-containing protein 3 (LYPD3) also exhibited a similar 
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pattern of expression in the NAF samples. Proteins associated with 
inflammation, cell growth and cell migration were also significantly increased 
and included attractin, protein S100-A8 and A9, cathepsin D, CSF1, insulin-
like growth factors-binding proteins 3 (IGFBP3), EGF and PDGF-C (Figure 
4-13). 
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Figure 4-12, A: Significantly increased in the cancer patients compares to healthy volunteer and patient with benign phyllodes. 
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Figure 4-13 B: Significantly increased in the cancer patients compares to healthy volunteer and patient with benign phyllodes.
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4.4.5 Diagnostic application 
One of my objectives was to understand whether analysing matched 
pairs would provide a more specific approach to detecting disease compared to 
normal. SDS PAGE showed that most matched pairs have similar protein band 
patterns, which was corroborated by the high correlation of proteomics profiles. 
Whilst some proteins were significantly different in bilateral samples, a more 
extensive longitudinal study is required to determine statistically valid 
differences between disease and healthy breast of an individual.  
The National Cancer Institute has coordinated the research of many 
institutions to accelerate the identification and validation of early stage cancer 
testing and detection (https://edrn.nci.nih.gov/). Of the 195 breast cancer 
proteins and genes under investigation by the NCI Early Detection Research 
Network, 46 are present in NAF of which 22 were detected in all 8 samples and 
7 were not found in plasma (Table 4-6). Among the candidate biomarkers 
detected in NAF were C-C motif chemokine 28, CSF1, EGFR, VEGFR1, 
VEGFA, ICAM1, KIT, HGFR, MMP9, metalloproteinase inhibitor 1 (TIMP1), 
osteopontin and Toll-like receptor 2. 
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Table 4-6: Biomarkers under investigation by the NCI Early Detection 
Research Network. 
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The expression of CD44 antigen was verified by western blot; higher 
expression was observed in NAF samples derived from patients with breast 
cancer (PD and PI) (Figure 4-8). The altered expression of CD44 had been 
reported in inflammatory responses and cellular malfunctioning during tumour 
progression (Basakran, 2015) but the exact role of CD44 is not clear. The high 
expression of vimentin (VIM) in cancer, correlates well with accelerated tumour 
growth, invasion, and poor prognosis (Satelli and Li, 2011). VIM has also been 
reported as a marker for epithelial-mesenchymal transition (EMT); a process by 
which epithelial cells lose their cell polarity and cell-cell adhesion characteristics 
(Kong et al., 2011). VIM was detected in all diseased NAF samples with two 
bands as 53kDa and 51kDa while in healthy volunteer only a single band at 
53kDa was detected (Figure 4-8). VIM has three positions for glycosylation 
(Wang et al., 2012) and increased of glycosylation modification had also be 
reported in different cancers (Pinho and Reis, 2015). VIM also contains many 
modified residues with phosphorylation and acetylation (Uniprot.org, 2015).  
Hence, these modifications, may be the reason for two bands of VIM, in NAF 
samples derived from patients.  
Cytochrome P450 3A4 (CYP3A4) was detected in 2 NAF samples by 
mass spectrometric analysis, which was verified by Western blotting (Figure 
4-8). CYP3A4 has an important role in converting tamoxifen to N-desmethyl-4-
hydroxytamoxifen, resulting in a 30 to 100-fold higher affinity for estrogen 
receptor than tamoxifen (Desta et al., 2004). CYP3A4, measured by 
immnuohistochemistry in normal and cancer breast tissue biopsies was found 
to be prognostic for patient response to docetaxel (Sakurai et al., 2011, Miyoshi 
et al., 2005) and by activity assay and western blot to correlate with ifosfamide 
activation (Schmidt et al., 2004). CYP3A4 is most strongly expressed in liver, 
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but its presence in NAF may provide a unique opportunity to screen for patients 
who are most likely to respond to prophylactic tamoxifen treatment. 
In our previous study, we found the increased expression of cofilin-1 
(CFL1) and calreticulin (CALR), in matched normal and disease breast tissues 
from DCIS and IC patients (Shaheed et al., 2013b), but no change in breast 
cancer cell lines and primary cells (Chapter 3). Validation studies of NAF 
samples also indicated no significant difference was observed for CFL1, by 
western blot, between matched pair of NAF samples (Figure 4-8). CALR is an 
endoplasmic reticulum chaperone protein and involved in tumour development 
but expression of CALR is mostly dependent on cell types and clinical stages of 
disease (Lu et al., 2015). CALR was detected as a single band (48kDa) in 
patient-derived NAF samples, with decreased expression in diseased breast as 
compare to normal breast (Figure 4-8). CALR is expressed on the cell 
membrane, promotes phagocytic uptake of apoptotic and cancer cells immune 
system (Obeid et al., 2007) and on cancer cell surface is important for 
immunogenic cell death (Lu et al., 2015, Gardai et al., 2005). Hence, decreased 
expression of CALR in diseased breast may correlate with failure of the immune 
system, one of hallmark of breast cancer (Hanahan and Weinberg, 2000).  
The total protein complement encapsulates a rich source of information 
about breast tissue composition and more specifically uncovers changes in 
expression relating to disease. Overall, the composition of the selected 
ND/NAFs was dominated by proteins representative of the basement 
membrane, extracellular milieu and interstitial fluid surrounding breast cells, with 
roles in tissue stability, cell adhesion and cell-cell communication. Significantly, 
quantitative changes in these proteins may be diagnostic of disease-related 
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changes. Their increased presence in NAF of the cancer patients may be 
indicative of stromal disruption and degradation as cells migrate or proliferate 
into the surrounding normal tissue environment. Furthermore, many of the 
proteins were associated with plasma membrane activity including growth 
factors, receptors, signal transduction accessory proteins, and ion and solute 
transporters. Intracellular components, particularly mitochondrial and nuclear 
proteins were under-represented, suggesting that there is little evidence of 
cellular lysis. Serum proteins, many of which are also present in milk as part of 
normal breast function, were also prevalent and indicative of transport between 
the blood stream, interstitial fluid surrounding the cells and ductal secretions 
(Beck et al., 2015).  
The collection of NAF remains challenging. In this study, samples were 
collected by manual massage techniques or when the patients presented with 
a natural discharge. Of those volunteers who consented, the success rate in 
NAF expression was approximately 50%. In order to screen for breast cancer 
specific biomarkers across a larger cohort increased success in expression and 
collection will be required. Improved expression rates up to 90% can be 
achieved with the aid of oxytocin nasal spray (Suijkerbuijk et al., 2010), 
supported by application of manual or mechanical pumps normally used for milk 
expression by mothers with preterm infants (Jones and Spencer, 2007). 
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4.5 CONCLUSIONS 
My aim was to determine whether NAF has the potential to provide 
diagnostic value in screening for breast cancer. The study has identified many 
physiologically and oncologically important proteins which warrant a more 
expansive study of a larger cohort of patients and healthy volunteers. One of 
my aims was to understand whether analysing matched pairs would provide a 
more specific approach to detecting disease compared to normal. SDS PAGE 
showed that most matched pairs have similar protein band patterns, which was 
corroborated by the high correlation of proteomics profiles. Whilst some proteins 
were significantly different in bilateral samples, a more extensive longitudinal 
study is required to determine if these are associated with specific disease 
stages.  
An average of 1265 proteins per sample, were identified by 2D LCMS, 
with a total of 1990 unique gene products, of which 567 were common to all 8 
samples. The complement of proteins included growth factors (including EGF, 
VEGF), growth factor receptors (including EGFR, Erbb3, VEGFR) and 35 
established breast cancer markers and breast associated proteins. Matched 
sample pairs shared the greatest similarity in composition (average Pearson 
correlation coefficient of 0.91), compared to those from other cases. The paired 
samples from the healthy volunteer had a unique profile dominated by milk 
proteins. Quantitative comparison of the non-cancer with cancer cases showed 
a significant increase in extracellular matrix and cell adhesion associated 
proteins. I identified double the number of proteins previously detected in NAF, 
including 300 not detected in plasma and 24% of the proteins currently part of 
the NCI Early Detection Research Network studying breast cancer.. The 
profiling of breast cancer markers like growth factors and receptors, required 
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immunoassays to prepare plasma samples for LC-MS analysis, but a single 
quantitative, multiplexed, target method by multiple reaction monitoring mass 
spectrometry can utilise the NAF samples efficiently by decreasing the sample 
preparation steps. 
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CHAPTER 5. DEVELOPMENT OF A NOVEL 
MULTIPLEX MRM-MS ASSAY FOR 
DETECTION OF BREAST CANCER.  
5.1 Introduction 
The new developments in the field of proteomics provide a more 
focused quantitative approach to verify and validate disease-related biomarkers 
and to understand the micro-environment of a cell. Although relative quantitative 
approaches; iTRAQ, SILAC and TMT, have their merits (Elliott et al., 2009), 
“absolute” quantitative approaches are particularly important for clinical 
implementation across large patient cohorts/ national medical services. An 
emerging technique that could satisfy this requirement for targeted quantitative 
analysis of a single or panel of tumour markers, is bottom-up Multiple reaction 
monitoring mass spectrometry (MRM-MS). This approach is more precise and 
accurate for quantitative analysis of disease related biomarkers in complex 
biomaterials, such as blood plasma and tissues. MRM-MS based targeted 
protein assay, offers two main advantages over immune-assays; (i) ability to 
develop a speciﬁc assay for any protein or post-translationally modiﬁed protein 
form, without the requirement for an antibody, (ii) multiplex assay (analysis of 
many peptides representative of many proteins in a single assay). Targeted 
peptide-based protein assays provide high throughput, quantitative proteomic 
data and have common application in the systematic development of assays for 
protein biomarker verification and validation studies (Liebler and Zimmerman, 
2013). MRM-MS approach has become increasingly popular analytical 
technique in the last few years, with 126 publications in PubMed for “MRM-MS 
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and Proteomics” and average of 17 papers per month in 2017 (Figure 5-1) 
(NCBI, 2017). The advancement of technologies in MS methods and software 
for targeted quantitation, provide the analytical scientist with a transformative 
platform for systematic, reliable, and essentially universal protein quantitation. 
 
Figure 5-1: Number of PubMed Publications on MRM-MS and Proteomics. 
In the MRM-MS approach, synthetic standard peptides for target 
proteins are used to optimise the LC-MS conditions then the optimised multiplex 
assay is used to calculate the concentration of the target proteins in biological 
samples from standard calibration curves of the synthetic standards. Peptides 
with unique sequences to the target protein are selected as representatives for 
the parent protein. Ideally tryptic peptides are selected for MRM-MS assay with 
sequence-speciﬁc digestions rules (see below selection of proteins and 
peptides). Each peptide ion (precursors) undergoes fragmentation in a tandem 
MS instrument, to produce b- and y- ions (products), which are N- and C-
terminal fragments of peptide ions respectively (Liebler, 2001). Both precursors 
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and resulting speciﬁc products, contain transitions that are speciﬁc for the 
monitored peptide sequences (Kitteringham et al., 2009, Elliott et al., 2009). The 
analysis of peptides through the signals created by precursors and their 
products ions, is called multiple reaction monitoring (MRM). The peak area of 
precursors and their products ions are determined as abundance of peptides 
and serve as the basis for quantitative comparisons. MRM-MS assay can 
measure multiple transitions in single method, which allows multiplexed analysis 
of hundreds of peptides. The multiplexity of a MRM-MS assays depends on 
three things; (i) type of MS instrument (ii) number of transitions for each peptide, 
and (iii) number of peptides monitored for each target protein (Zhao et al., 
2009b, Doerr, 2013).  The multiplexity of MRM-MS assay can be increased by 
monitoring the MRM transitions during speciﬁc elution time windows for speciﬁc 
peptides. The multiplex analysis, allow systematic quantification of multiple 
proteins networks and pathways in single LC-MS run, which is not possible with 
immunoblotting assays (Zhao et al., 2009b).  
The gold standard MRM-MS assay is on based stable isotope dilution 
(SID), in which isotope labelled peptides are used as internal standard to 
measure the abundance of target peptides. Most common type of labelled 
peptides have incorporation of [13C615N2] lysine or [13C615N4] arginine (Doerr, 
2013). SID-based MRM-MS assay, provide high sensitivity, specificity and 
<20% coefficient variations because standards are usually spiked into samples 
after trypsin digestion and thus serve to decrease the subsequent analytical 
steps variations. But synthesis of peptide standards for SID is challenging to get 
isotopic purity (>95%) and also very expensive (£500-£800 per peptide), if 
monitoring large number of peptides in a multiplex assay (Liebler and 
Zimmerman, 2013). 
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The simplest and easy MRM-MS methods is based on light peptides 
(LP) or label free peptides, where standard peptides are used to draw the 
calibration curves then abundance of target peptides in biological samples, is 
measured by using these curves(Doerr, 2013). Light standard peptides are very 
easy to synthesizes with >99% purity and also very cheap (£100-£300 per 
peptide) but are analysed separately in MRM-MS assay, resulting in higher 
measurement variation, because of undetected or uncorrected variations in 
diﬀerences in peptide recovery and MS instrument performance (Liebler and 
Zimmerman, 2013). The LP-based MRM-MS assay, has been compared to the 
SID method and performed surprisingly well, with measurement CVs ranging 
from 20 to 30% while on SID method measurement CVs was 15 to 20% (Zhang 
et al., 2011). 
MRM-MS assay is performed on a mass spectrometer with multiple 
mass analysers; the first mass analyser (Q1) is set to only transmit the target 
mass (parent), the collision energy is optimized to produce charged daughters 
of the selected parent in the second mass analyser (Q2), and the third mass 
analyser (Q3) is set to transmit these daughters only. Therefore, only this exact 
parent transition is detected. In addition, the method preparation on MRM 
analysis involves parameters (collision energy, cone voltage, retention time) of 
mass spectrometry that need to be optimized for the best transmission and 
sensitivity of each transition ion and to avoid any overlaps during detection 
(Liebler and Zimmerman, 2013). 
In this study, three Waters instruments; Xevo® TQD, Micromass® 
Quattro Premier XE and Micromass® Quattro Ultima with different MassLynx 
versions (Table 5-1), were evaluated for performance (dynamic range, 
  
224 
 
sensitivity, multiplexity), based on availability at different stages during the 
project timeline, to obtaine a highly sensitive and selective method for the 
targeted biomarker proteins in complex biological samples. Waters Quattro 
Ultima is a standard triple Quadrupole mass spectrometer with Electrospray 
(ES) and Chemical ionisation (APcI) sources and Z-shaped ions pathway, which 
allow charged particles only while the neutrals and the solvent go straight. 
Micromass® Quattro Premier XE was first generation of mass spectrometer with 
T-Wave collision cell, which provide high speed MRM data acquisition. The 
Waters Xevo TQD is an advance benchtop mass spectrometer with multiple 
ionisation options, T-wave collision cell and Intellistart features.  Intellistart 
features of Xevo TQD provide; automated SIR and MRM method development, 
mass calibration, column performance test, integrated sample and calibrant 
delivery system (WatersCorporation, 2017a). The comparison of main features 
of three instruments, used in this study to develop multiplex MRM-MS assay, 
are presented in Table 5-1 (WatersCorporation, 2017a).  
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Table 5-1: Comparison of Xevo TQD, Quattro Premier XE and Quattro Ultima, used for multiplex MRM-MS assay. 
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The advantages of MRM-MS assays; multiplexing capability, low 
development cost (without cost of mass spectrometer), sensitivity (limit of 
quantification; LOQ), specificity, and high sample throughput, eliminate the need 
for antibody based assays for verification and validation of protein biomarkers 
(Liebler and Zimmerman, 2013). Recently, a large-scale MRM-MS study was 
performed on depleted human plasma to detect more than 100 putative cancer 
biomarkers like Alpha-fetoprotein (hepatocellular carcinoma), PSA (prostate 
cancer), CA-125 (non-small cell lung cancer), CA19.9 (pancreatic cancer), CA 
15.3 (breast cancer), leptin, prolactin, osteopontin, and IGF-II (ovarian 
cancer), CD98 and fascin (lung cancer),   CEA (malignant pleural effusion), 
Her-2/neu (stage IV breast cancer), Bladder Tumor Antigen (urothelial cell 
carcinoma), Thyroglobulin (thyroid cancer metastasis) (Hüttenhain et al., 
2012). This approach was impressive but depletion step added some 
drawbacks; cost to the assay, potential removal of clinically relevant high-
abundance proteins, potential increase in experimental variation and bottleneck 
in sample throughput. Furthermore, depletion can remove low molecular weight 
proteins due to weak, non-covalent binding to the depletion column or carrier 
proteins such as albumin (Percy et al., 2013). The method used by Domanski 
et al. for determination of 67 cardiovascular disease (CVD) biomarkers like 
fetuin A, factor VII, eotaxin-1, cystatin C, macrophage inflammatory protein-1β, 
matrix metalloproteinase-2 and matrix metalloproteinase-9, level in un-depleted 
human plasma, was robust (<20% CV), sensitive (accuracy 80-100%), and 
high-throughput in a 30-min analysis (Domanski et al., 2012b). While the MRM-
MS assay used by Chen et al. for the quantitation of 63 putative protein 
biomarkers of bladder cancer in human urine, had 71.1% sensitivity and 75.0% 
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specificity for differentiating bladder cancer from non-cancerous patients (Chen 
et al., 2012).  
From the published literature, there have been three MRM-MS based 
studies for the differentiation of breast cancer. First MRM-MS based study was 
conducted by Whiteaker and his co-workers in 2007 on HER2/Neu-driven 
mouse model and identified fibulin-2 and osteopontin as potential diagnostic 
biomarkers for breast cancer (Whiteaker et al., 2007). A large-scale SI-MRM-
MS assay was conducted by Kennedy et al 2014, for 319 target proteins 
expressed in 30 breast cancer cell lines. The median precision of MRM assay 
was 5.4% and the quantity of specific target proteins in breast cell lines was able 
to differentiate the molecular subtypes of breast cancer (Kennedy et al., 2014). 
Marchi et al 2016, applied MRM-MS on ER+ breast cancer tissues and serum 
and proposed programmed cell death protein 4 (PDCD4), cingulin (CGN), Ras 
GTPase-activating protein-binding protein 2 (G3BP2), and OCIA domain-
containing protein 1 (OCIAD1) as potential biomarker for ER+ breast cancer (De 
Marchi et al., 2016). But this study was more focused on expression of PDCD4, 
CGN, G3BP2, and OCIAD1 in tamoxifen resistance ER+ breast cancer. 
The lengthy time and laborious procedures, are two main draw backs 
for using cancer protein biomarkers as diagnostic approach, especially their 
veriﬁcation and validation in large numbers of patient samples. A rapid, 
sensitive, and robust analytical method is required for breast cancer biomarkers, 
to bridge this gap between discovery and pre-clinical validation. Ideally, this 
method should also be multiplexed; allowing multiple proteins to be analysed 
simultaneously in a single LC-MS experiment, to increase the throughput and 
minimize sample consumption (Liebler and Zimmerman, 2013). The focus of 
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method development in this study, was to develop a multiplex quantitative 
proteomics assay for the detection and differentiation of breast cancer and its 
phenotypes, without pre-analytical afﬁnity-based depletion or enrichment steps.  
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5.2 Selection of proteins and peptides for MRM-
MS assay 
The first step in MRM-MS assay development was the selection of 
target proteins inferred from previous discovery experiments and correlating 
scientiﬁc literature. For this study, in addition to the 6 target proteins, 2 control 
proteins were included (Table 5-2).  
In our discovery project (Shaheed et al., 2013b)on tissue biopsies, we 
identified an average of 826 proteins, of which 402 were common in 
fibroadenoma (benign tumors, three patients), DCIS (noninvasive cancer, three 
patients), and invasive ductal carcinoma (four patients). After excluding those 
originating from blood, 59 proteins were significantly changed in tumor 
compared with normal tissues, with the majority associated with invasive 
carcinomas. We found increased expression of cofilin-1 (CFL1), prostaglandin 
E synthase 3 (PTGES3), SH3 domain-binding glutamic acid-rich-like protein 3 
(SH3BGRL3), and 10 kDa heat shock protein, mitochondrial (HSPE1). The 
expression of membrane primary amine oxidase (AOC3) and hormone-
sensitive lipase (LIPE) was decreased in tissue with advance stages of breast 
cancer (Shaheed et al., 2013a).  Β-Actin and serum albumin were included as 
indicators of the cellularity and serum component present in each sample.  
The next step was to select the peptides that will be suitable for MRM 
analysis. Key steps in the workﬂow for conﬁguring MRM-MS assays for proteins 
are summarized in Figure 5-2. The speciﬁcity and accuracy of the MRM-MS 
assay requires selection of proteotypic peptides, whose sequences are unique 
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to each target protein biomarker. The MRM-MS assay is based on tryptic 
peptides, which typically range from 8 to 25 amino acids in length and should 
be reproducibly generated by a standard trypsin digestion procedure. The tryptic 
peptides usually form multiply charged positive ions to collect useful sequence 
information through MS/MS fragmentations (Lange et al., 2008, Picotti and 
Aebersold, 2012).  
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Table 5-2: List of proteins selected for MRM-MS assay and expression in breast cancer. 
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Peptides which may have post translational modifications, such as 
phosphorylation or acetylation, were avoided. Peptides with residues 
susceptible to artefactual modiﬁcations during sample preparation; methionine 
(oxidation), cysteine (oxidation and carbamidomethylation), were also avoided 
for MRM-MS assay. Peptides with missed cleavages containing sequences 
adjacent basic residues, e.g. Lys-Lys,Arg-Arg, Lys-Arg, were also avoided to 
decrease digestion variability as these are inefficiently cleaved (Lange et al., 
2008, Picotti and Aebersold, 2012). Proteotypic peptides are a very specific 
signature for the protein biomarker. Ideally, three proteotypic peptides are used 
representing the full protein sequence – N-terminal, C-terminal and middle 
regions, however this was not always possible. 
 
Figure 5-2:  Workﬂow for the design of a MRM-MS assay. 
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The selection of peptides is an empirical exercise that is the 
combination of both ideal characteristics and practical limitation. Larger proteins 
yield more signature peptides than smaller protein, so sequence of proteins play 
important role in peptide selection. If the target proteins have signiﬁcant 
sequence homology or members of closely related isoforms, then it can be 
difficult to follow to the peptide selection criteria described above. Our previous 
breast cancer study provided peptide identification of the target proteins 
(Shaheed et al 2013) (Shaheed et al., 2013a). 
An important aspect of peptides selection is to include those that have 
been previously observed in LC-MS analyses and thus are known to be 
detectable in MRM-MS assay (Picotti and Aebersold, 2012). This information 
can be gathered from previous discovery data or online repositories such as 
PeptideAtlas (PeptideAtlas, 2017), the Global Proteome Machine Database 
(GPM, 2016), the Human Proteome map (Kim et al., 2014), the MaxQuant 
Database (Schaab et al., 2012) and PRIDE (Vizcaíno et al., 2016).  For proteins 
or peptides not found in any Spectral library databases, computational software 
tools;  Skyline (MacLean et al., 2010), ESP predictor (Fusaro et al., 2009) and 
PeptideSieve (Thermo Scientific) can predict the most likely MS-observable 
peptides. These software packages are trained with MS data sets and 
fragmentation models to link characteristics of peptides to the probability of 
peptide formation and detection. Proteotypic peptide candidates for each 
protein were identified by following the steps in Figure 5-2 and described above. 
Table 5-3 represents the final panel of proteins and peptides for MRM-MS 
analysis. 
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Table 5-3: Panel of proteins and peptides for MRM-MS analysis.
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5.3 Materials and methods 
5.3.1 Chemicals and Reagents 
Where ever possible, the highest-grade chemicals and reagents were 
used in this study, and are described in Chapter 2 General Materials and 
Methods; Section 2.1 Chemicals and Reagents. All mobile phases and solutions 
including water, acetonitrile, methanol, and formic acid, were prepared with LC-
MS grade solvents from Sigma Aldrich. 
5.3.2 Synthetic peptides 
5.3.2.1 Stock peptides 
For each targeted protein, one to three associated peptides were 
selected using the rules in section 5.2 above. These peptides were purchased 
from Severn Biotech Ltd UK, with >99% purity in quantities of 2-4 mg. Prior to 
MRM-MS analysis, these peptides were resuspended in HPLC grade water and 
aliquoted as 1 nmol/uL, lyophilized and stored in -200C.  
5.3.2.2 Working solution 
Each aliquoted peptide was resuspended in HPLC grade water by 
vortexing to produce a working solution of 100 pmol/L and then further 2-fold 
serial diluted to 3 fmol/L, with HPLC water prior to LC-MS analysis. MALDI-MS 
analysis and all optimisation of MRM-MS assay was conducted with 100 
pmol/uL working peptides solution. 
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5.3.3 MALDI Mass spectrometry 
All the synthetic peptides were analysed manually on the Ultraflex II 
(Bruker), to confirm the sequence and purity of peptides. A mixture containing; 
1L of synthetic peptide (at a concentration of xx pmol/l) and 1L of α-cyano-
4-hydroxycinnamic acid MALDI Matrix, was applied on the MTP AnchorChip 
(Bruker) and analysed on the Ultraflex II. An MS spectrum was generated (100 
shots) in reflectron time-of-flight mode, to confirm the correct mass. Acquired 
MS/MS spectrum (200 shots, in LIFT mode) for individual peptide, was searched 
against SwissProt data base, using Mascot server 2.4.0, to unambiguously 
confirm the sequence of peptide and identity of the protein. 
5.3.4 Sample preparation 
All biological samples (cell lines, tissue biopsies, serum and NAF) 
(Table 5-4), were prepared, using classical bottom-up proteomics workflows, as 
previously described in Chapter 2 (Section 2.9). Briefly, urea extraction buffer 
containing protease inhibitor cocktail, was used to extract protein from cell lines, 
but for primary human tissue biopsies, a dual buffer system (RIPA and urea) 
was used followed by probe sonication (Shaheed et al., 2013a). 
5.3.5 Protein determination 
The protein concentration of each sample was measured using the 
Bradford assay (Bradford, 1976) protein quantification kit, according to the 
manufacturer’s instructions (see Chapter 2, Section X). Each protein extract 
(200 μg of protein) from cell lines and tissue biopsies, was precipitated overnight 
with 100% acetone, to remove extraction buffer, at −20°C and centrifuged for 
20 min at 13 400 rpm at 4°C. The pellet was resuspended in 8M urea in 400mM 
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ammonium bicarbonate (AMBIC) and protein concentration was again 
measured by Bradford assay, to check the efficiency of acetone precipitation. 
Each protein sample (50 µg of protein) from cell lines, tissue biopsies, 
NAF and serum, was reduced with 50 mM DTT for 15 min at 60°C, alkylated 
with 100 mM IAA at ambient temperature for 15 min in the dark, and digested 
with 3 μL of a 1 mg/mL solution of modified sequencing grade trypsin (Roche 
Diagnostics) at 37°C for 20 hrs. After digestion, each sample was desalted on 
an Isolute C18 desalting column according to the manufacturer’s instructions 
and lyophilized. A simple work flow for the preparation of samples for proteomics 
analysis is presented in Figure 5-3. 
 
Figure 5-3: Representation of proteomics work flow for the preparation of samples. 
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Table 5-4: List of samples used in this study with biopsy types and 
characteristics. 
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5.3.6 LC-MRM-MS analysis 
All experiments were performed on standard-ﬂow LC-MRM/MS 
platforms with Xevo TQD, Quattro Premier XE or Quattro Ultima triple 
quadrupole mass spectrometers (Waters, Manchester, UK). Quattro Ultima was 
coupled to Waters Alliance 2695 HPLC Separation system, Quattro Premier XE 
with Waters Acquity UPLC Separation system and Xevo TQD with on-line 
Waters Acquity I-Class UPLC separation system. The same HPLC separation 
conditions were used for separating target peptides; solvent A and solvent B 
(please see Chapter 2, Table 2-3 for full details) on a Luna C18 column (2 mm 
ID x 25 cm length, 5µm particle size, Phenomenex Inc., Macclesfield, UK). A 
linear gradient of 3 to 40% solvent B was applied for 38 minutes then 40% to 
90% for 2 minutes followed by a column wash for 10 minutes using 90% solvent 
B and column equilibration for 10 minutes using 10% solvent B prior to the next 
injection (Chapter 2, Table 2-3). To enhance chromatographic performance, the 
column was maintained at 30oC for all experiments, while the auto-sampler was 
set at 8oC. In the quantitation experiments, two blanks were run between each 
sample concentration level and the synthetic standard peptides were analysed, 
in order of increasing concentration to minimize sample carryover. All standard 
peptides and samples were analysed in triplicate. All instruments were 
controlled by MassLynx workstation software (Table 5-1) and were operated in 
the positive ion mode. The HPLC/UPLC retention time, cone voltage and 
collision energy were optimized using synthetic reference peptides (Table 5-6 
and Table 5-7). Calibration curves were prepared with the synthetic peptides 
(Table 5-3) before quantitative analysis of trypsin digests of cell lines, tissue 
biopsies, serum and NAF. 
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5.3.7 MRM-MS Data analysis 
All MRM data was processed, evaluated, and visualized with 
TargetLynx™ (Waters) Quantitative and Qualitative Analysis software, as 
described (WatersCorporation, 2017b). After automated chromatographic peak 
selection and integration by TargetLynx, MRM data was also manually verified 
to ensure correct chromatographic peak selection and integration. From the 
calibration curves of standard peptides, dynamic range, the lower limit of 
quantitation and peptides concentration values (in fmoles/µL) were determined 
in biological samples. The amount of each target protein, was calculated by 
average concentration of signature peptides in each sample. 
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5.4 Results 
5.4.1 MALDI MS and MS/MS data 
All the synthetic peptides had the expected molecular weights and the 
MS/MS data identified the peptide and protein correctly (Table 5-5). The Mascot 
score for all synthetic peptides was greater than 23 (significant, p<0.05). 
 
Table 5-5: Verification of synthetic peptides analysed by MALDI MS against 
SwissProt database. 
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5.4.2 Optimizing the MRM-MS transitions 
Prior to multiplex MRM scheduling, all target peptides were analysed 
separately to optimise LC-MS conditions. The retention time (RT) of each 
peptide and its transitions, was checked and a retention time segment was set 
to 2-4 minutes in multiplex assay, for each targeted peptide with its expected 
RT in the centre based on the individual synthetic peptides analysis. The (Figure 
5-4) represent the retention time in HPLC and charge status of target precursors 
selected for multiplex MRM-MS assay. 
 
Figure 5-4: Retention time and charge status of target precursors in multiplex MRM-
MS assay. 
The optimised values of cone voltage (CV), collision energy (CE) and 
Dwell time for Quattro Ultima and Premier XE, were determined manually while 
on Xevo TQD, a fully automated option in MassLynx (WatersCorporation, 
2017b) was used to calculate cone voltage, Dwell time and collision energy 
values for individual peptides were then verified manually (Table 5-6). From 18 
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target peptides; 15 precursors were selected with 2+-charge status and 3 
precursors with 3+-charge status, on the base of peak intensity and MRM-MS 
rules. The transition ions of each peptide were selected by following rules:  
a) precursor ions with positive charge states of 2+ or 3+,  
b) y or b series of fragment ions with a charge state of one,  
c) the three most intense fragment ions in the MS/MS spectra from 
untargeted analysis, and  
d) m/z of precursor and transition ions between 200 and 1500.  
All selected transitions were also manually checked by 
comparing the full scan MS2 data from three Waters instruments against MS2 
data acquired on MALDI MS analysis, to conﬁrm identity of transitions with the 
expected properties. The final list of all transitions selected for multiplex MRM-
MS assay is presented in Table 5-7. The transitions that produced the highest 
corresponding peaks and free from co-eluting ions, was then selected as the 
representative transition to be used in the ﬁnal MRM-MS assay. After optimising 
the LC-MS conditions (Table 5-6 and Table 5-7) for each peptide a multiplex 
MRM-MS assay was generated to check the LoD and LoQ of three instruments. 
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Table 5-6: Optimised Dwell time, Cone voltage and Collison energy (CE) conditions for multiplex MRM-MS assay, using synthetic 
peptides of target proteins.
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Table 5-7: Optimised Retention time (RT) and transitions for multiplex MRM/MS assay, using synthetic peptides of target proteins.
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5.4.3 Calibration curves of the synthetic peptides  
 
After optimising the LC-MRM/MS assay, calibration curves were 
generated by titrating a mixture of standard peptides (from 100 pmol/uL to 0.003 
pmol/uL, 2-fold serial dilutions). Three peptides of cofilin-1 (CFL1); 
LGGSAVISLEGKPL (CFL1-1), EILVGDVGQTVDDPYATFVK (CFL-1-2) and 
YALYDATYETK (CFL-1-3), had dynamic range from 25 pmoles to 0.01 pmoles 
(Limit of Detection, LoD). The Limit of Quantitation (LoQ) on Xevo TQD, for CFL-
1-1, CFL-1-2 and CFL-1-3, was 0.08 pmoles, 0.04 pmoles and 0.02 pmoles 
respectively (Table 5-8, Figure 5-5, A, B, and C). The values of linear regression 
for CFL1-1 (R2: 0.9633), CFL1-2 (R2: 0.9898) and CFL1-3(R2: 0.9945), were 
higher in Xevo TQD as compare to other two instruments, with ten points 
calibration curves (Figure 5-5.).  
10 kDa heat shock protein, mitochondrial (HSPE1) was represented by 
three peptides; FLPLFDR (HSPE1-1), SAAETVTK (HSPE1-2), and 
VLQATVVAVGSGSK (HSPE1-3). The LoD of HSPE1-1 was up to 0.0002 
pmoles (R2: 0.9846) on Xevo TQD while on Quattro Ultima was only 1.56 
pmoles (R2: 0.9552) (Figure 5-5, D). Similar kind of dynamic range was also 
observed on Quattro Ultima for other two peptides; HSPE1-2 and HSPE1-3, 
with linear regression of R2: 0.995 and R2: 0.9814 respectively (Table 5-8, 
Figure 5-5, E, F).  
The LoD for SH3BGRL3-1 was 0.001 pmoles Xevo TQD and other two 
peptides; SH3BGRL3-2 and SH3BGRL3-3, also have higher sensitivity on Xevo 
TQD, with ten and eleven points calibration curves respectively (Table 5-8, 
Figure 5-6, B, D, E).  
The dynamic range (LoD and LoQ) for two peptides of prostaglandin E 
synthase 3 (PTGES3); DVNVNFEK (PTGES3-1) and LTFSCLGGSDNFK 
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(PTGES3-2), was 0.01 pmoles and 0.3 pmoles on Xevo TQD with linear 
regression R2:0.999 and R2:0.9568 respectively (Figure 5-6, E, F).   
  
248 
 
 
Figure 5-5: Representative standard curves from the multiplex LC-MRM/MS analysis of 6 peptides (CFL1 and HSPE1). 
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Serum albumin (ALB) was represented by a single peptide; 
LVNEVTEFAK (ALB-1), in this study. The LoD for ALB-1 on Xevo TQD, was 2.4 
fmoles (R2:0.9944), with fourteen points calibration curve (Figure 5-6, F). The 
LoQ for AOC3-1 was 0.6 fmoles, while AOC3-2 and AOC3-3, had 40 fmoles, on 
Xevo TQD (Table 5-8, Figure 5-7, A, B, C). Two peptides of hormone-sensitive 
lipase (LIPE); EQALGLEPALGR (LIPE-1) and ALVYYAQR (LIPE-2), had 0.02 
pmoles as LoQ on Xevo (Figure 5-7, D, E) while single peptide of actin, 
cytoplasmic 1 (ACTB); GYSFTTTAER (ACTB-1), was up to 0.02 pmoles (LoD) 
on Xevo TQD, 0.2 pmoles on Premier XE (Figure 5-7, F).  
 
Table 5-8: Summary of LoD and LoQ all standard peptides on three platforms. 
Overall, Xevo TQD provided better dynamic range and sensitivity for 
multiplex MRM-MS assay. The dynamic range of multiplex assay was from 
average 0.2 fmoles to 20 pmoles for standard peptides, with 14 points 
calibration curves. On this basis, the biological samples (Table 5-4) were 
analysed on Xevo TQD and concentration of target peptides were determined 
by using the standards calibration curves of synthetic peptides. 
  
250 
 
 
Figure 5-6: Representative standard curves from the multiplex LC-MRM/MS analysis of 6 peptides (SH3BGRL3, PTGES3 and ALB).
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Figure 5-7: Representative standard curves from the multiplex LC-MRM/MS analysis of 6 peptides (AOC3, LIPE and ACTB). 
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A comparison of the LOD across the 3 platforms indicated that the 
Ultima was least sensitive (HSPE1-3 = 3 pmoles), then the Premier was next 
(HSPE1-3 = 0.2 pmoles), and the Xevo was most sensitive (HSPE1-3 = 0.01 
pmoles). Based on measurements at 3 pmoles the sensitivity of the three 
instruments was compared for all target peptides. T-Test statistics was applied 
on peak areas of all 18-peptides at 3 pmoles. There was significant difference 
between the sensitivity of three instruments; Xevo-TQD vs Premier XE (p value 
0.0290), Xevo-TQD vs Quattro Ultima (p value 0.0006), and Premier XE vs 
Quattro Ultima (p value 0.0108) (Figure 5-8).  
 
Figure 5-8: Sensitivity comparison of multiplex MRM-MS assay on three 
different platforms. 
Overall, the Xevo TQD provided better dynamic range and sensitivity 
for a multiplex MRM-MS assay compared to the other two platforms. The 
dynamic range was 6 orders of magnitude (0.2 fmoles to 20 pmoles, 14 points 
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calibration curves, triplicate analyses) for standard peptides, compared to The 
Premier XE (3 orders of magnitude) and Quattro Ultima (2 orders of magnitude). 
On this basis, the biological samples were analysed, and target peptide 
concentrations determined, by using the standards calibration curves prepared 
on Xevo TQD (Table 5-4). 
5.4.4 Multiplex analysis of biological materials 
Using the optimised MRM-MS assay for the 6 targets and 2 control 
proteins, the proteotypic peptide levels were analysed in biological materials - 
breast cell lines, tissues, serum, and nipple aspirate fluid, to determine; - 
a) whether the peptides can be detected  
b)  whether the levels between healthy and tumour can be differentiated, 
and  
c) whether a multiplex assay for detection of breast cancer could be 
developed.  
5.4.4.1 Breast cell lines 
Initially, the multiplex assay was applied to eight breast cell lines; MCF-
7, ZR-75, MDA-MB-453, MDA-MB-468, MDA-231, HB2, MCF-10A and HMEC. 
All cell lines were analysed in triplicate on the Xevo TQD by optimised MRM-
MS assay (Supplementary Table 5.1).   
All, three peptides of cofilin-1; CFL1-1, CFL1-2 and CFL1-3, were 
detected and quantified in breast cell lines with dynamic range of 128.5 fmoles 
to 425.90 fmoles in 1.25µg of digest used for LC-MRM-MS analysis (Table 5-9). 
The expression of cofilin-1 was significantly higher (p<0.05) in a cell line 
representative of claudin-low type breast cancer (MDA-MB-231) as compared 
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to HMEC (Figure 5-9,A). The coefficient of variations (CV) of all peptides of 
cofilin-1 in triplicate analysis, was less than 8% (Table 5-9). 
 
Table 5-9: Replicate analyses of three peptides of Cofilin-1 in breast cell lines. 
Three peptides of 10 kDa heat shock protein, mitochondrial (HSPE1), 
were detected in all breast cell lines with high expression (p<0.05) in luminal 
type (MCF-7, ZR-75, and MDA-MB-453 breast cancer cell lines, as compare to 
HMEC. There was also significant difference (p value was 0.01) between 
luminal and basal type breast cancer phenotype ( Figure 5-9, B, Supplementary 
Table 5.1). In MCF-7, SH3BGRL3-1, SH3BGRL3-2 and SH3BGRL3-3 were 
detected with highest amount 25.77 fmoles, 16.93 fmoles and 26.13 fmoles 
respectively (Supplementary Table 5.1). So, the average amount of SH3BGRL3 
was significantly higher (p value 0.018), in luminal A (MCF-7) type breast cancer 
compared to HMEC ( Figure 5-9, D Supplementary Table 5.1). Only one peptide 
of prostaglandin E synthase 3 (PTGES3), was detected in all cell lines. T-test 
analysis, of the five cell lines; MCF-7, MDA-MB-453, MDA-MB-231, HB2 and 
MCF-10A, had p values <0.0001 compared to HMEC, while ZR-75 and MDA-
MB-468 had p values <0.001 and <0.01 respectively (Figure 5-9, C 
Supplementary Table 5.1). 
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Membrane primary amine oxidase (AOC3) levels, were determined by a single 
peptide; AOC3-3, because AOC3-1 and AOC3-2 were not detected in any 
breast cell lines. On the base of triplicate values of AOC3-3, I determined the 
amount of AOC3 in breast cell lines, with highest amount of 68.93 fmoles in 
MCF-7 and 56.73 fmoles in MDA-MB-231 and were significantly different, 
p<0.0001 and p= 0.04, respectively compared to HMEC levels (Figure 5-10, A). 
From two peptides of hormone-sensitive lipase (LIPE), only LIPE-2 was 
detected in cell lines with highest amount of 12.07 fmoles in the Claudin-low 
breast cell line (MDA-MB-231, p value <0.01) (Figure 5-10, B). In breast cell 
lines, the amount of actin, cytoplasmic 1 (ACTB), was in range from 350.80 
fmoles to 1990.0 fmoles for ZR-75 and MDA-MB-231 respectively. On T-Test 
analysis, I found that only ZR-75, has significant difference (p< 0.05), from 
control cell line (HMEC) Figure 5-10, C). 
As expected, serum albumin (ALB), was not detected in any analysis of 
Breast cell lines. Using this multiplex MRM-MS assay, I quantified 6 target 
proteins and one control protein in breast cell lines.  
  
256 
 
 
Figure 5-9: Expression of Cofilin-1, HSPE1, SH3BGRL3 and PTGES3 in breast cell lines.
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Figure 5-10: Expression of AOC3, LIPE, ACTB and ALB in breast cell lines. 
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5.4.4.2 Tissue biopsies 
In this study, I used a panel of 8 breast tissue samples from 4 patients 
with breast cancer. From each individual, 2 biopsies were collected, one 
cancerous and the other non-cancerous as determined by histopathological 
examination. Among the 4 patients, 1 patient had fibroadenoma (PTT1), 2 were 
classified as having invasive carcinoma (IC) (PTT3 and PTT4), and 1 as mixed 
ductal carcinoma in situ (DCIS) and invasive carcinoma (IC) (PTT2). Detailed 
information about these tissues is provided in Table 5-4 and each tissue biopsy 
was measured in technical triplicates. I calculated the dynamic range of target 
proteins in breast tissues based on their prospective proteotypic peptides and 
calibration curves (Supplementary Table 5.2). 
The average amount of three peptides of cofilin-1 was high in tumour 
tissues, collected from invasive carcinoma patient (PTT3) compared to matched 
normal tissue (p value <0.0001). but significantly decreased in fibroadenoma 
patient (PTT1) (p value 0.0027). (Figure 5-11). Two peptides of 10 kDa heat 
shock protein; HSPE1-1 and HSP1-3 were detected in all tissue biopsies while 
HSPE1-2 was only detected in PTT1 (fibroadenoma) and PTT3 (invasive 
carcinoma). The highest amount of HSPE1-3 (23.93 fmoles), was observed in 
PTT3-T while HSPE1-2 was also detected in same sample at a high amount of 
7.00 fmoles (Supplementary data section 5.1). The average amount of HSPE1, 
was significantly higher in cancerous tissues of invasive carcinoma patient 
(PTT3, P value 0.0098) as compare to normal tissues (Figure 5-11, B). The 
expression of SH3 domain-binding glutamic acid-rich-like protein 3 (SH3BGR3), 
was significantly different between matched diseased and normal tissues for the 
fibroadenoma patient (PTT1) (p<0.004) where it was decreased, but was 
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increased in invasive carcinoma patients PTT3 (p<0.0001) and PTT4 (p<0.05) 
Figure 5-11, D). 
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Figure 5-11: Expression of CFL-1, HSPE1, PTGES3 and SH3BGRL3 in breast tissue biopsies. 
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Hormone-sensitive lipase (LIPE) and Membrane primary amine oxidase 
(AOC3), were also quantified in all tissue sample. No significant difference was 
observed between normal and tumour tissues for both proteins (LIPE and 
AOC3), but expression level was different between patients (Figure 5-12, A, B, 
Supplementary table 5.2). 
The amount of Actin, cytoplasmic 1 (ACTB), was high in PTT2, both 
normal (142.37 fmoles) and tumour (111.13 fmoles) sample but significant 
difference (p value 0.003), was only observed in PTT4 with amount of 9.20 
fmoles in normal and 52.93 fmoles in tumour (Figure 5-12, C). The average 
dynamic range (LoD and LoQ) of Serum albumin in tissue biopsies was from 
3.33 fmoles to 232.1 fmoles in triplicate analysis. In three patients, PTT1, PTT3 
and PTT4, a significance difference was observed in matched normal and 
tumour pairs (Figure 5-12, D) (Supplementary table 5.2).  
  
262 
 
 
Figure 5-12: Expression of ACTB, ALB, LIPE and AOC3 in breast tissue biopsies.
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5.4.4.3 Serum 
In serum samples (Table 5-4), only 8 peptides for 6 target proteins were 
detected (Supplementary table 5.3). Furthermore, only single peptides were 
detected for cofilin-1, prostaglandin E synthase 3, and heat shock protein 10 - 
CFL1-2, PTGES3-1 and HSPE1-3 respectively. There was no significance 
difference between healthy volunteers and breast cancer patients, for Cofilin-1 
and HSPE1 (Figure 5-13, A,B) and AOC3 (p value 0.4127, Figure 5-14, A). The 
amount of PTGES3 was high (p value 0.0357) in serum derived from cancer 
patients; 2.62 fmoles compared to healthy volunteers; 1.34 fmoles (Figure 5-13, 
C).  
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Figure 5-13: Expression of CFL1, HSPE1, PTGES3 and SH3BGRL3 in serum samples. 
  
265 
 
 
Figure 5-14: Expression of AOC3, LIPE, ACTB and ALB in serum samples.  
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5.4.4.4 Nipple aspirate fluid 
Eight NAF samples were analysed, matched pairs collected from both 
breasts of 4 patients (Table 5-4). All samples were analysed in triplicate and the 
amount of target proteins, was calculated from calibration curves of standard 
peptides. Of a total of 18 peptides investigated 9 were detected above the LoQ, 
13 were at the LOD and 5 were not detected. As a consequence, nine peptides 
representing 7 target proteins, were quantified (only AOC3 was omitted) in the 
NAF sample with MRM-MS assay (Supplementary table 5.4).  The average 
amount of cofilin-1 was significantly high (p value 0.04) in breast with ductal 
carcinoma (PTN3) compared to normal breast (Figure 5-15, A). The average 
amount of HSPE1, was high (12.70 fmoles) in breast with ductal carcinoma; 
PTN3, as compare to normal breast (1.25 fmoles), with p value <0.0001 (Figure 
5-15, B). The expression of PTGES3 was decreased significantly in disease 
breast of PTN3 (p value <0.0001) and PTN4 (p value 0.007) (Figure 5-15, C). 
SH3BGRL3-3, was detected and quantified in NAF, with decreased expression 
(p value o.453) in breast with lobular carcinoma (PTN2) (Figure 5-15, D). The 
expression of serum albumin (ALB) was high (p value 0.002) in breast with 
fibrocystic changes (PTN1-L) as compared to breasts with cancer (Figure 
5-16,D).   
Highest amount (4.23 fmoles) of Hormone-sensitive lipase (LIPE), was 
observed in normal breast of PTN3, with p value <0.0001, compared to breast 
with tumour. (Figure 5-16,B). The average amount of actin, cytoplasmic 1 
(ACTB) in NAF was from 14.27 fmoles to 123.77 fmoles in all NAF samples, 
with clear difference in left and right breasts. The significant difference was 
observed in PTN2 (pvalue 0.0196) and PTN3 (pvalue 0.0189) (Figure 5-16,C).
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Figure 5-15: Expression of CFL1, HSPE1, PTGES3 and SH3BGRL3 in nipple aspirate fluid. 
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Figure 5-16: Expression of AOC3, LIPE, ACTB and ALB in nipple aspirate fluid. 
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5.4.4.5  MRM-MS assay coefficient of variation in biological samples 
In breast cell lines, the CV (%) for target proteins was in dynamic range 
of 1% to 35% with median of 6% for all quantified proteins (Figure 5-17). The 
median CV for tissues was 10% but two proteins; AOC3 and LIPE, have higher 
CV of 55%, in one patient (PTT3). The dynamic range of CV of MRM-MS in 
serum samples, was from 3% to 74% but median for all target proteins was 
17%.  One peptide of LIPE had higher CV (%) for three NAF samples, which 
resulted 88%, 81% and 78% of CV for target protein (LIPE) in these samples. 
The average CV in NAF samples was 18% for all quantified proteins (Figure 
5-17). 
In this study, the multiplex MRM-MS assay for 8 target proteins, had LoD and 
LoQ in fmoles/1.25µg of lysate, with median CV% of 6% in breast cell lines and 
10% in tissue biopsies. This sensitivity was achieved without depletion and 
enrichment of proteomics samples. A multiplex immuno-MRM assay developed 
by Schoenherr et al 2012, for quantification of estrogen receptor (ER) and 
human epidermal growth factor receptor 2 (HER2) levels in breast cancer cell 
lines and tissue biopsies, had LoD fmoles/mg of lysate and reproducibility of 
method was median coefficients of variation of approximately 10% in breast cell 
lines and 23% in tissue biopsies (Schoenherr et al., 2012)
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Figure 5-17: CV values for the multiplexed MRM-MS assays measured in breast cell lines (BCL), tissue biopsies, serum, and nipple aspirate fluid (NAF), 
consisting of targets (18 peptides, 8 proteins).
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5.5 Discussion 
Detection of secreted disease biomarkers in biological fluids by 
analytical methods is required to improve cancer diagnosis and prognosis in a 
clinical setting. These methods should be sensitive, robust, and rapid, as well 
as multiplexed assays. The current paradigm in protein biomarkers studies is 
that a panel of proteins may provide increased diagnostic accuracy compared 
to a single protein biomarker (Addona et al., 2011, Neagu et al., 2011).  We, 
and others, have found that a multiplexed assay has a higher diagnostic and 
prognostic value than screening for individual protein biomarker (Domanski et 
al., 2012a, Chen et al., 2012, Shaheed et al., 2013a). Based on these findings, 
a targeted, multiplexed LC-MRM/MS approach was developed, with synthetic 
peptides for the quantitation of a panel of candidate breast cancer biomarker 
proteins in un-depleted and non-enriched human cell lines, tissue biopsies, 
serum and NAF. 
The best method for comparison of peptide or protein in a biological 
system, is stable isotope (SI) dilution, in which a stable isotope-labelled 
synthetic peptide is used as an internal standard for each target peptide. 
SI−MRM assay provides the best analytical performance and characteristics for 
all targeted peptide, with typical linearity over 4−5 orders of magnitude, 
coefficient of variation (method reproducibility) <20%, and limits of detection 
(LoD) in cell and tissue lysates in the range of femtomoles per milligram of 
protein (Addona et al., 2009, Keshishian et al., 2009, Zhang et al., 2011). The 
main disadvantage of SI-MRM assays is the cost and high-purity isotope-
labelled peptides for a multiplexed assay (Liebler and Zimmerman, 2013). 
QconCAT polypeptides provide a more economical way to generate heavy 
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isotope-labelled peptides in a multiplex assay (>100 target proteins) (Chen and 
Turko, 2014, Brownridge et al., 2012). An advantage of using QcanCAT 
polypeptides is to minimise the sample processing variations, that can be 
introduced due to trypsin digestion, because QconCAT reference standards and 
biological samples are mixed together before digestion step (Brownridge et al., 
2012). However, QconCAT technology is more complicated; (i) selection of 
target peptides, (ii) synthesis of genes for target peptides (iii), sub-cloning the 
genes in to an expression vector, (iv) expression of heavy isotope labelled 
polypeptide, and time consuming construction (2-3 months) (Meng and 
Veenstra, 2011, Chen and Turko, 2014). The need for a more cost-effective 
multiplex strategy for studies involving large number of peptides or proteins led 
to the development of a “light” peptide approach, in which calibration curves of 
standard peptides are prepared before and after measurement of trypsin-
digested biological samples.  In this latter case, the cost of synthetic peptides 
standards is considerably less for the high purity (>99%) products and in 
amounts suitable for assay development (1 to 4 mg) (Zhang et al., 2011, Liebler 
and Zimmerman, 2013). The light peptides based (LP) MRM assay is the best 
choice in such situation, as this assay can be optimised quickly without the cost 
and delay involved in obtaining the SI labelled peptides. 
LP-MRM approach seems straight forward but precise quantification of 
target peptides can be challenging because samples and standards peptides 
are analysed separately on LC-MS. So, variations introduced due to LC-MS 
fluctuations (ionisation and solvents mixing) or background matrix of samples, 
result in ion suppression or enhancement of co-eluting analytes from one 
analysis to the other and also within one LC-MS analysis (Lange et al., 2008). 
Despite these limitations, LP-MRM quantification can be performed with high 
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accuracy, if the sample processing is well controlled and the samples are closely 
related in protein composition and background matrix (Wasinger et al., 2013, 
Liebler and Zimmerman, 2013). 
To develop a multiplex MRM assay, the performance of the three 
Waters triple-quadrupole mass spectrometers; Xevo TQD, Premier XE and 
Quattro Ultima, for 18-target peptides was compared. All target peptides were 
analysed separately to optimise LC-MS conditions. To increase the multiplexity 
of MRM-MS assays, a timed acquisition mode, termed scheduled MRM 
acquisition, can be performed to increase the number of peptides analysed in a 
single chromatographic run, while maintaining the highest degree of sensitivity 
and MRM transition duty cycle (Stahl-Zeng et al., 2007). In scheduled MRM 
analysis, the transitions of target peptides were acquired only during a deﬁned 
elution time window. Hence, the retention time (RT) of each peptide must be 
established and the LC conditions must be stable and reproducible. In optimised 
MRM-MS assay, all transitions of a target peptide were acquired within two 
minutes of elution time window (Figure 5-4). 
Quattro Ultima is operated with MassLynx NT, which allowed only 
monitoring of 30 MRM transitions in a single method (WatersCorporation, 
2017b), so I created two methods; 9 peptides or 27 transitions for each method. 
In that case, Quattro Ultima consumed double time and samples compare to 
Xevo TQD and Premier XE. The T- Wave (travelling Wave) feature in the Xevo-
TQD and Premier XE instruments, improved the sensitivity, selectivity and 
speed of analysis on both instruments compared to the Quattro Ultima 
(WatersCorporation, 2017a). The Waters Xevo TQD also featured; IntelliStart 
Technology, digital detector with dynamic range of 4 x 106, and scan speed up 
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to 10,000 Da/s, which provided the high speed and high quality data for 
qualitative and quantitative applications (WatersCorporation, 2017a). In the 
optimised MRM-MS assay developed here, the dynamic range of standard 
peptides at 20 pmoles/µL, was 1 x 106 for HSPE1-1 while for all other peptides 
was an average 5 x 105 on Xevo TQD. The average dynamic range of Quattro 
Ultima and Premier XE, was 1 x 104 and 1 x 103 respectively, for the same 
concentration of standard peptides. The calibration curves of target peptides 
generated on Xevo TQD, had better LoD and LoQ as compare to Premier XE 
and Quattro Ultima. A limitation of Quattro Ultima and Premier XE was the 
relatively low resolution of precursor m/z measurements, which may allow 
interference from background contaminants in complex mixtures. Both 
instruments were also limited by their duty cycle, the rate at which transitions 
can be acquired with an acceptable signal-to-noise ratio (WatersCorporation, 
2017a, Liebler and Zimmerman, 2013).  
A plasma study conducted by the National Cancer Institute (NCI), 
across multiple laboratories and instrument platforms, found that multiplexed SI-
MR-MS based assays were highly reproducible and transferable across 
laboratories, achieving CV’s in the range of 10−25%. The LoD and LoQ values 
were in the high hundreds of nanograms per millilitre to low micrograms per 
millilitre concentration ranges in unfractionated plasma samples (Addona et al., 
2009).  In this study, the reproducibility (median CV) of LP-MRM-MS assay in 
serum and NAF sample, was 17% and 18% respectively. The reproducibility 
(CV%) of MRM assay can be improve by using stable isotope labelled peptides 
and increasing the LC-MS analysis time or decreasing the amount of sample 
being analysed to minimise the interference of background matrix (Doerr, 2013).  
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The Xevo TQD-optimised MRM-MS assay for breast cancer-associated 
biological samples was evaluated. In breast cell lines, total 7 proteins were 
quantified with 13 peptides, in all eight cell lines in triplicate analysis. The 
sensitivity of assay was highest in tissue biopsies; 14 peptides were above LoQ 
that represented 7 target proteins. In NAF samples more peptides and proteins 
were quantified compared to serum sample (Figure 5-18).  NAF is secreted 
continuously from breast’s ducts to maintain the normal physiology of breast 
(Sauter et al., 1997a). Thus, protein biomarkers secreted from the primary 
tumour have high concentration in ducts before travel in the lymphatic and/or 
blood systems (Gilbey et al., 2004), which mean NAF represent a true micro 
environment of breast physiology. In our MRM-MS multiplex assay, more 
proteins and peptides were detected in NAF than in serum (Figure 5-18), which 
make it an ideal biofluid, for clinical verification and validation of protein 
biomarkers in breast cancer patients.  
 
Figure 5-18: Sensitivity of multiplex MRM-MS assay in breast cell lines (BCL), 
tissues biopsies, serum, and nipple aspirate fluid (NAF). 
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One peptide of PTGES3; LTFSCLGGSDNFK, selected because of the 
limited availability of unique peptides, but was less than ideal. As part of the 
Mudpit strategy, protein samples were reduced with dithiothreitol and treated 
with iodoacetamide to modify cysteine and prevent recombination of disulphide 
bridges of cysteine, (Weerapana et al., 2010). As cysteine is very reactive and 
prone to oxidation, it may have been modified prior to sample preparation, 
changing the peptide mass and preventing it from being detected in biological 
samples.  
The sensitivity of the MRM-MS assay depended on several factors, 
including sample type (e.g., bioﬂuids, tissue, cell line, and immune-precipitates) 
and whether any enrichment or fractionation techniques were incorporated prior 
to MRM analysis. In MRM-MS assay, the high abundant co-eluting peptides in 
complex mixture scans can suppress transitions of a targeted peptide. The 
fractionation of peptides with strong cation exchange chromatography and 
depletion of high abundance proteins by immunoaffinity, can increase the LoD 
and LoQ of a MRM-MS assay in more complex samples like tissues and serum 
but extra steps can lead to greater technical variation (Keshishian et al., 2009, 
Fortin et al., 2009).  
Cofilin-1 plays an important role in breast cancer invasion and 
metastasis (Wang et al., 2007). The expression of cofilin-1 is increased in breast 
cancer tissue biopsies compared to normal (Wang et al., 2007, Shaheed et al., 
2013a). A study conducted, on 30 lung cancer patients and 30 healthy 
volunteers, found high expression of CFL1 in serum collected from patients with 
stage III and IV lung cancer compared to stage II patients and healthy volunteers 
(Zheng et al., 2013). In this study, I found that the amount of cofilin-1 was high 
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in tumour tissues collected from invasive carcinoma patients, while no 
significance difference was observed in serum samples collected from breast 
cancer patients and healthy volunteers. One matched pair of NAF samples; 
PTN3, collected from ductal carcinoma patients, had high expression cofilin-1 
in diseased breast as compare to normal breast. Cofilin-1 showed increased 
expression in diseased sample compared to normal and can used as a potential 
biomarker for early detection of breast cancer (Satoh et al., 2017) and a large-
scale study will provide more confidence about its sensitivity and specificity.  
The co-chaperone PTGES3 regulates estrogen receptor (ER) and 
promotes tumour cell adhesion and invasion (Oxelmark et al., 2006). In our 
pervious study, along with other published research, we reported the increased 
expression of PTGES3  in breast cancer (Simpson et al., 2011, Shaheed et al., 
2013a). PTGES3 was also detected with high concentration in all serum 
samples derived from breast cancer patients. But in nipple aspirate fluid, the 
amount of PTGES3 was decreased in breasts with ductal carcinoma as 
compare to healthy breast. The altered expression of PTGES3 in cell line, 
tissue, serum and NAF samples, suggested its status as biomarker may be 
specific for Luminal type breast cancer (Katsyv et al., 2016). Chaperone protein; 
HSPE1, was reported to decreased in basal type cancer as compare to luminal 
type breast cancer (Coumans et al., 2014). High expression of HSPE1 was also 
observed in diseased tissues and NAF, collected from two invasive carcinomas 
and one ductal carcinoma patients respectively. So, increased expression of 
HSPE1 could be potential biomarker for Luminal and claudin-low type breast 
cancers (Lianos et al., 2015).  
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The increased expression of SH3 domain binding glutamic acid-rich 
protein like 3 (SH3BGRL3) promotes the epithelial-mesenchymal transition, cell 
migration, and proliferation in EGFR+ bladder cancer (Michalak et al., 2016). In 
this study, we found higher expression of SH3BGRL3 in ER+ breast cancer cell 
lines (MCF-7) and no significant expression difference was observed in EGFR+ 
breast cell lines (MDA-MB-453, MDA-MB-468 and MDA-MB-453). The 
expression SH3BGRL was decreased in NAF samples collected from diseased 
breast compared to healthy.  
The expression of AOC3 and LIPE had been reported to decrease in 
invasive lobular and ductal carcinomas of the breast (Zhao et al., 2004, Kim et 
al., 2015). Low expression was also observed in two NAF samples collected 
from patients lobular and ductal carcinomas, suggesting both proteins as 
potential biomarkers for breast cancer. The expression of albumin (ALB) was 6-
fold less in NAF samples compared to serum and showed no relationship to 
breast cancer. This observation suggested, less plasma content in NAF 
samples, therefore enabling the omission of immunodepletion to see less 
abundant proteins, and making NAF a better option for verification and 
validation of protein biomarkers. The control for cellularity, ACTB (Guo et al., 
2013), had highest amount in breast cell lines average of 1.2 pmoles in 1.25µg 
of cell lysate while in NAF was quantified as 40 fmoles indicating a lower level 
of cellular components in NAF samples.  
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5.6 Conclusions 
In this study, a rapid and robust MRM-MS assay was established using 
synthetic standard peptides for the multiplexed quantitation of 8 candidate 
proteins in total extracts from human breast cell lines and un-depleted (without 
removal of the most abundant proteins such as serum albumin) tissue biopsies, 
and liquid biopsies serum and nipple aspirate fluid.  The optimised protocol for 
MRM-MS of cofilin-1, PTGES3, HSPE1, SH3BGRL3, AOC3 and LIPE in breast 
cancer biopsies (cell lines, tissue, serum and NAF) described here provides an 
approach for a large-scale investigation of co-relation expression (i.e 
biomarkers amount vs patient’s characteristics; grade and histological type 
and/or tumour differentiation status, lymph node status, metastasis, etc.). 
Moreover, its implementation in a retrospective cohort and the results showed 
here are a significant step toward the validation process of these proteins as 
prognostic biomarkers. Despite the high-to-moderate abundance levels of these 
target proteins in nipple aspirate fluid, they remained “putative” biomarkers that 
need further verification and validation before clinical use. Addition of other 
diagnostic and prognostic biomarkers in to this multiplex assay from the NAF 
discovery work (Chapter 4), could help to improve the sensitivity and specificity 
of an assay for breast cancer detection. More proteins and peptides were 
detected and quantified in NAF compared to other samples. Nipple aspirate fluid 
was the preferred sample source for investigation of breast cancer since its 
collection is non-invasive and has the potential to provide a comprehensive 
picture of the physiological status of an individual through comprehensive 
quantitative proteomic approach. 
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CHAPTER 6. FINAL DISCUSSION AND FUTURE 
DIRECTIONS 
6.1 Discussion 
Proteomics has a potential value to study the structure and function of 
proteins in complex biological samples. Large scale quantitative proteomics 
analysis to understand cellular function is now possible due to developments in 
MS, computational algorithms and biochemical technologies. Advancements in 
protein fractionation and labelling techniques have also improved identification 
of less abundant proteins in biological samples. Studies characterising breast 
cancers prior to these investigations were limited by technological capabilities 
or only focused on the proteome of tissue biopsies and immortalised cell lines 
(Geiger et al., 2012, Lawrence et al., 2015) for diagnostic and prognostic 
biomarkers of breast cancer, not truly convenient for the clinical environment. 
Because of heterogeneity of breast cancer, it is challenging to differentiate 
between each subtype on the basis of a single gene or protein. Therefore, a 
group of markers may serve as a more specific and sensitive signature for 
diagnosing different types of breast cancer. The application of some of the latest 
advancements in MS proteomics (Orbitrap Fusion, MRM-MS), to carefully 
acquired breast cancer biopsies, has provided data-rich characterisation of the 
disease.    
Before identifying phenotype-specific markers, one of the fundamental 
property of iTRAQ quantification, the dynamic range compression of reporter 
ions, was investigated. (Chapter 3). Orbitrap Fusion, using SPS mode for 
isobaric tagging experiment (MS3 for reporter ion measurements), exhibited 
improved dynamic range due to reduced background chemical noise, compared 
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to the Ultraflex II. Furthermore, the Orbitrap Fusion acquired signiﬁcantly more 
peptide species per unit time and with greater accuracy making it the instrument 
of choice for quantitative proteomic analysis.  
We use the iTRAQ data to examine the functional networks of proteins 
within the established breast cancer subtypes. We reasoned that analysis at the 
protein level, rather than genes and transcripts, may more directly reflect 
microenvironment of breast cancer. There is a low correlation between the copy 
number of gene and relative expression at proteins because many genomic 
variations are not or only partially translated to the protein level (Geiger et al., 
2010, Zhang et al., 2014a, Tyanova et al., 2016). The correlation between 
mRNA and protein level is also not clear, therefore only studying mRNA does 
not necessarily reflect  active cellular processes and functions (Nagaraj et al., 
2011, Schwanhäusser et al., 2011).  From our proteomics results of 
phenotypically well-characterised breast cancer cell lines, 2467 proteins were 
identified on both instruments (Orbitrap Fusion and Ultraflex II), of which 1430 
were common. We demonstrated that analysis at the proteomics level could 
differentiate coherent changes in cellular and molecular processes, and identify 
key molecular networks associated with each subtype of breast cancer. To that 
end, protein signatures were identified for five different phenotypes of breast 
cancer; luminal A (MCF-7, 34 proteins), luminal B (ZR-75, 42 proteins), HER2 
(MDA-MB-453, 40 proteins), basal like (MDA-MB-468, 91 proteins) and the 
largest signature (499 proteins) associated with the stem cell-derived cancer 
cell line, MDA-MB-231 (Chapter 3, section 3.3.5). Previously, direct 
comparisons of cancer phenotypes and protein levels in large-scale proteomics 
projects have shown signature proteins in cancer cell lines (Nagaraj et al., 2011, 
Tyanova et al., 2016, Geiger et al., 2010). But these studies were more focused 
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on comparison within transfected cell lines. Our study, which was a comparison 
of HMEC against cancer cell lines, showed that that expression levels of 
proteins are not directly related to breast cancer. In particular, the proteomic 
data recapitulated the down-regulation of 56 proteins including ALDH1A3, 
ALDH1L2, KRT15, KRT16, KRT17, KRT6B, and up-regulation of 18 proteins 
include TPD52, CDK1, MCM2, MCM3, MCM5, in all breast cell lines, normal 
and tumourogenic, compared to HUMEC. Hence, it is possible that expression 
of these proteins was not related to breast cancer, but rather to cell culture 
conditions or generic cell immortalisation processes. Therefore, selection of the 
right control was important to determine the proteomic signatures of breast 
cancer subtypes. Our iTRAQ based data constituted a system wide, quantitative 
view of the proteomes of the breast cancer cell lines, which served as the basis 
for further downstream biological interpretation and clinical validation using 
biopsy samples. 
Breast secretions (nipple aspirate fluid [NAF]), as a potential diagnostic 
value in breast cancer were investigated (Chapter 4), as they are produced by 
epithelial cells lining breast ducts and lobules which are most commonly 
associated with the disease. Matched pairs of NAF were characterised for 
protein amount and SDS PAGE profile. SDS PAGE showed that most matched 
pairs have similar protein band patterns, which was corroborated by the high 
correlation of proteomics profiles. Four pairs from a healthy individual, and 
patients with benign phyllodes, ductal carcinoma in situ (DCIS) and invasive 
carcinoma, were analysed with an Orbitrap Fusion mass spectrometer using a 
label-free quantitation strategy (Chapter 4). We have identified more than 
double the number of proteins previously detected in NAF making this the most 
complete proteomic study to date. Within the NAF proteome, were 300 proteins 
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not found in plasma and 24% of the proteins currently part of the NCI Early 
Detection Research Network studying breast cancer (https://ednr.nci.nih.gov). 
The presence of drug metabolising enzymes in NAF, such as CYP1A1, could 
provide useful prognostic markers for the patient’s responsiveness to 
chemotherapy.  
The NAF database was explored for proteins that had previously been 
identified as members of the phenotype-specific clusters, to determine if NAF 
could provide indicators of cancer phenotype as well as stage (Chapter 3). A 
total 784 proteins were common in NAF and breast cancer cell lines, including 
324 associated with our specific breast cancer phenotype signatures (Table 
6-1). Four luminal A (FBP1, KRT18, KRT8, and S100A16) 10 luminal B, 7 
HER2-type, 17 basal-like and 64 claudin-low signature proteins, were identified 
in all NAF samples.  
A total 784 proteins were common in NAF and breast cancer cell lines, 
including 324 associated with our specific breast cancer phenotype signatures. 
In NAF, there was also 56 proteins which differentiate between luminal and 
basal type of breast cancer (Chapter 3, Section 3.3.5.1), including CD44 
(already a developed biomarker for colon and breast cancer (Basakran, 2015)) 
and Von Hippel-Lindau disease tumour suppressor (VHL, associated with 
inherited familial cancer syndrome; retinal, cerebellar and spinal 
hemangioblastoma, as well as renal cell carcinoma and pancreatic tumours) 
(Stolle, 2016).  Analysis of these potential phenotype markers would provide an 
excellent focus for further validation. 
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Table 6-1: Comparison of phenotype signature with clinical stages of breast cancer. 
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            We also identified 183 proteins that are differentially expressed in the 
healthy volunteer compared to the patients with malignancies (benign, DCIS and 
invasive carcinoma) NAF samples, which may correlate with phenotype-specific 
markers (Table 6-2). Of these, 45 proteins had significantly different levels (t-test 
p<0.05) in the healthy volunteer (both paired samples) relative to the patients with 
disease (3 matched pairs). These may be predictive biomarkers for different 
phenotypes of breast cancer and could be the very earliest measures of 
tumourigenicity. The NAF from the diseased patients have 138 potential 
phenotype biomarkers that were significantly changed compared to the healthy 
volunteer (7 for luminal A, 9 for luminal B, 11 for HER2, 14 for basal-like and 52 
for claudin-low type). Therefore, these panels of phenotype-associated proteins 
could provide extra value in disease stratification, also in terms of disease stage. 
This provides an excellent focus for screening a larger series of NAF samples to 
define their role in breast cancer early detection, diagnosis and prognosis. 
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Table 6-2: The expression of phenotype specific proteins in healthy and cancerous NAF. 
The collection of NAF is non-invasive compared to tissue biopsies and 
circumvents the limitations of plasma (e.g. 10 orders of magnitude in protein 
abundance). So NAF is a valuable source for biomarker discovery associated 
with origin of the disease and provides important information about cancer 
progression and specific to different phenotype of breast cancer.  
The collection of NAF sample from the same donor can be challenging in 
expression and collection. This process can be improved to 90% of cases with 
the aid of oxytocin nasal spray (Suijkerbuijk et al., 2010), supported by application 
of manual or mechanical pumps normally used for milk expression by mothers 
with preterm infants (Jones and Spencer, 2007). Oxytocin is a peptide hormone 
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plays a role in child birth and with stimulation of the nipples from breastfeeding 
(Chiras, 2013). 
NAF contained many breast cancer markers, growth factors and 
receptors that have been detected in plasma, but required a number of 
independent assays (immunoassays and mass spectrometry). We evaluated the 
effectiveness of three LC/MRM-MS platforms (Quattro Premier, Quattro Ultima 
and Xevo TQD) for the development of a single multiplexed assay, using a 
preliminary panel of 8 biomarkers (Chapter 5). Furthermore, we compared the 
MRM and iTRAQ results of selected putative biomarkers (CFN1, PTGES3, 
HSPE1) with Western blotting using breast cancer cell line extracts (Figure 6.1). 
In all three cases, the MRM and iTRAQ results exhibited very encouraging 
correlation in expression for each cell line relative to HMEC controls, but poor 
correlation with Western blotting. As Western blotting is based on completely 
different methodology this is not unexpected. The average of CV of MRM-MS 
multiplex assay was; 9% in cell lines, 17 % in tissue biopsies, 22% in serum 
samples and 24% in nipple aspirate fluid. Previous research has shown that light 
peptides-based (LP) MRM assays easily exceeded the performance of typical 
Western blotting, yielding CVs ranging from 10-40% for the former compared to 
0-100% for the latter, for target peptides and proteins (Fortin et al., 2009, Picotti 
et al., 2013, Liebler and Zimmerman, 2013). To date this is the first study to 
develop a multiplexed MRM assay for phenotype and stage-specific breast 
cancer detection. 
 
. 
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Figure 6-1: (A) ACTB, CFL-1, HSPE1 and PTGES3 Western blot analysis of phenotypic cell lines. Comparison of three analytical 
methods; Western blotting, iTRAQ and MRM-MS, for expression of (B) CFL-1, (C) HSPE1 and (D) PTGES3 in breast cell lines. 
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MRM-MS approach is more precise and accurate compared to traditional 
immune assays, for quantitative analysis of disease related biomarkers in 
complex biomaterials, such as blood plasma and tissues. MRM-MS based 
targeted protein assay, offers two main advantages over immune-assays; (i) 
ability to develop a speciﬁc assay for any protein or post-translationally modiﬁed 
protein form, without the requirement for an antibody, (ii) multiplex assay 
(analysis of many peptides representative of many proteins in a single assay). 
Targeted peptide-based protein assays provide high throughput, quantitative 
proteomic data and have common application in the systematic development of 
assays for protein biomarker verification and validation studies (Liebler and 
Zimmerman, 2013). 
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6.2 Future directions 
We have here shown for the first time that global profiling of phenotype-
specific breast cancer cell lines compared to primary cells, is possible with high 
quantification accuracy at Orbitrap Fusion, to define protein panels for each 
breast cancer phenotypes. The liquid biopsy approach using NAF provides a 
breakthrough in oncoproteomics to reveal novel diagnostic and prognostic 
applications. We have the potential to develop a multiplex MRM-MS assay using 
the Orbitrap Fusion to measure phenotype and stage-specific biomarkers using 
different clinical materials. The high degree of analytical and quantitative 
reproducibility which provides a solid basis for the extension of this analytical 
method to validate the findings presented in the thesis; - 
▪ Use meta-analysis to refine the panel of phenotype- and stage-specific 
markers for multiplexed MRM-MS assay development 
▪ Use tissue microarray of selected targets to correlation expression with 
phenotype, stage and outcome 
▪ Incorporate stable-isotope-labelled synthetic peptide standards into the 
MRM assay to enable absolute quantification and improve assay 
reproducibility 
▪ Investigate NAF samples for additional molecular (mRNA, miRNA [15] 
and biological (ductal cells, exosomes, microbe [16] signatures to 
complement proteomics profiling 
• For the creation of a substantial NAF biofluid bank, various methods of 
collection should be explored with clinical, health and community 
partners and volunteers, such as manual or mechanical pumps used for 
milk and by oxytocin nasal spray (Suijkerbuijk et al., 2010, Jones and 
Spencer, 2007).  
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Finally, by combining the proteome profiling, miRNA analysis (Canto et 
al., 2016) and characterization of the microbiome (Chan et al., 2016a) in NAF, 
will improve our knowledge about the microenvironment of breast cancer, which 
will result in development of novel breast cancer detection and treatment 
strategies. 
The use of specific fractionation schemes, increase the identified and 
quantified peptides and proteins.  A systematic and efficient analysis of vast 
genomic and proteomic data sets is a major challenge for researchers today. To 
overcome limitations of current proteomics strategies with regard to the dynamic 
range of peptides, cost and time, alternative mass spectrometry-based 
approaches are being explored. Targeted strategies exemplified by DIA and 
MRM-MS detect, quantify, and possibly collect a product ion spectrum to 
confirm the identity of a peptide with much greater sensitivity because the 
precursor ion is not detected in the full mass spectrum (Doerr, 2015). A 
systematic and efficient evaluation of proteomics results requires (1) automatic 
retrieval of user defined customised database; (2) an intuitive graphical  platform 
to display and analyse experimental data (3) efficient bioinformatics software 
tools for data interpretation, prediction of function, and modelling; (4) scalability 
and reconstruction of data base and bioinformatics tools (Chandramouli and 
Qian, 2009). Further technological developments like DIA and MRM-MS will 
enable a larger proportion of the proteome to be visualized and will further 
enhance our ability to characterize biological systems. As such, these advances 
in proteomics will impact diagnostic research and development. 
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